

# CITATION REPORT

List of articles citing

p53, the cellular gatekeeper for growth and division

DOI: 10.1016/s0092-8674(00)81871-1  
Cell, 1997, 88, 323-31.

**Source:** <https://exaly.com/paper-pdf/28323640/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2289	Expression of TMEM87B interacting with the human papillomavirus type 18 E6 oncogene in the Hela cDNA library by a yeast two-hybrid system. <b>1994</b> , 20, 421		
2288	Interactions of the human papillomavirus E7 protein with cell cycle regulators. <b>1996</b> , 7, 327-37	75	
2287	Asbestos, the mesothelial cell and malignancy: a matter of life or death. <b>1997</b> , 17, 657-9		26
2286	Increases in DNA lesions and the DNA damage indicator Gadd45 following transient cerebral ischemia. <b>1997</b> , 75, 383-392		41
2285	The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. <b>1997</b> , 272, 30651-61		63
2284	Genomes and DNA conformation. <b>1997</b> , 378, 1397-404		7
2283	Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. <b>1997</b> , 11, 1226-41		419
2282	Brca2 is required for embryonic cellular proliferation in the mouse. <b>1997</b> , 11, 1242-52		222
2281	Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. <b>1997</b> , 11, 2822-34		319
2280	Altered P53 conformation. <b>1997</b> , 11, 1087-94		2
2279	Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. <b>1997</b> , 272, 25602-7		158
2278	Tamoxifen exerts oestrogen-agonistic effects on proliferation and plasminogen activation, but not on gelatinase activity, glycogen metabolism and p53 protein expression, in cultures of oestrogen-responsive human endometrial adenocarcinoma cells. <b>1997</b> , 3, 1019-27		11
2277	HSP70 binding sites in the tumor suppressor protein p53. <b>1997</b> , 272, 19471-9		70
2276	Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine requires p53. <b>1997</b> , 272, 30619-22		73
2275	Ataxia-telangiectasia and the Nijmegen breakage syndrome: related disorders but genes apart. <b>1997</b> , 31, 635-62		415
2274	Cellular response to DNA damage from a potent carcinogen involves stabilization of p53 without induction of p21(waf1/cip1). <b>1997</b> , 18, 2313-8		34
2273	Interaction between replication protein A and p53 is disrupted after UV damage in a DNA repair-dependent manner. <b>1997</b> , 94, 7186-91		92

2272	Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. <b>1997</b> , 94, 9648-53	252
2271	The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. <b>1997</b> , 94, 13181-6	81
2270	p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family?. <b>1997</b> , 94, 14753-8	49
2269	Current concepts of apoptosis. <b>1997</b> , 3, e6	
2268	p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. <b>1997</b> , 17, 7220-9	150
2267	Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation. <b>1997</b> , 17, 6255-64	111
2266	ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. <b>1997</b> , 17, 7328-41	163
2265	The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. <b>1997</b> , 17, 5923-34	136
2264	Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. <b>1997</b> , 17, 7306-16	79
2263	The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. <b>1997</b> , 8, 469-76	31
2262	Regulation of apoptosis by integrin receptors. <b>1997</b> , 19, 541-5	18
2261	Epothilones: novel microtubule-stabilising agents. <b>1997</b> , 6, 867-73	24
2260	Tying it all together: epigenetics, genetics, cell cycle, and cancer. <b>1997</b> , 277, 1948-9	162
2259	The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. <b>1997</b> , 239, 617-20	46
2258	Overexpression of GML promotes radiation-induced cell cycle arrest and apoptosis. <b>1997</b> , 241, 481-5	22
2257	Genomic structure and chromosomal localization of mouse cyclin G1 gene. <b>1997</b> , 46, 483-6	6
2256	Essential and perilous: V(D)J recombination and DNA damage checkpoints in lymphocyte precursors. <b>1997</b> , 9, 199-206	25
2255	14-3-3sigma is a p53-regulated inhibitor of G2/M progression. <b>1997</b> , 1, 3-11	1062

2254	Coupling cell division and cell death to microtubule dynamics. <b>1997</b> , 9, 807-14		184
2253	Cell multiplication. <b>1997</b> , 9, 893-900		
2252	Recruitment of p300/CBP in p53-dependent signal pathways. <i>Cell</i> , <b>1997</b> , 89, 1175-84	56.2	621
2251	Lonely no more: p53 finds its kin in a tumor suppressor haven. <i>Cell</i> , <b>1997</b> , 90, 829-32	56.2	75
2250	DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. <i>Cell</i> , <b>1997</b> , 91, 325-34	56.2	1720
2249	Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. <i>Cell</i> , <b>1997</b> , 91, 649-59	56.2	1400
2248	Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. <i>Cell</i> , <b>1997</b> , 90, 595-606	56.2	2184
2247	The cat and mouse games that genes, viruses, and cells play. <i>Cell</i> , <b>1997</b> , 88, 573-5	56.2	119
2246	Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. <b>1997</b> , 420, 25-7		1465
2245	Integrating genetic approaches into the discovery of anticancer drugs. <b>1997</b> , 278, 1064-8		577
2244	Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination. <b>1997</b> , 61, 995-9		94
2243	Transcription Abnormalities Potentiate Apoptosis of Normal Human Fibroblasts. <b>1997</b> , 3, 852-863		47
2242	Apoptosis in tumorigenesis and cancer therapy. <b>1997</b> , 2, d353-79		41
2241	Gene expression induced by cerebral ischemia: an apoptotic perspective. <b>1997</b> , 17, 815-32		224
2240	Fifty Years of Studies of the Biology and Therapy of Childhood Leukemia. <b>1997</b> , 90, 4243-4251		144
2239	Mechanisms of induction of skin cancer by UV radiation. <b>1997</b> , 2, d538-51		110
2238	p53-induced apoptosis in the human T-ALL cell line CCRF-CEM. <b>1997</b> , 15, 2429-37		33
2237	Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. <b>1997</b> , 15, 2387-97		131

2236	Mdm2: keeping p53 under control. <b>1997</b> , 15, 1001-10	217
2235	The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints. <b>1997</b> , 15, 3025-35	106
2234	A novel protein with strong homology to the tumor suppressor p53. <b>1997</b> , 15, 1363-7	229
2233	Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. <b>1997</b> , 16, 298-302	219
2232	KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. <b>1997</b> , 17, 141-3	927
2231	Genetic interaction between HAP1/REF-1 and p53. <b>1997</b> , 17, 145	38
2230	Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. <b>1997</b> , 17, 453-6	174
2229	Partial rescue of the prophase I defects of Atm-deficient mice by p53 and p21 null alleles. <b>1997</b> , 17, 462-6	101
2228	Tumour-suppressor genes. Killer in search of a motive?. <b>1997</b> , 389, 122-3	39
2227	Defining tumour-suppressor genes. <b>1997</b> , 389, 123-123	3
2226	A model for p53-induced apoptosis. <b>1997</b> , 389, 300-5	2181
2225	The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. <b>1997</b> , 1333, F151-78	62
2224	Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. <b>1997</b> , 7, 860-9	338
2223	Ordering the multiple pathways of apoptosis. <b>1997</b> , 7, 294-301	14
2222	Sunlight and the onset of skin cancer. <b>1997</b> , 13, 410-4	505
2221	Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation. <b>1997</b> , 16, 7382-92	87
2220	Destabilization of the RB tumor suppressor protein and stabilization of p53 contribute to HPV type 16 E7-induced apoptosis. <b>1997</b> , 239, 97-107	214
2219	Mechanisms of transcriptional regulation of cellular genes by SV40 large T- and small T-antigens. <b>1997</b> , 15, 135-54	47

2218	Apoptosis: a new pharmacodynamic endpoint. <b>1997</b> , 14, 1659-71	32
2217	A closer view of an oncoprotein-tumor suppressor interaction. <b>1997</b> , 4, 791-4	6
2216	Protein acetylation: more than chromatin modification to regulate transcription. <b>1997</b> , 4, 885-8	29
2215	Facts in cancer genetics. <b>1997</b> , 32, 9-17	3
2214	Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. <b>1997</b> , 99, 824-31	108
2213	Epithelial apoptosis. <b>1997</b> , 19, 711-20	52
2212	Use of a membrane-localized green fluorescent protein allows simultaneous identification of transfected cells and cell cycle analysis by flow cytometry. <b>1997</b> , 29, 286-91	99
2211	Biological significance and molecular mechanisms of p53-induced apoptosis. <b>1998</b> , 3, 237-44	11
2210	Signal transduction and the regulation of apoptosis: roles of ceramide. <b>1998</b> , 3, 317-34	36
2209	Role of nitric oxide in mediation of macrophage cytotoxicity and apoptosis. <b>1998</b> , 17, 39-53	140
2208	The cell death response to gamma-radiation in MCF-7 cells is enhanced by a neuroleptic drug, pimozide. <b>1998</b> , 51, 83-95	30
2207	Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. <b>1998</b> , 51, 29-38	62
2206	New insights into the kinetic resistance to anticancer agents. <b>1998</b> , 27, 225-35	11
2205	Apoptosis resistance in tumor cells. <b>1998</b> , 27, 293-308	4
2204	Role of p27 in prostate carcinogenesis. <b>1998</b> , 17, 337-44	59
2203	Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. <b>1998</b> , 17, 159-69	433
2202	p53-inducible human homologue of Drosophila seven in absentia (Siah) inhibits cell growth: suppression by BAG-1. <b>1998</b> , 17, 2736-47	165
2201	Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. <b>1998</b> , 17, 2748-58	121

2200	p53 is a general repressor of RNA polymerase III transcription. <b>1998</b> , 17, 3112-23	149
2199	How p53 binds DNA as a tetramer. <b>1998</b> , 17, 3342-50	187
2198	p53 facilitates pRb cleavage in IL-3-deprived cells: novel pro-apoptotic activity of p53. <b>1998</b> , 17, 3587-96	61
2197	The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. <b>1998</b> , 17, 4668-79	223
2196	The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. <b>1998</b> , 17, 5001-14	867
2195	A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression. <b>1998</b> , 17, 5015-25	75
2194	Isolation of cDNAs encoding novel transcription coactivators p52 and p75 reveals an alternate regulatory mechanism of transcriptional activation. <b>1998</b> , 17, 6723-9	225
2193	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. <b>1998</b> , 17, 1847-59	142
2192	Cloning and chromosomal mapping of the human p53-related KET gene to chromosome 3q27 and its murine homolog Ket to mouse chromosome 16. <b>1998</b> , 9, 899-902	55
2191	p53-dependent cell cycle control: response to genotoxic stress. <b>1998</b> , 8, 325-36	166
2190	Two regions of simian virus 40 large T-antigen independently extend the life span of primary C57BL/6 mouse embryo fibroblasts and cooperate in immortalization. <b>1998</b> , 243, 303-12	26
2189	Levels of p53 in Epstein-Barr virus-infected cells determine cell fate: apoptosis, cell cycle arrest at the G1/S boundary without apoptosis, cell cycle arrest at the G2/M boundary without apoptosis, or unrestricted proliferation. <b>1998</b> , 251, 217-26	18
2188	Tumor suppressors. Teaming up to restrain cancer. <b>1998</b> , 391, 233-4	11
2187	Bacterial diplomacy. <b>1998</b> , 391, 234-234	
2186	p53 and brain tumors: from gene mutations to gene therapy. <b>1998</b> , 8, 599-613	50
2185	Cell suicide for beginners. <b>1998</b> , 396, 119-22	556
2184	p19ARF links the tumour suppressor p53 to Ras. <b>1998</b> , 395, 125-6	563
2183	Impacts on Earth in the Late Triassic. <b>1998</b> , 395, 126-126	1

2182	Wild-type function of the p53 tumor suppressor protein is not required for apoptosis of mouse hepatoma cells. <b>1998</b> , 5, 87-95	17
2181	The levels of integrin alpha v beta 5 may predict the susceptibility to adenovirus-mediated gene transfer in human lung cancer cells. <b>1998</b> , 5, 361-8	53
2180	Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. <b>1998</b> , 5, 605-13	34
2179	Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. <b>1998</b> , 5, 728-39	59
2178	The study of apoptotic cells by flow cytometry. <b>1998</b> , 12, 1013-25	102
2177	Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. <b>1998</b> , 16, 1241-7	135
2176	The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells. <b>1998</b> , 16, 1617-24	136
2175	A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect. <b>1998</b> , 16, 1429-41	21
2174	Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. <b>1998</b> , 16, 1603-10	112
2173	Identification of an allosteric binding site on the transcription factor p53 using a phage-displayed peptide library. <b>1998</b> , 16, 1993-9	35
2172	SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors. <b>1998</b> , 16, 2103-14	30
2171	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors. <b>1998</b> , 16, 2115-22	35
2170	Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. <b>1998</b> , 16, 2229-41	71
2169	Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. <b>1998</b> , 16, 2177-83	189
2168	mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells. <b>1998</b> , 16, 2249-57	10
2167	p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. <b>1998</b> , 16, 2965-74	140
2166	'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain. <b>1998</b> , 16, 3169-76	80
2165	Isolation of canine p53 cDNA and detailed characterization of the full length canine p53 protein. <b>1998</b> , 16, 1077-84	31



2164	Mutant p53 protein expression interferes with p53-independent apoptotic pathways. <b>1998</b> , 16, 3269-77	119
2163	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. <b>1998</b> , 16, 1369-72	70
2162	Superinduction of wild-type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis. <b>1998</b> , 17, 241-6	54
2161	Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. <b>1998</b> , 17, 199-205	233
2160	p53 protein is activated during muscle differentiation and participates with MyoD in the transcription of muscle creatine kinase gene. <b>1998</b> , 17, 347-56	47
2159	Radioresistant MTP53-expressing rat embryo cell transformants exhibit increased DNA-dsb rejoining during exposure to ionizing radiation. <b>1998</b> , 16, 1789-802	37
2158	Excision of mismatched nucleotides from DNA: a potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein. <b>1998</b> , 17, 261-70	69
2157	p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. <b>1998</b> , 17, 845-51	121
2156	Reduced telomeric signals and increased telomeric associations in human lung cancer cell lines undergoing p53-mediated apoptosis. <b>1998</b> , 17, 901-6	23
2155	Endogenous p53 regulation and function in early stage Friend virus-induced tumor progression differs from that following DNA damage. <b>1998</b> , 17, 1119-30	13
2154	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. <b>1998</b> , 16, 2527-39	83
2153	Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. <b>1998</b> , 17, 651-6	96
2152	Spi-1 transgenic mice develop a clonal erythroleukemia which does not depend on p53 mutation. <b>1998</b> , 16, 2989-95	18
2151	Induced p53 expression in lung cancer cell line promotes cell senescence and differentially modifies the cytotoxicity of anti-cancer drugs. <b>1998</b> , 17, 1923-30	93
2150	Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer. <b>1998</b> , 17, 2323-32	28
2149	Cytoplasmic retention of mutant tsp53 is dependent on an intermediate filament protein (vimentin) scaffold. <b>1998</b> , 16, 3423-34	46
2148	Mdm2 association with p53 targets its ubiquitination. <b>1998</b> , 17, 2543-7	205
2147	Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity. <b>1998</b> , 17, 2743-51	48

2146	Regulation of CAK kinase activity by p53. <b>1998</b> , 17, 2733-41	60
2145	Mouse models in tumor suppression. <b>1998</b> , 17, 3385-400	71
2144	Increased Mdm2 expression in rat brain after transient middle cerebral artery occlusion. <b>1998</b> , 18, 658-69	27
2143	Intercellular delivery of functional p53 by the herpesvirus protein VP22. <b>1998</b> , 16, 440-3	258
2142	Cloning and functional analysis of human p51, which structurally and functionally resembles p53. <b>1998</b> , 4, 839-43	465
2141	Translocations, cancer and the puzzle of specificity. <b>1998</b> , 19, 121-4	87
2140	ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. <b>1998</b> , 19, 175-8	407
2139	Analysis of p53, p16MTS, p21WAF1 and H-ras in archived bladder tumours from workers exposed to aromatic amines. <b>1998</b> , 77, 1573-9	20
2138	P53 tumour suppressor gene and germ cell neoplasia. <b>1998</b> , 106, 85-9	39
2137	Tumor suppressors: from genes to function and possible therapies. <b>1998</b> , 14, 8-9	6
2136	Cerebellar cell lines established from a p53-deficient adult mouse. <b>1998</b> , 813, 172-6	17
2135	Fewer chromosome aberrations and earlier apoptosis induced by DNA synthesis inhibitors, a topoisomerase II inhibitor or alkylating agents in human cells with normal compared with mutant p53. <b>1998</b> , 401, 39-53	30
2134	Apoptin specifically causes apoptosis in tumor cells and after UV-treatment in untransformed cells from cancer-prone individuals: a review. <b>1998</b> , 400, 447-55	23
2133	Murine tumor suppressor models. <b>1998</b> , 400, 391-407	10
2132	Transgenic assays for mutations and cancer: current status and future perspectives. <b>1998</b> , 400, 337-54	24
2131	On the origins of tumor mutations in cancer genes: insights from the p53 gene. <b>1998</b> , 405, 145-54	34
2130	Ubiquitin, E6-AP, and their role in p53 inactivation. <b>1998</b> , 78, 129-39	77
2129	From peptides to drugs via phage display. <b>1998</b> , 3, 370-378	68

2128	Multisite phosphorylation and the integration of stress signals at p53. <b>1998</b> , 10, 159-66	171
2127	The papillomavirus E6 proteins. <b>1998</b> , 1378, F1-19	35
2126	Progress in understanding the molecular pathogenesis of human lung cancer. <b>1998</b> , 1378, F21-59	77
2125	The p16INK4a/CDKN2A tumor suppressor and its relatives. <b>1998</b> , 1378, F115-77	359
2124	An insight into the life of p53: a protein coping with many functions! Review of the 9th p53 Workshop, Crete, May 9-13, 1998. <b>1998</b> , 1378, R43-54	8
2123	p53- and p21-independent apoptosis of squamous cell carcinoma cells induced by 5-fluorouracil and radiation. <b>1998</b> , 34, 529-37	34
2122	p53 tumour suppressor. <b>1998</b> , 8, R476	
2121	Role of the human RAD51 protein in homologous recombination and double-stranded-break repair. <b>1998</b> , 23, 247-51	443
2120	The INK4a/ARF tumor suppressor: one gene--two products--two pathways. <b>1998</b> , 23, 291-6	226
2119	Inhibiting CDK inhibitors: new lessons from DNA tumor viruses. <b>1998</b> , 23, 337-41	34
2118	Regulation of cyclin G1 during murine hepatic regeneration following Dipin-induced DNA damage. <b>1998</b> , 28, 537-46	28
2117	Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. <b>1998</b> , 75, 933-40	47
2116	TP53 genetic alterations in head-and-neck carcinomas from Brazil. <b>1998</b> , 76, 13-8	18
2115	Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients. <b>1998</b> , 79, 147-52	10
2114	A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation. <b>1998</b> , 77, 854-9	81
2113	Why is p53 protein stabilized in neoplasia? Some answers but many more questions?. <b>1998</b> , 184, 348-50	26
2112	p53-dependent X-ray-induced modulation of cytokine mRNA levels in vivo. <b>1998</b> , 186, 24-30	7
2111	An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth-regulated cross-reacting species p170. <b>1998</b> , 186, 254-61	7

2110	Integration of the central death pathway in cellular decision-making. <b>1998</b> , 177, 518-24	
2109	Role of tumor suppressor genes in transplacental lung carcinogenesis. <b>1998</b> , 21, 177-84	14
2108	Modulation of p53 protein conformation and DNA-binding activity by intracellular chelation of zinc. <b>1998</b> , 21, 205-14	92
2107	Enhanced expression of anti-apoptotic proteins in human papillomavirus-immortalized and cigarette smoke condensate-transformed human endocervical cells: Correlation with resistance to apoptosis induced by DNA damage. <b>1998</b> , 22, 95-101	16
2106	DNA adduct levels associated with p53 induction and delay of MCF-7 cells in S phase after exposure to benzo[ <i>g</i> ]chrysene dihydrodiol epoxide enantiomers. <b>1998</b> , 23, 115-20	16
2105	Molecular alterations associated with improved survival in pancreatic cancer patients treated with radiation or chemotherapy. <b>1998</b> , 5, 269-72	15
2104	Tumor-suppressor genes in pancreatic cancer. <b>1998</b> , 5, 383-91	35
2103	The effect of pyrimidine nucleosides on adenosine-induced apoptosis in HL-60 cells. <b>1998</b> , 124, 471-7	14
2102	p53 status in radiation-induced soft-tissue sarcomas. <b>1998</b> , 174, 427-30	4
2101	Cell death induced by high-linear-energy transfer carbon beams in human glioblastoma cell lines. <b>1998</b> , 15, 71-6	33
2100	[Molecular genetics of epithelial ovarian neoplasms: correlations with phenotype and biological behavior]. <b>1998</b> , 19, 95-103	4
2099	[Success and prospects in gastroenterology]. <b>1998</b> , 39, 373-80	
2098	Apoptosis in cell culture. <b>1998</b> , 9, 152-6	125
2097	The challenge of p53: linking biochemistry, biology, and patient management. <b>1998</b> , 16, 248-60	14
2096	Targeting cancer cell death with a bcl-XS adenovirus. <b>1998</b> , 19, 279-88	10
2095	Apoptosis by p53: mechanisms, regulation, and clinical implications. <b>1998</b> , 19, 345-62	18
2094	p53 and p53-regulated genes in bladder cancer. <b>1998</b> , 82, 710-20	25
2093	In vivo analysis of germ cell apoptosis reveals the existence of stage-specific 'social' control of germ cell death in the seminiferous epithelium. <b>1997</b> , 20, 373-9	10

2092	Stem cells in the testis. <b>1998</b> , 79, 67-80	171
2091	Anti-apoptotic strategies of lymphotropic viruses. <b>1998</b> , 19, 474-9	71
2090	Cloning and comparative sequence analysis of TP53 in Xiphophorus fish hybrid melanoma models. <b>1998</b> , 212, 31-8	19
2089	p53 suppresses cytokine induced, Stat5 mediated activation of transcription. <b>1998</b> , 143, 143-54	21
2088	How is the mutational status for tumor suppressors p53 and p16(INK4A) in MFH of the bone?. <b>1998</b> , 123, 147-51	10
2087	p53 gene mutations in rectal cancer associated with schistosomiasis japonica in Chinese patients. <b>1998</b> , 131, 215-21	32
2086	Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. <b>1998</b> , 133, 35-45	13
2085	Sebaceous carcinoma. Tumor progression through mutational inactivation of p53. <b>1998</b> , 105, 497-506	62
2084	Expression of a cDNA from apple encoding a homologue of DAD1, an inhibitor of programmed cell death. <b>1998</b> , 139, 165-174	31
2083	Distinct mode of apoptosis induced by genotoxic agent etoposide and serum withdrawal in neuroblastoma cells. <b>1998</b> , 62, 43-55	34
2082	p54 where are you?. <b>1998</b> , 39, 762-4	3
2081	cDNA cloning and expression analysis of flounder p53 tumour suppressor gene. <b>1998</b> , 121, 235-42	22
2080	Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy. <b>1998</b> , 194, 821-30	21
2079	DNA damage activates p53 through a phosphorylation-acetylation cascade. <b>1998</b> , 12, 2831-41	927
2078	Phosphorylation of p53 serine 15 increases interaction with CBP. <b>1998</b> , 273, 33048-53	336
2077	Electrophoretic DNA analysis for the detection of apoptosis. <b>1998</b> , 9, 247-51	10
2076	Apoptin-induced apoptosis: potential for antitumor therapy. <b>1998</b> , 1, 99-103	6
2075	Tumor suppressor gene therapy for cancer: from the bench to the clinic. <b>1998</b> , 1, 205-10	2

2074	Modulation of mitomycin C-induced sister chromatid exchanges and cell cycle delay by buthionine sulfoximine and reduced glutathione in mouse bone marrow cells in vivo. <b>1998</b> , 413, 227-34		15
2073	Spermatogonial stem cells. <b>1998</b> , 10, 694-701		266
2072	The fight of viruses against apoptosis. <b>1998</b> , 8, 82-7		171
2071	Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines. <b>1998</b> , 34, 1783-8		50
2070	Review article Alterations in cyclin D1, p53, and the cell cycle related elements Implications for distinct genetic pathways of urinary bladder carcinogenesis. <b>1998</b> , 4, 58-72		5
2069	p300/MDM2 complexes participate in MDM2-mediated p53 degradation. <b>1998</b> , 2, 405-15		351
2068	p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. <b>1998</b> , 2, 305-16		1765
2067	Production of a polyclonal antibody raised against recombinant flounder p53 protein. <b>1998</b> , 120, 351-6		5
2066	Cancer--a degenerative disorder?. <b>1998</b> , 24, 362-6		9
2065	The evolutionary biology of death and human malignancy. <b>1998</b> , 24, 568-72		2
2064	Apoptosis and programmed cell death: a role in cerebral ischemia. <b>1998</b> , 52, 264-9		29
2063	Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer. <b>1998</b> , 29, 949-54		86
2062	Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. <i>Cell</i> , <b>1998</b> , 93, 81-91	56.2	465
2061	The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. <i>Cell</i> , <b>1998</b> , 92, 713-23	56.2	1316
2060	ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. <i>Cell</i> , <b>1998</b> , 92, 725-34	56.2	1394
2059	The DNA replication and damage checkpoint pathways induce transcription by inhibition of the Crt1 repressor. <i>Cell</i> , <b>1998</b> , 94, 595-605	56.2	424
2058	Disruption of actin microfilaments by cytochalasin D leads to activation of p53. <b>1998</b> , 430, 353-7		62
2057	Cell cycle arrest following exposure of EBV-immortalised B-cells to gamma irradiation correlates with inhibition of cdk2 activity. <b>1998</b> , 439, 297-301		13

2056	Proapoptotic gene BAX is frequently mutated in hereditary nonpolyposis colorectal cancers but not in adenomas. <b>1998</b> , 114, 268-74	77
2055	Apc1638N: a mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts. <b>1998</b> , 114, 275-83	109
2054	MDM2 expression during mouse embryogenesis and the requirement of p53. <b>1998</b> , 74, 189-93	40
2053	Impacts on Earth in the Late Triassic. <b>1998</b> , 395, 126-126	8
2052	Idiotypic immunization induces immunity to mutated p53 and tumor rejection. <b>1998</b> , 4, 710-2	52
2051	Regulation of Apoptosis by Adenovirus E1A and E1B Oncogenes. <b>1998</b> , 8, 505-513	60
2050	Cloning of a novel gene (ING1L) homologous to ING1, a candidate tumor suppressor. <b>1998</b> , 83, 232-5	51
2049	Reactive Oxygen Species: Their Relation to Pneumoconiosis and Carcinogenesis. <b>1998</b> , 106, 1151	29
2048	Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. <b>1998</b> , 159, 1437-43	73
2047	Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. <b>1998</b> , 273, 26061-8	144
2046	Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. <b>1998</b> , 95, 11963-8	325
2045	Tumor surveillance via the ARF-p53 pathway. <b>1998</b> , 12, 2984-91	554
2044	New developments in the multi-site phosphorylation and integration of stress signalling at p53. <b>1998</b> , 74, 729-37	30
2043	Molecular pathogenesis of transplacentally induced mouse lung tumors. <b>1998</b> , 24, 557-77	20
2042	Tumor-specific mutation spectra in the human p53 gene: From carcinogen "fingerprints" to functional consequences. <b>1998</b> , 16, 31-45	2
2041	Monitoring and Signaling of Radiation-Induced Damage in Mammalian Cells. <b>1998</b> , 150, S92	71
2040	Molecular Biology to Radiation Oncology: A Model for Translational Research? Opportunities in Basic and Translational Research From a Workshop Sponsored by the National Cancer Institute, Radiation Research Program, January 26-28, 1997, Bethesda, Maryland. <b>1998</b> , 150, 134	5
2039	Butyrate Attenuates BCL2 L Expression in Human Fibroblasts and Acts in Synergy with Ionizing Radiation to Induce Apoptosis. <b>1998</b> , 149, 187	21

2038	Like p53, the proliferation-associated protein p120 accumulates in human cancer cells following exposure to anticancer drugs. <b>1998</b> , 244, 368-73	9
2037	Rearrangement of the p53 gene in human breast tumours. <b>1998</b> , 245, 388-91	11
2036	Regulation of the p53 protein by protein kinase C alpha and protein kinase C zeta. <b>1998</b> , 245, 514-8	32
2035	Chromatin relaxation by overexpression of mutant p53, HPV16-E6, or cyclin G transgenes. <b>1998</b> , 242, 235-43	12
2034	Sympathetic neuron survival and proliferation are prolonged by loss of p53 and neurofibromin. <b>1998</b> , 11, 19-28	40
2033	p53: radiosensitivity and antiangiogenic effects. <b>1998</b> , 64, 7-11	4
2032	MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. <b>1998</b> , 153, 1425-33	147
2031	Nitrosative and oxidative stress induced heme oxygenase-1 accumulation in rat mesangial cells. <b>1998</b> , 342, 77-84	30
2030	The mutagenic potential of DNA double-strand break repair. <b>1998</b> , 96-97, 119-29	35
2029	Mechanisms of p53-induced apoptosis: in search of genes which are regulated during p53-mediated cell death. <b>1998</b> , 102-103, 491-6	25
2028	Expression of Fas system-related genes in the testis during development and after toxicant exposure. <b>1998</b> , 102-103, 503-8	33
2027	Current Techniques in Neurosurgery. <b>1998</b> ,	
2026	Regulation of G1 phase. <b>1998</b> , 22, 1-34	14
2025	Enhanced phosphorylation of p53 by ATM in response to DNA damage. <b>1998</b> , 281, 1674-7	1558
2024	Requirement for p53 and p21 to sustain G2 arrest after DNA damage. <b>1998</b> , 282, 1497-501	2249
2023	A comparative study of p53 immunoexpression in parathyroid hyperplasias secondary to uremia, primary hyperplasias, adenomas and carcinomas. <b>1998</b> , 139, 78-83	12
2022	p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. <b>1998</b> , 95, 13194-9	124
2021	A DNA damage and stress inducible G protein-coupled receptor blocks cells in G2/M. <b>1998</b> , 95, 12334-9	126



2020	Identification of a novel p53 functional domain that is necessary for mediating apoptosis. <b>1998</b> , 273, 13030-6	130
2019	Importance of changes in epithelial cell turnover during Helicobacter pylori infection in gastric carcinogenesis. <b>1998</b> , 43 Suppl 1, S27-32	56
2018	Adenovirus E4orf6 oncoprotein modulates the function of the p53-related protein, p73. <b>1998</b> , 95, 15683-7	46
2017	Chapter 1 Apoptosis as a gene-directed program of cell death. <b>1998</b> , 13, 1-55	0
2016	The p53 tumor suppressor inhibits transcription of the TATA-less mouse DP1 promoter. <b>1998</b> , 273, 10972-8	25
2015	To die or not to die: an overview of apoptosis and its role in disease. <b>1998</b> , 279, 300-7	380
2014	Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. <b>1998</b> , 90, 1130-7	65
2013	p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. <b>1998</b> , 188, 2033-45	704
2012	The activity of differentiation factors induces apoptosis in polyomavirus large T-expressing myoblasts. <b>1998</b> , 9, 1449-63	28
2011	Human and mouse homologs of Schizosaccharomyces pombe rad1(+) and Saccharomyces cerevisiae RAD17: linkage to checkpoint control and mammalian meiosis. <b>1998</b> , 12, 2560-73	91
2010	Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function. <b>1998</b> , 12, 1975-85	60
2009	Differential regulation of p53-dependent and -independent proliferating cell nuclear antigen gene transcription by 12 O 6 A4 oncoprotein requires CBP. <b>1998</b> , 273, 17303-6	11
2008	Induction of mutations in Ki-ras and INK4a in liver tumors of mice exposed in utero to 3-methylcholanthrene. <b>1998</b> , 19, 1045-52	18
2007	IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. <b>1998</b> , 26, 205-13	332
2006	Identification of a novel class of genomic DNA-binding sites suggests a mechanism for selectivity in target gene activation by the tumor suppressor protein p53. <b>1998</b> , 12, 2102-7	93
2005	Immunohistochemical detection of c-erbB-2 and p53 in benign breast disease and breast cancer risk. <b>1998</b> , 90, 1262-9	92
2004	Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis. <b>1998</b> , 143, 547-60	428
2003	Regulation of apoptosis-associated genes in the regenerating liver. <b>1998</b> , 18, 123-40	31

2002	The gene expression index c-myc x E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells. <b>1998</b> , 19, 18-24	29
2001	Modulation of Mdm2 expression and p53-induced apoptosis in immortalized human ovarian granulosa cells. <b>1998</b> , 139, 4688-700	56
2000	Development of a syngeneic bovine fibroblast cell line: implications for the study of bovine cytotoxic T lymphocytes. <b>1998</b> , 11, 37-48	9
1999	Thyroid hormone receptor is a negative regulator in p53-mediated signaling pathways. <b>1998</b> , 17, 743-50	28
1998	The complexity of p53 modulation: emerging patterns from divergent signals. <b>1998</b> , 12, 2973-83	1017
1997	Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. <b>1998</b> , 95, 13012-7	385
1996	pRB plays an essential role in cell cycle arrest induced by DNA damage. <b>1998</b> , 95, 11945-50	197
1995	Chapter 10 Cell regeneration. <b>1998</b> , 267-293	
1994	Cell cycle progression: new therapeutic target for vascular proliferative disease. <b>1998</b> , 98, 82-9	284
1993	Cell and molecular mechanisms of pathogenesis and treatment of cancer. <b>1998</b> , 74, 77-88	3
1992	The relationship between Bcl2, Bax and p53: consequences for cell cycle progression and cell death. <b>1998</b> , 4, 1099-109	331
1991	The G1-phase growth-arresting action of interleukin-1 is independent of p53 and p21/WAF1 function. <b>1998</b> , 273, 30517-23	16
1990	Pyrrolidine dithiocarbamate prevents p53 activation and promotes p53 cysteine residue oxidation. <b>1998</b> , 273, 18898-905	61
1989	Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53. <b>1998</b> , 273, 29156-63	56
1988	Wild-type p53-mediated induction of rat mdr1b expression by the anticancer drug daunorubicin. <b>1998</b> , 273, 15387-94	37
1987	An important role for the retinoblastoma protein in staurosporine-induced G1 arrest in murine embryonic fibroblasts. <b>1998</b> , 273, 3803-7	15
1986	Endothelin-induced apoptosis of A375 human melanoma cells. <b>1998</b> , 273, 12584-92	86
1985	Biomarkers in benign breast disease: risk factors for breast cancer. <b>1998</b> , 90, 1247-8	19

1984	Cooperation of a single lysine mutation and a C-terminal domain in the cytoplasmic sequestration of the p53 protein. <b>1998</b> , 273, 19817-21	46
1983	p53 is essential for developmental neuron death as regulated by the TrkA and p75 neurotrophin receptors. <b>1998</b> , 143, 1691-703	249
1982	Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations. <b>1998</b> , 12, 3831-42	325
1981	The p53 network. <b>1998</b> , 273, 1-4	565
1980	A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer. <b>1998</b> , 9, 2075-82	143
1979	The therapeutic potential of targeting the cell cycle. <b>1998</b> , 7, 865-87	42
1978	Centrosome amplification as a possible mechanism for numerical chromosome aberrations in cerebral primitive neuroectodermal tumors with TP53 mutations. <b>1998</b> , 83, 266-9	72
1977	E1A signaling to p53 involves the p19(ARF) tumor suppressor. <b>1998</b> , 12, 2434-42	490
1976	JNK targets p53 ubiquitination and degradation in nonstressed cells. <b>1998</b> , 12, 2658-63	253
1975	Oncogene-dependent regulation of caspase activation by p53 protein in a cell-free system. <b>1998</b> , 273, 28378-83	70
1974	Two new p73 splice variants, gamma and delta, with different transcriptional activity. <b>1998</b> , 188, 1763-8	345
1973	Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis. <b>1998</b> , 273, 19207-12	149
1972	Stabilization of p53 by adenovirus E1A occurs through its amino-terminal region by modification of the ubiquitin-proteasome pathway. <b>1998</b> , 273, 20036-45	29
1971	Inactivation of tumor suppressor p53 by mot-2, a hsp70 family member. <b>1998</b> , 273, 29586-91	183
1970	Shigella-induced apoptosis is dependent on caspase-1 which binds to IpaB. <b>1998</b> , 273, 32895-900	307
1969	DNA methylation in urological malignancies (review).. <b>1998</b> , 13, 151	1
1968	The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. <b>1998</b> , 13, 225-32	8
1967	Protein synthesis and transcriptional inhibitors control N-methyl-N'-nitro-N-nitrosoguanidine-induced levels of APC mRNA in a p53-dependent manner. <b>1998</b> , 13, 733-40	4

1966	The replication inhibition activity of the WT1 tumor suppressor protein resides in its N-terminal 298 amino acid region, and does not require specific binding of the protein to the replication origin sequence. <b>1998</b> , 13, 1275-80	
1965	Frequent microsatellite instability and loss of heterozygosity in the region including BRCA1 (17q21) in young patients with gastric cancer. <b>1998</b> , 12, 1245-51	15
1964	Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. <b>1998</b> , 18, 3692-8	163
1963	The role of retinoblastoma and p53 tumor suppressor pathways in human mammary epithelial cell immortalization. <b>1998</b> , 12, 499-507	7
1962	Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. <b>1998</b> , 18, 7288-93	447
1961	Molecular oncology: diagnostic and prognostic assessment of human cancers in the clinical laboratory. <b>1998</b> , 16, 485-502	3
1960	Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene. <b>1998</b> , 77, 374-84	20
1959	p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. <b>1998</b> , 95, 6163-8	123
1958	Nasal Epithelium as a Sentinel for Airborne Environmental Pollution. <b>1998</b> , 46, 352-364	59
1957	HIV-1 Tat interacts with cyclin T1 to direct the P-TEFb CTD kinase complex to TAR RNA. <b>1998</b> , 63, 371-80	64
1956	Ischemic Neuronal Apoptosis: A View Based on Free Radical-Induced DNA Damage and Repair. <b>1998</b> , 4, 88-95	3
1955	MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification. <b>1998</b> , 18, 536-45	52
1954	KARP-1 is induced by DNA damage in a p53- and ataxia telangiectasia mutated-dependent fashion. <b>1998</b> , 95, 7664-9	41
1953	Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. <b>1998</b> , 95, 10842-7	61
1952	Non-p53 p53RE binding protein, a human transcription factor functionally analogous to P53. <b>1998</b> , 95, 6681-6	27
1951	The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. <b>1998</b> , 18, 6457-73	303
1950	Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies. <b>1998</b> , 18, 1611-21	137
1949	No requirement for V(D)J recombination in p53-deficient thymic lymphoma. <b>1998</b> , 18, 3495-501	74

1948	Molecular genetics of childhood leukemias. <b>1998</b> , 20, 1-11	51
1947	Immunohistochemical analysis of p53 and p21(WAF1/Cip1) expression in primary intracranial germ cell tumors. <b>1998</b> , 5, e2	5
1946	Characterization of the p53-dependent postmitotic checkpoint following spindle disruption. <b>1998</b> , 18, 1055-64	439
1945	Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells. <b>1998</b> , 95, 11927-32	37
1944	Apoptosis and expression of Bax, Bcl-x, and Bcl-2 apoptotic regulatory proteins in colorectal carcinomas, and association with p53 genotype/phenotype. <b>1998</b> , 51, 254-61	36
1943	Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. <b>1998</b> , 95, 6399-402	157
1942	CD95(APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells. <b>1998</b> , 75, 251-73	41
1941	Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. <b>1998</b> , 95, 8292-7	765
1940	CD95(APO-1/Fas)-mediated apoptosis: live and let die. <b>1999</b> , 71, 163-210	282
1939	Polyamine analogue-mediated cell cycle responses in human melanoma cells involves the p53, p21, Rb regulatory pathway. <b>1998</b> , 26, 609-14	11
1938	The BRCA2 gene product functionally interacts with p53 and RAD51. <b>1998</b> , 95, 13869-74	213
1937	Identification of an additional negative regulatory region for p53 sequence-specific DNA binding. <b>1998</b> , 95, 6079-84	81
1936	Soft Tissue Sarcomas and p53 Mutations. <b>1998</b> , 4, 365-372	29
1935	Cell Cycle Exit: Growth Arrest, Apoptosis, and Tumor Suppression Revisited. <b>1998</b> , 4, 205-213	11
1934	Inhibition of UV-Induced p53 Mutations by Sunscreens: Implications for Skin Cancer Prevention. <b>1998</b> , 3, 52-56	6
1933	Human papillomaviruses and associated malignancies. <b>1998</b> , 16, 330-7	130
1932	Rapid sequencing of the p53 gene with a new automated DNA sequencer. <b>1998</b> , 44, 1397-1403	15
1931	The Chimeric E2A-HLF Transcription Factor Abrogates p53-Induced Apoptosis in Myeloid Leukemia Cells. <b>1998</b> , 92, 1397-1405	34

1930	Cyclic AMP delays G2 progression and prevents efficient accumulation of cyclin B1 proteins in mouse macrophage cells. <b>1998</b> , 23, 357-65	11
1929	Human T-cell lymphotropic/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain. <b>1998</b> , 72, 8852-60	152
1928	Reactive oxygen species: their relation to pneumoconiosis and carcinogenesis. <b>1998</b> , 106 Suppl 5, 1151-5	72
1927	Genetic alterations in head and neck squamous cell carcinomas. <b>1999</b> , 32, 897-904	24
1926	Cell cycle control, checkpoint mechanisms, and genotoxic stress. <b>1999</b> , 107 Suppl 1, 5-24	180
1925	Polyamine depletion arrests cell cycle and induces inhibitors p21(Waf1/Cip1), p27(Kip1), and p53 in IEC-6 cells. <b>1999</b> , 276, C684-91	145
1924	Nitric oxide triggers programmed cell death (apoptosis) of adult rat ventricular myocytes in culture. <b>1999</b> , 277, H1189-99	21
1923	Tumor Markers of Radiation Sensitivity. <b>1999</b> , 6, 385-392	2
1922	Age-dependent atrophy and microgravity travel: what do they have in common?. <b>1999</b> , 13 Suppl, S167-74	31
1921	DNA repair, DNA replication, and UV mutagenesis. <b>1999</b> , 4, 1-5	31
1920	Psoriasis, PUVA, and skin cancer--molecular epidemiology: the curious question of T-->A transversions. <b>1999</b> , 4, 11-6	15
1919	Ubiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression. <b>1999</b> , 5, 21-34	75
1918	Overlapping and divergent actions of estrogen and the neurotrophins on cell fate and p53-dependent signal transduction in conditionally immortalized cerebral cortical neuroblasts. <b>1999</b> , 19, 6994-7006	31
1917	Hypoxia-inducible factor-1alpha mediates hypoxia-induced delayed neuronal death that involves p53. <b>1999</b> , 19, 6818-24	168
1916	At the crossroads of inflammation and tumorigenesis. <b>1999</b> , 190, 1367-70	109
1915	Biochemical and Genetic Control of Apoptosis: Relevance to Normal Hematopoiesis and Hematological Malignancies. <b>1999</b> , 93, 3587-3600	115
1914	Regulated Genomic Instability and Neoplasia in the Lymphoid Lineage. <b>1999</b> , 94, 3997-4010	108
1913	The Potential of Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class as Effective Antiproliferative Agents III: The Effect of the Ligands on Molecular Targets Involved in Proliferation. <b>1999</b> , 94, 781-792	149

1912	In Vitro Evaluation of Fludarabine in Combination With Cyclophosphamide and/or Mitoxantrone in B-Cell Chronic Lymphocytic Leukemia. <b>1999</b> , 94, 2836-2843	153
1911	MDM2 suppresses p73 function without promoting p73 degradation. <b>1999</b> , 19, 3257-66	282
1910	Two polymorphic variants of wild-type p53 differ biochemically and biologically. <b>1999</b> , 19, 1092-100	566
1909	Disruption of functions of wild-type p53 by hetero-oligomerization. <b>1999</b> , 15, 413-22	3
1908	In vivo radiosensitizing effect of the adenovirus E1A gene in murine and human malignant tumors. <b>1999</b> , 15, 1163-8	7
1907	DNA reactions, mutagenic action and stealth properties of polycyclic aromatic hydrocarbon carcinogens (review). <b>1999</b> , 14, 103-11	13
1906	Acyclic nucleotide analogues suppress growth and induce apoptosis in human leukemia cell lines. <b>1999</b> , 14, 745-52	4
1905	Cisplatin-induced p53-independent growth arrest and cell death in cancer cells. <b>1999</b> , 15, 1097-102	4
1904	Mutation and transcription analyses of the p63 gene in cervical carcinoma. <b>1999</b> , 15, 1149-53	14
1903	Interference with gene expression induces rapid apoptosis in p53-null T lymphoma cells. <b>1999</b> , 6, 1216-21	2
1902	The therapeutic potential of iron chelators. <b>1999</b> , 8, 2141-2158	37
1901	Dormant tumor-suppressor pathways in tumors. <b>1999</b> , 20, 541-2	4
1900	Lung cancer and past occupational exposure to asbestos. Role of p53 and K-ras mutations. <b>1999</b> , 20, 667-74	35
1899	The Fas system, a regulator of testicular germ cell apoptosis, is differentially up-regulated in Sertoli cell versus germ cell injury of the testis. <b>1999</b> , 140, 852-8	240
1898	Molecular mechanisms of androgen-independent growth of human prostate cancer LNCaP-AI cells. <b>1999</b> , 140, 5054-9	68
1897	Involvement of the Fas/Fas ligand system in p53-mediated granulosa cell apoptosis during follicular development and atresia. <b>1999</b> , 140, 2307-17	108
1896	Cell cycle arrest and astrocytic differentiation resulting from PTEN expression in glioma cells. <b>1999</b> , 91, 822-30	35
1895	Potential roles for p53 in nucleotide excision repair. <b>1999</b> , 20, 1389-96	50

1894	Zn(2+) fingers and cervical cancer. <b>1999</b> , 91, 1180-1	3
1893	Mutation and methylation status of p53 gene promoter in human breast tumours. <b>1999</b> , 20, 341-6	9
1892	Radiation down-regulates replication origin activity throughout the S phase in mammalian cells. <b>1999</b> , 27, 803-9	50
1891	Progress in cancer genetics: Lessons from pancreatic cancer. <b>1999</b> , 10, S4-S8	35
1890	Alterations of SAG mRNA in human cancer cell lines: requirement for the RING finger domain for apoptosis protection. <b>1999</b> , 20, 1899-903	30
1889	Strain-dependent lung tumor formation in mice transplacentally exposed to 3-methylcholanthrene and post-natally exposed to butylated hydroxytoluene. <b>1999</b> , 20, 2159-65	31
1888	Expression of granulosa cell-specific genes and induction of apoptosis in conditionally immortalized granulosa cell lines established from H-2Kb-tsA58 transgenic mice. <b>1999</b> , 60, 1078-86	6
1887	Okadaic acid mediates p53 hyperphosphorylation and growth arrest in cells with wild-type p53 but increases aberrant mitoses in cells with non-functional p53. <b>1999</b> , 20, 1043-8	19
1886	Effect of p53 protein redox states on binding to supercoiled and linear DNA. <b>1999</b> , 274, 25749-55	41
1885	Rapid analysis of gene expression (RAGE) facilitates universal expression profiling. <b>1999</b> , 27, 4609-18	34
1884	A novel MDMX transcript expressed in a variety of transformed cell lines encodes a truncated protein with potent p53 repressive activity. <b>1999</b> , 274, 8299-308	74
1883	Stress-induced JNK activation is independent of Gadd45 induction. <b>1999</b> , 274, 29595-8	44
1882	Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. <b>1999</b> , 274, 24263-9	119
1881	p53 and tumor necrosis factor alpha regulate the expression of a mitochondrial chloride channel protein. <b>1999</b> , 274, 36488-97	105
1880	p21(WAF1/Cip1) functions as a suppressor of malignant skin tumor formation and a determinant of keratinocyte stem-cell potential. <b>1999</b> , 96, 9089-94	165
1879	Inhibitory phosphorylation of PP1alpha catalytic subunit during the G(1)/S transition. <b>1999</b> , 274, 29470-5	68
1878	p53 gene mutations are not required for early dissemination of cancer cells. <b>1999</b> , 96, 6942-6	42
1877	Cell and molecular biology of simian virus 40: implications for human infections and disease. <b>1999</b> , 91, 119-34	276



1876	Genetic disorders associated with cancer predisposition and genomic instability. <b>1999</b> , 63, 189-221	47
1875	Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene. <b>1999</b> , 96, 4378-83	40
1874	Benzo[a]pyrene activates the human p53 gene through induction of nuclear factor kappaB activity. <b>1999</b> , 274, 35240-6	72
1873	Mechanisms of G2 arrest in response to overexpression of p53. <b>1999</b> , 10, 3607-22	154
1872	Increased levels of E2F-1-dependent DNA binding activity after UV- or gamma-irradiation. <b>1999</b> , 27, 491-5	66
1871	Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. <b>1999</b> , 96, 424-8	490
1870	Reduced expression of the CDK inhibitor p27(KIP1) in rat two-stage bladder carcinogenesis and its association with expression profiles of p21(WAF1/Cip1) and p53. <b>1999</b> , 20, 1697-708	10
1869	DNA photodamage stimulates melanogenesis and other photoprotective responses. <b>1999</b> , 4, 35-40	125
1868	Induction of p53-dependent, insulin-like growth factor-binding protein-3-mediated apoptosis in glioblastoma multiforme cells by a protein kinase Calpha antisense oligonucleotide. <b>1999</b> , 55, 396-402	60
1867	Role for p300 in stabilization of p53 in the response to DNA damage. <b>1999</b> , 274, 1883-6	77
1866	Structure and function in the p53 family. <b>1999</b> , 6, 1169-73	92
1865	p53 suppresses the activation of the Bcl-2 promoter by the Brn-3a POU family transcription factor. <b>1999</b> , 274, 15237-44	117
1864	Use of UvrABC nuclease to quantify benzo[a]pyrene diol epoxide-DNA adduct formation at methylated versus unmethylated CpG sites in the p53 gene. <b>1999</b> , 20, 1085-9	29
1863	Intestinal tumorigenesis in the Apc1638N mouse treated with aspirin and resistant starch for up to 5 months. <b>1999</b> , 20, 805-10	51
1862	An unexpected role for p53 in augmenting SV40 large T antigen-mediated tumorigenesis. <b>1999</b> , 380, 203-11	20
1861	Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators. <b>1999</b> , 380, 879-87	63
1860	Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer. <b>1999</b> , 52, 555-68	70
1859	aHIF: a natural antisense transcript overexpressed in human renal cancer and during hypoxia. <b>1999</b> , 91, 143-51	191

1858	Comparative analysis of p73 and p53 regulation and effector functions. <b>1999</b> , 147, 823-30	67
1857	Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. <b>1999</b> , 190, 411-21	98
1856	De novo programmed cell death in oral cancer. <b>1999</b> , 34, 241-9	40
1855	hMutSalpha- and hMutLalpha-dependent phosphorylation of p53 in response to DNA methylator damage. <b>1999</b> , 96, 12384-8	146
1854	Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. <b>1999</b> , 96, 14973-7	361
1853	Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. <b>1999</b> , 96, 3077-80	296
1852	Mechanisms of hypoxia-induced endothelial cell death. Role of p53 in apoptosis. <b>1999</b> , 274, 8039-45	121
1851	Transcriptional activation of the human glutathione peroxidase promoter by p53. <b>1999</b> , 274, 12061-6	188
1850	Rearrangement in the Coding and 5' Region of P53 Gene in Human Oral Tumors. <b>1999</b> , 48, 305-309	3
1849	p53 as a target for improved cancer therapy. <b>1999</b> , 3, 347-353	2
1848	Increased bax expression is associated with cell death induced by ganciclovir in a herpes thymidine kinase gene-expressing glioma cell line. <b>1999</b> , 10, 679-88	29
1847	Helicobacter pylori induces apoptosis in gastric mucosa through an upregulation of Bax expression in humans. <b>1999</b> , 34, 375-83	60
1846	The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2. <b>1999</b> , 96, 14801-6	122
1845	Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. <b>1999</b> , 274, 16531-5	88
1844	3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). <b>1999</b> , 274, 21926-31	299
1843	Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor. <b>1999</b> , 96, 11693-5	126
1842	Mutually compensatory mutations during evolution of the tetramerization domain of tumor suppressor p53 lead to impaired hetero-oligomerization. <b>1999</b> , 96, 3595-9	62
1841	Activation of the cell death program by nitric oxide involves inhibition of the proteasome. <b>1999</b> , 274, 19581-6	92

1840	c-Abl neutralizes the inhibitory effect of Mdm2 on p53. <b>1999</b> , 274, 8371-4	82
1839	A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain. <b>1999</b> , 274, 32699-703	96
1838	Regulation of p53 expression by thymidylate synthase. <b>1999</b> , 96, 3769-74	101
1837	p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. <b>1999</b> , 274, 18709-14	123
1836	Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. <b>1999</b> , 96, 3993-8	134
1835	Role of human Cds1 (Chk2) kinase in DNA damage checkpoint and its regulation by p53. <b>1999</b> , 274, 31463-7	72
1834	Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells. <b>1999</b> , 274, 11022-9	65
1833	Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53. <b>1999</b> , 274, 17003-10	43
1832	p53-induced DNA bending and twisting: p53 tetramer binds on the outer side of a DNA loop and increases DNA twisting. <b>1999</b> , 96, 1875-80	106
1831	High expression of MDM2 protein and low rate of p21(WAF1/CIP1) expression in SCID mice Epstein Barr virus-induced lymphoproliferation. <b>1999</b> , 47, 1315-22	4
1830	Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints. <b>1999</b> , 96, 13369-74	151
1829	Mitogen-activated protein kinase is involved in the degradation of p53 protein in the bryostatins-1-induced differentiation of the acute promyelocytic leukemia NB4 cell line. <b>1999</b> , 274, 1677-82	29
1828	Molecular evolution of the thermosensitive PAb1620 epitope of human p53 by DNA shuffling. <b>1999</b> , 274, 28042-9	21
1827	The molecular basis of asbestos induced lung injury. <b>1999</b> , 54, 638-52	240
1826	P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. <b>1999</b> , 96, 6937-41	477
1825	p53 and human cancer: the first ten thousand mutations. <b>2000</b> , 77, 81-137	675
1824	A 40-kDa NF1-like protein, not YY1, binds to the rat p53 promoter for transactivation in various rat organs. <b>1999</b> , 77, 209-214	7
1823	Infection with vaccinia virus alters regulation of cell cycle progression. <b>1999</b> , 18, 837-43	23

1822	Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. <b>1999</b> , 99, 1656-9	109
1821	Infection and atherosclerosis: emerging mechanistic paradigms. <b>1999</b> , 100, e20-8	324
1820	Cadmium induces conformational modifications of wild-type p53 and suppresses p53 response to DNA damage in cultured cells. <b>1999</b> , 274, 31663-70	139
1819	CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. <b>1999</b> , 274, 1879-82	150
1818	Inhibition of hTAFII32-binding implicated in the transcriptional repression by central regions of mutant p53 proteins. <b>1999</b> , 274, 7748-55	2
1817	Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. <b>1999</b> , 274, 34924-31	86
1816	Thioredoxin-dependent redox regulation of p53-mediated p21 activation. <b>1999</b> , 274, 35809-15	312
1815	Identification and classification of p53-regulated genes. <b>1999</b> , 96, 14517-22	386
1814	The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. <b>1999</b> , 146, 917-28	327
1813	Physical and functional interaction between p53 and the Werner's syndrome protein. <b>1999</b> , 274, 29463-9	138
1812	One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. <b>1999</b> , 274, 33747-56	57
1811	Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis. <b>1999</b> , 96, 3092-7	119
1810	p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. <b>1999</b> , 274, 12229-35	231
1809	Recruitment of ATM protein to double strand DNA irradiated with ionizing radiation. <b>1999</b> , 274, 25571-5	91
1808	Molecular and cellular correlates of methotrexate response in childhood acute lymphoblastic leukemia. <b>1999</b> , 35, 1-20	7
1807	Novel anticancer drug discovery. <b>1999</b> , 3, 500-9	133
1806	The PIK-related kinases intercept conventional signaling pathways. <b>1999</b> , 6, R129-36	56
1805	Influence of p53 on herpes simplex virus type 1 vectors for cancer gene therapy. <b>1999</b> , 3, 34-48	5

1804	SV40-immortalized human keratinocytes as an in vitro model system for studying environmental carcinogens. <b>1999</b> , 44, 7-16	
1803	Rôles de P53 dans le cycle cellulaire, l'apoptose et le cancer. <b>1999</b> , 1999, 35-42	1
1802	'Loop' domain deletional mutant of Bcl-xL is as effective as p29Bcl-xL in inhibiting radiation-induced cytosolic accumulation of cytochrome c (cyt c), caspase-3 activity, and apoptosis. <b>1999</b> , 43, 423-30	8
1801	P53 deletion is not a frequent event in multiple myeloma. <b>1999</b> , 106, 717-9	58
1800	Expression of Bcl-2 and Bax in oligodendrogliomas and their relationship to apoptosis. <b>1999</b> , 25, 400-7	4
1799	Role of Pax-5 in the regulation of a mid-hindbrain organizer's activity. <b>1999</b> , 41, 59-72	190
1798	Molecular mechanisms of ionizing radiation-induced apoptosis. <b>1999</b> , 77, 263-71	102
1797	Thymidine dinucleotide mimics the effect of solar simulated irradiation on p53 and p53-regulated proteins. <b>1999</b> , 112, 25-31	49
1796	Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. <b>1999</b> , 113, 1099-105	325
1795	Hereditary stability and variation in evolution and development. <b>1999</b> , 1, 113-22	8
1794	Inhibition of telomerase limits the growth of human cancer cells. <b>1999</b> , 5, 1164-70	883
1793	DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage. <b>1999</b> , 400, 81-3	120
1792	DNA protection by stress-induced biocrystallization. <b>1999</b> , 400, 83-5	299
1791	Chronic Ethanol-Initiated Apoptosis in Hepatocytes Is Induced by Changes in Membrane Biogenesis and Intracellular Transport. <b>1999</b> , 23, 334-343	13
1790	p53 tumor suppressor gene mutations in transformed cutaneous T-cell lymphoma: a study of 12 cases. <b>1999</b> , 26, 369-78	28
1789	Apoptosis: a two-edged sword in aging. <b>1999</b> , 887, 1-11	43
1788	Tumor cells utilize multiple pathways to down-modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis. <b>1999</b> , 887, 150-63	32
1787	Homologous recombination between heterologs during repair of a double-strand break. Suppression of translocations in normal cells. <b>1999</b> , 886, 183-6	9

1786	Activation of caspases in p53-induced transactivation-independent apoptosis. <b>1999</b> , 90, 180-7	30
1785	Human p53-p51 (p53-related) fusion protein: a potent BAX transactivator. <b>1999</b> , 90, 596-9	5
1784	Mutant mice live longer. <b>1999</b> , 402, 243, 245	15
1783	Molten rocks in motion. <b>1999</b> , 402, 245-247	2
1782	p53 inhibition by the LANA protein of KSHV protects against cell death. <b>1999</b> , 402, 889-94	578
1781	Folding by association. <b>1999</b> , 6, 99-102	29
1780	Mechanism of folding and assembly of a small tetrameric protein domain from tumor suppressor p53. <b>1999</b> , 6, 191-8	93
1779	The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. <b>1999</b> , 5, 335-9	228
1778	p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells. <b>1999</b> , 6, 271-80	54
1777	Apoptosis at the time of embryo implantation in mouse and rat. <b>1999</b> , 6, 533-45	103
1776	Role for cyclin D1 in UVC-induced and p53-mediated apoptosis. <b>1999</b> , 6, 565-9	28
1775	The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer. <b>1999</b> , 6, 291-301	25
1774	Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells. <b>1999</b> , 6, 428-36	24
1773	Adenovirus lacking the 19-kDa and 55-kDa E1B genes exerts a marked cytotoxic effect in human malignant cells. <b>1999</b> , 6, 554-63	21
1772	NIH 3T3 cells malignantly transformed by mot-2 show inactivation and cytoplasmic sequestration of the p53 protein. <b>1999</b> , 9, 261-9	38
1771	p73 mutations and expression in adult de novo acute myelogenous leukemia. <b>1999</b> , 13, 985-90	25
1770	PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. <b>1999</b> , 18, 127-37	191
1769	Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. <b>1999</b> , 18, 477-85	368

1768	Surface plasmon resonance measurements reveal stable complex formation between p53 and DNA polymerase alpha. <b>1999</b> , 18, 769-74	31
1767	Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. <b>1999</b> , 18, 551-7	74
1766	Inhibition of RNA polymerase II as a trigger for the p53 response. <b>1999</b> , 18, 583-92	246
1765	The bovine papillomavirus type 1 E6 oncoprotein sensitizes cells to tumor necrosis factor alpha-induced apoptosis. <b>1999</b> , 18, 607-15	10
1764	Phosphorylation of the DNA repair protein APE/REF-1 by CKII affects redox regulation of AP-1. <b>1999</b> , 18, 1033-40	92
1763	p53 represses ribosomal gene transcription. <b>1999</b> , 18, 1119-24	127
1762	MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice. <b>1999</b> , 18, 1419-34	32
1761	Phosphorylation of p53 protein in response to ionizing radiation occurs at multiple sites in both normal and DNA-PK deficient cells. <b>1999</b> , 18, 1521-7	20
1760	hRAD17, a structural homolog of the Schizosaccharomyces pombe RAD17 cell cycle checkpoint gene, stimulates p53 accumulation. <b>1999</b> , 18, 1689-99	18
1759	Inactivation of the p53-homologue p73 by the mdm2-oncoprotein. <b>1999</b> , 18, 2101-6	135
1758	p53 inhibits entry into mitosis when DNA synthesis is blocked. <b>1999</b> , 18, 283-95	66
1757	p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. <b>1999</b> , 18, 1921-34	112
1756	Definition of a p53 transactivation function-deficient mutant and characterization of two independent p53 transactivation subdomains. <b>1999</b> , 18, 2405-10	63
1755	c-Myc and E1A induced cellular sensitivity to activated NK cells involves cytotoxic granules as death effectors. <b>1999</b> , 18, 2181-8	11
1754	Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. <b>1999</b> , 18, 2189-99	65
1753	The double-stranded RNA activated protein kinase PKR physically associates with the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 in vitro. <b>1999</b> , 18, 2690-702	179
1752	p19ARF prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts. <b>1999</b> , 18, 2718-27	31
1751	Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. <b>1999</b> , 18, 3205-12	175

1750	An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. <b>1999</b> , 18, 3199-204	156
1749	p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. <b>1999</b> , 18, 3633-42	75
1748	Effect of transition metals on binding of p53 protein to supercoiled DNA and to consensus sequence in DNA fragments. <b>1999</b> , 18, 3617-25	55
1747	Modulations of glucocorticoid-induced apoptosis linked to the p53 deletion and to the apoptosis susceptibility gene Rapop1 (Radiation-induced apoptosis 1). <b>1999</b> , 18, 4282-5	9
1746	Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. <b>1999</b> , 18, 3810-20	86
1745	Mdm2 binds p73 alpha without targeting degradation. <b>1999</b> , 18, 3923-9	188
1744	p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome. <b>1999</b> , 18, 3970-8	30
1743	Promoter specificity and stability control of the p53-related protein p73. <b>1999</b> , 18, 4171-81	130
1742	Cell cycle arrest and morphological alterations following microinjection of NIH3T3 cells with Pur alpha. <b>1999</b> , 18, 4254-61	51
1741	New p73 variants with altered C-terminal structures have varied transcriptional activities. <b>1999</b> , 18, 4993-8	128
1740	Papillomavirus E2 induces p53-independent apoptosis in HeLa cells. <b>1999</b> , 18, 4538-45	72
1739	Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis. <b>1999</b> , 18, 4689-98	83
1738	Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant. <b>1999</b> , 18, 4699-709	19
1737	Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants. <b>1999</b> , 18, 4546-53	51
1736	Control of E2F activity by p21Waf1/Cip1. <b>1999</b> , 18, 5381-92	121
1735	Maintenance of genomic integrity by p53: complementary roles for activated and non-activated p53. <b>1999</b> , 18, 7706-17	140
1734	RNA synthesis block by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. <b>1999</b> , 18, 5765-72	59
1733	The role of wild-type p53 in the differentiation of primary hemopoietic and muscle cells. <b>1999</b> , 18, 5831-5	25



1732	wt p53 dependent expression of a membrane-associated isoform of adenylate kinase. <b>1999</b> , 18, 5879-88	47
1731	Mutational analysis of p51A/TAp63gamma, a p53 homolog, in non-small cell lung cancer and breast cancer. <b>1999</b> , 18, 3761-5	50
1730	Down-regulation of the stathmin/Op18 and FKBP25 genes following p53 induction. <b>1999</b> , 18, 5954-8	115
1729	Regulation of p53 stability. <b>1999</b> , 18, 7637-43	346
1728	Regulation of p53 in response to DNA damage. <b>1999</b> , 18, 7644-55	742
1727	Alternative pathways for the extension of cellular life span: inactivation of p53/pRb and expression of telomerase. <b>1999</b> , 18, 7676-80	48
1726	Induction of the TRAIL receptor KILLER/DR5 in p53-dependent apoptosis but not growth arrest. <b>1999</b> , 18, 6411-8	93
1725	Testicular wild-type p53 expression in transgenic mice induces spermiogenesis alterations ranging from differentiation defects to apoptosis. <b>1999</b> , 18, 6521-30	36
1724	Cytokine response gene 6 induces p21 and regulates both cell growth and arrest. <b>1999</b> , 18, 6573-82	53
1723	Molecular interactions between telomerase and the tumor suppressor protein p53 in vitro. <b>1999</b> , 18, 6785-94	72
1722	Ectopic expression of human p53 inhibits entry into S phase and induces apoptosis in the Drosophila eye imaginal disc. <b>1999</b> , 18, 6767-75	44
1721	ATM: a mediator of multiple responses to genotoxic stress. <b>1999</b> , 18, 6135-44	235
1720	The cellular response to p53: the decision between life and death. <b>1999</b> , 18, 6145-57	488
1719	Inhibition of the putative tumor suppressor gene TIMP-3 by tumor-derived p53 mutants and wild type p53. <b>1999</b> , 18, 7608-15	34
1718	Gamma-rays-induced death of human cells carrying mutations of BRCA1 or BRCA2. <b>1999</b> , 18, 7334-42	122
1717	Identification of a novel mouse p53 target gene DDA3. <b>1999</b> , 18, 7765-74	38
1716	p53 induces TAP1 and enhances the transport of MHC class I peptides. <b>1999</b> , 18, 7740-7	74
1715	DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis. <b>1999</b> , 18, 7883-99	353

1714	Twenty years of p53 research: structural and functional aspects of the p53 protein. <b>1999</b> , 18, 7621-36	505
1713	p53 status of newly established acute myeloid leukaemia cell lines. <b>1999</b> , 79, 407-15	19
1712	Prognostic role of p27Kip1 and apoptosis in human breast cancer. <b>1999</b> , 79, 1572-8	61
1711	Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland. <b>1999</b> , 80, 1445-52	17
1710	The expression of p73 is increased in lung cancer, independent of p53 gene alteration. <b>1999</b> , 80, 1623-9	69
1709	Proteolytic cleavage of p53 mutants in response to mismatched DNA. <b>1999</b> , 81, 212-8	8
1708	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature. <b>1999</b> , 2, 227-233	22
1707	Esthesioneuroblastoma: reflections of a 21-year experience. <b>1999</b> , 109, 1539-43	118
1706	Improved nonisotopic PCR-SSCP for screening of p53 mutations. <b>1999</b> , 32, 233-5	4
1705	HPV16 E6 oncoprotein inhibits apoptosis induced during serum-calcium differentiation of foreskin human keratinocytes. <b>1999</b> , 257, 383-96	36
1704	Expression of the HPV E7 oncoprotein mimics but does not evoke a p53-dependent cellular DNA damage response pathway. <b>1999</b> , 258, 406-14	44
1703	The interaction between p53 and papillomaviruses. <b>1999</b> , 9, 387-95	33
1702	Tumor suppressor genes in rodent lung carcinogenesis-mutation of p53 does not appear to be an early lesion in lung tumor pathogenesis. <b>1999</b> , 156, 70-7	10
1701	Cell cycle checkpoints as therapeutic targets. <b>1999</b> , 4, 389-400	10
1700	Generation of p53 suppressor peptide from the fragment of p53 protein. <b>1999</b> , 25, 115-28	8
1699	The biological response of MCF7 breast cancer cells to proteasome inhibition or gamma-radiation is unrelated to the level of p53 induction. <b>1999</b> , 4, 99-107	2
1698	Apoptin-induced apoptosis: a review. <b>1999</b> , 4, 317-9	5
1697	A portrait of the Bcl-2 protein family: life, death, and the whole picture. <b>1999</b> , 19, 365-77	37

1696	Protein kinase CK2-dependent regulation of p53 function: Evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable. <b>1999</b> , 191, 187-199	31
1695	Differential binding of NF1 transcription factor to P53 gene promoter and its depletion in human breast tumours. <b>1999</b> , 26, 223-30	10
1694	Bcl-2, survivin and variant CD44 v7-v10 are downregulated and p53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. <b>1999</b> , 202, 53-61	60
1693	p53 Family members p63 and p73 are SAM domain-containing proteins. <b>1999</b> , 8, 1708-10	128
1692	Change in oligomerization specificity of the p53 tetramerization domain by hydrophobic amino acid substitutions. <b>1999</b> , 8, 1773-9	16
1691	p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. <b>1999</b> , 18, 6027-36	385
1690	In vitro transcription assay with the purified 40kDa NF1-like protein binding to the rat p53 promoter. <b>1999</b> , 47, 427-34	2
1689	Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. <b>1999</b> , 18, 22-7	546
1688	Excess beta-catenin promotes accumulation of transcriptionally active p53. <b>1999</b> , 18, 3054-63	187
1687	Increased apoptosis induction by 121F mutant p53. <b>1999</b> , 18, 4424-37	94
1686	The promoter of a novel human papillomavirus (HPV77) associated with skin cancer displays UV responsiveness, which is mediated through a consensus p53 binding sequence. <b>1999</b> , 18, 5359-69	72
1685	Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. <b>1999</b> , 18, 5609-21	184
1684	Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1. <b>1999</b> , 18, 6462-71	433
1683	A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking. <b>1999</b> , 18, 1660-72	557
1682	Oncogenic Ras inhibits Fas ligand-mediated apoptosis by downregulating the expression of Fas. <b>1999</b> , 18, 1824-31	126
1681	Structure, Recognition, and Processing of Cisplatin-DNA Adducts. <b>1999</b> , 99, 2467-98	2456
1680	p53 independent, region-specific epithelial apoptosis is induced in the rat epididymis by deprivation of luminal factors. <b>1999</b> , 53, 188-97	43
1679	Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. <b>1999</b> , 18, 6845-54	546

1678	Viruses and apoptosis. <b>1999</b> , 53, 577-628	602
1677	Introduction: p53--the first twenty years. <b>1999</b> , 55, 9-11	107
1676	The dual role model for p53 in maintaining genomic integrity. <b>1999</b> , 55, 12-27	111
1675	Mechanisms of p53-mediated apoptosis. <b>1999</b> , 55, 28-37	258
1674	p53 in embryonic development: maintaining a fine balance. <b>1999</b> , 55, 38-47	132
1673	The role of p53 in tumour suppression: lessons from mouse models. <b>1999</b> , 55, 48-63	161
1672	Clinical implications of p53 mutations. <b>1999</b> , 55, 64-75	180
1671	Covalent and noncovalent modifiers of the p53 protein. <b>1999</b> , 55, 76-87	118
1670	Early events in the formation of a tissue structure from dispersed bovine adrenocortical cells following transplantation into scid mice. <b>1999</b> , 77, 666-76	20
1669	Effect on different mutant p53 on cell sensitivity to cytostatics. <b>1999</b> , 127, 293-295	
1668	p53 and the CNS: tumors and developmental abnormalities. <b>1999</b> , 19, 61-77	18
1667	Genetic abnormalities involved in the pathogenesis of gallbladder carcinoma. <b>1999</b> , 6, 237-44	79
1666	p53 gene mutations and overexpression of p53 product in cancerous and noncancerous biliary epithelium in patients with pancreaticobiliary maljunction. <b>1999</b> , 6, 286-93	28
1665	The presence of transcription factors in chicken albumin, yolk and blastoderm. <b>1999</b> , 35, 357-63	4
1664	Relationship of p21(WAF1/CIP1/SDI1) to cell proliferation in primary cultures of adrenocortical cells. <b>1999</b> , 22, 39-44	
1663	DNA damage and DNA damage-inducible protein Gadd45 following ischemia in the P7 neonatal rat. <b>1999</b> , 116, 133-40	26
1662	Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs. <b>1999</b> , 134, 510-21	73
1661	Genetic evolutionary staging of early non-small cell lung cancer: the P53 --> HER-2/NEU --> ras sequence. <b>1999</b> , 118, 259-67	15

1660	New approaches to understanding p53 gene tumor mutation spectra. <b>1999</b> , 431, 199-209	154
1659	5-methylcytosine at HpaII sites in p53 is not hypermutable after UVC irradiation. <b>1999</b> , 431, 93-103	8
1658	Tumors in tadpoles: the <i>Xenopus</i> embryo as a model system for the study of tumorigenesis. <b>1999</b> , 15, 385-8	16
1657	Decreased thymosin beta4 in apoptosis induced by a variety of antitumor drugs. <b>1999</b> , 57, 1105-11	33
1656	Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells. <b>1999</b> , 117, 99-115	21
1655	Aberrations of cell cycle and cell death in normal development of the chick embryo growth plate. <b>1999</b> , 108, 227-38	11
1654	p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. <b>1999</b> , 23, 871-80	30
1653	p53 gene deletion and trisomy 12 in hairy cell leukemia and its variant. <b>1999</b> , 23, 1041-5	37
1652	The p53 family: same response, different signals?. <b>1999</b> , 5, 387-92	60
1651	Cell proliferation and apoptosis. <b>1999</b> , 11, 745-52	160
1650	Sources of bias in the detection and reporting of p53 mutations in human cancer: analysis of the IARC p53 mutation database. <b>1999</b> , 14, 229-33	15
1649	Apoptosis-associated proteins and the development of oral squamous cell carcinoma. <b>1999</b> , 35, 77-85	47
1648	Cell cycle proteins and the development of oral squamous cell carcinoma. <b>1999</b> , 35, 333-42	85
1647	p53 does not control the spindle assembly cell cycle checkpoint but mediates G1 arrest in response to disruption of microtubule system. <b>1999</b> , 23, 323-34	26
1646	Lymphoma development in Sjögren's syndrome: novel p53 mutations. <b>1999</b> , 42, 1466-72	70
1645	Induction of apoptosis and differentiation in neuroblastoma and astrocytoma cells by the overexpression of Bin1, a novel myc interacting protein. <b>1999</b> , 74, 313-322	34
1644	Regulation of prostate cancer cell division by glucose. <b>1999</b> , 180, 431-8	54
1643	"p53: Twenty Years On" in Trieste, Italy, May 20-22, 1999. <b>1999</b> , 181, 371-4	1

1642	Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer. <b>1999</b> , 25, 65-9	5
1641	Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. <b>1999</b> , 25, 91-6	64
1640	Patterns of genetic alterations in pancreatic cancer: a pooled analysis. <b>1999</b> , 33, 111-22	11
1639	Heterozygous Ap <sup>rt</sup> mouse model: Detection and study of a broad range of autosomal somatic mutations in vivo. <b>1999</b> , 34, 84-89	9
1638	Alteration of G1 cell-cycle protein expression and induction of p53 but not p21/waf1 by the DNA-modifying carcinogen 2-acetylaminofluorene in growth-stimulated hepatocytes in vitro. <b>1999</b> , 24, 36-46	8
1637	Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53. <b>1999</b> , 24, 197-208	14
1636	Cdkn2a encodes functional variation of p16INK4a but not p19ARF, which confers selection in mouse lung tumorigenesis. <b>1999</b> , 25, 92-8	18
1635	Cleavage of double-stranded copy RNA by RNase 1 and RNase T1 provides a robust means to detect p53 gene mutations in clinical specimens. <b>1999</b> , 20, 1149-61	9
1634	Amplified CDK2 and cdc2 activities in primary colorectal carcinoma. <b>1999</b> , 85, 546-553	23
1633	p53 Protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. <b>1999</b> , 85, 1293-1299	51
1632	p53 Alteration in regional lymph node metastases from prostate carcinoma. <b>1999</b> , 85, 2455-2459	33
1631	Influence of p53 status on prognosis in preoperatively irradiated rectal carcinoma. <b>1999</b> , 85, 2541-2548	36
1630	Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells. <b>1999</b> , 80, 930-4	34
1629	Functional analyses of a unique p53 germline mutant (Y236delta) associated with a familial brain tumor syndrome. <b>1999</b> , 82, 17-22	5
1628	A functional and quantitative mutational analysis of p53 mutations in yeast indicates strand biases and different roles of mutations in DMBA- and BBN-induced tumors in rats. <b>1999</b> , 83, 700-5	5
1627	c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. <b>1999</b> , 84, 562-7	46
1626	Bivariate analysis of the p53 pathway to evaluate Ad-p53 gene therapy efficacy. <b>1999</b> , 38, 201-213	16
1625	Cellular manifestations of human papillomavirus infection in the oral mucosa. <b>1999</b> , 71, 10-5	32

1624	p53 and Bax: putative death factors in taste cell turnover. <b>1999</b> , 413, 168-80	34
1623	The p53 pathway. <b>1999</b> , 187, 112-26	1128
1622	Insights into cancer from transgenic mouse models. <b>1999</b> , 187, 43-60	93
1621	Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer. <b>1999</b> , 187, 8-18	131
1620	Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. <b>1999</b> , 187, 237-41	36
1619	Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice. <b>1999</b> , 188, 322-8	39
1618	Strategies for enhancing viral-based gene therapy using ionizing radiation. <b>1999</b> , 7, 261-9	15
1617	Overexpression of the human manganese superoxide dismutase (MnSOD) transgene in subclones of murine hematopoietic progenitor cell line 32D cl 3 decreases irradiation-induced apoptosis but does not alter G2/M or G1/S phase cell cycle arrest. <b>1999</b> , 7, 331-42	38
1616	Role for p53 in the recovery of transcription and protection against apoptosis induced by ultraviolet light. <b>1999</b> , 1, 276-84	46
1615	Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. <b>1999</b> , 286, 2528-31	741
1614	How does leflunomide modulate the immune response in rheumatoid arthritis?. <b>1999</b> , 12, 301-15	15
1613	Differential regulation of E2F transcription factors by p53 tumor suppressor protein. <b>1999</b> , 18, 911-22	9
1612	Growth arrest of melanoma cells is differentially regulated by contact inhibition and serum deprivation. <b>1999</b> , 18, 357-67	32
1611	Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene. <b>1999</b> , 10, 579-90	63
1610	Function and sequence analyses of tumor suppressor gene p53 of CHO.K1 cells. <b>1999</b> , 18, 315-21	33
1609	The role of CD95 system in chemotherapy. <b>1999</b> , 2, 85-90	12
1608	Free radicals and reactive oxygen species in programmed cell death. <b>1999</b> , 52, 451-63	45
1607	The difference between p53 mutation frequency in haematological and non-haematological malignancies: possible explanations. <b>1999</b> , 53, 326-8	3

1606	Radiation inducible DNA repair processes in eukaryotes. <b>1999</b> , 81, 161-71	29
1605	p53 gene mutations and p21 protein expression induced independently of p53, by TGF-beta and gamma-rays in squamous cell carcinoma cells. <b>1999</b> , 35, 278-83	14
1604	Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. <b>1999</b> , 35, 1258-63	122
1603	The INK4A/ARF locus and its two gene products. <b>1999</b> , 9, 22-30	442
1602	Cellular response to DNA damage. Link between p53 and DNA-PK. <b>1999</b> , 322, 113-20	6
1601	Human papilloma virus type 16 E6 gene expression in oral exophytic epithelial lesions as detected by in situ rtPCR. <b>1999</b> , 87, 197-208	20
1600	RB regulates the stability and the apoptotic function of p53 via MDM2. <b>1999</b> , 3, 181-93	227
1599	Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. <b>1999</b> , 3, 579-91	321
1598	Implications de l'apoptose en pathologie. <b>1999</b> , 14, 16-31	
1597	p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas. <b>1999</b> , 263, 173-6	30
1596	NMDA receptor mediated Ca <sup>2+</sup> responses in neurons differentiated from p53 <sup>-/-</sup> immortalized Murine neural stem cells. <b>1999</b> , 264, 165-7	9
1595	Comparative analysis of invertebrate Tc6 sequences that resemble the vertebrate V(D)J recombination signal sequences (RSS). <b>1999</b> , 36, 481-8	4
1594	Sensitive detection of the binding of E2F to its promoter by exonuclease III- and BssHII-protection PCR assays. <b>1999</b> , 39, 85-92	4
1593	Identification of a novel gene encoding a p53-associated protein. <b>1999</b> , 235, 93-101	44
1592	Mesotheliomas induced in rats by the fibrous mineral erionite are independent from p53 alterations. <b>1999</b> , 147, 55-61	4
1591	Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin. <b>1999</b> , 65, 167-75	66
1590	The Molecular Basis of Canine Melanoma: Pathogenesis and Trends in Diagnosis and Therapy. <b>1999</b> , 13, 163-174	59
1589	The Molecular and Cellular Basis of Radiosensitivity: Implications for Understanding How Normal Tissues and Tumors Respond to Therapeutic Radiation. <b>1999</b> , 17, 56-72	84



1588	Gene therapy for lung cancer. <b>1999</b> , 23, 191-207		10
1587	Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. <b>1999</b> , 18, 2149-55		106
1586	Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death. <b>1999</b> , 18, 4681-8		44
1585	The ataxia-telangiectasia related protein ATR mediates DNA-dependent phosphorylation of p53. <b>1999</b> , 18, 3989-95		110
1584	Mechanism of action for leflunomide in rheumatoid arthritis. <b>1999</b> , 93, 198-208		219
1583	Apoptosis of retinal ganglion cells in glaucoma: an update of the molecular pathways involved in cell death. <b>1999</b> , 43 Suppl 1, S151-61		159
1582	Simian virus 40-transformed metallothionein null cells showed increased sensitivity to cadmium but not to zinc, copper, mercury or nickel. <b>1999</b> , 64, PL145-50		22
1581	Cardiomyocyte apoptosis with enhanced expression of P53 and Bax in right ventricle after pulmonary arterial banding. <b>1999</b> , 65, 925-33		34
1580	Transcriptional activation of the human S100A2 promoter by wild-type p53. <b>1999</b> , 445, 265-8		55
1579	MDM2 interacts with MDMX through their RING finger domains. <b>1999</b> , 447, 5-9		243
1578	Induction of p53 dependent apoptosis upon overexpression of a nuclear protein tyrosine phosphatase. <b>1999</b> , 453, 308-12		23
1577	Specific loss of chondromodulin-I gene expression in chondrosarcoma and the suppression of tumor angiogenesis and growth by its recombinant protein in vivo. <b>1999</b> , 458, 436-40		52
1576	G1 versus G2 cell cycle arrest after adriamycin-induced damage in mouse Swiss3T3 cells. <b>1999</b> , 461, 299-305		45
1575	p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. <i>Cell</i> , <b>1999</b> , 97, 527-38	56.2	812
1574	Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. <i>Cell</i> , <b>1999</b> , 99, 143-53	56.2	577
1573	Nitric oxide and cell death. <b>1999</b> , 1411, 401-14		297
1572	Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines. <b>1999</b> , 1, 80-9		13
1571	Lens fibre cell differentiation - A link with apoptosis?. <b>1999</b> , 31, 163-83		96

1570	Endothelial cells regulate the proliferation of monocytes in vitro. <b>1999</b> , 147, 25-32	7
1569	Rearrangement in the coding and 5' region of p53 gene in human oral tumors. <b>1999</b> , 48, 305-9	3
1568	Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. <b>1999</b> , 18, 4438-45	130
1567	Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. <b>1999</b> , 18, 7002-10	356
1566	Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. <b>1999</b> , 18, 1805-14	275
1565	DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. <b>1999</b> , 18, 1815-23	236
1564	Regulation of the p53 tumor suppressor protein. <b>1999</b> , 274, 36031-4	434
1563	Mutation and expression of the p51 gene in human lung cancer. <b>1999</b> , 1, 71-9	18
1562	p53-independent inhibition of proliferation and p21(WAF1/Cip1)-modulated induction of cell death by the antioxidants N-acetylcysteine and vitamin E. <b>1999</b> , 1, 544-56	31
1561	GADD45 induction of a G2/M cell cycle checkpoint. <b>1999</b> , 96, 3706-11	522
1560	Biology of Marrow Stromal Cell Lines Derived from Long-Term Bone Marrow Cultures of Trp53-Deficient Mice. <b>1999</b> , 152, 29	11
1559	TP53 Tumor Suppressor Protein in Normal Human Fibroblasts Does Not Respond to 837 MHz Microwave Exposure. <b>1999</b> , 151, 710	9
1558	Differentiation-related changes in the cell cycle traverse. <b>1999</b> , 189, 1-58	55
1557	Apoptosis: definition, mechanisms, and relevance to disease. <b>1999</b> , 107, 489-506	248
1556	Presenilin overexpression arrests cells in the G1 phase of the cell cycle. Arrest potentiated by the Alzheimer's disease PS2(N141I)mutant. <b>1999</b> , 155, 135-44	57
1555	Different responses of epidermal and hair follicular cells to radiation correlate with distinct patterns of p53 and p21 induction. <b>1999</b> , 155, 1121-7	55
1554	Circadian variation in the expression of cell-cycle proteins in human oral epithelium. <b>1999</b> , 154, 613-22	136
1553	Safety and antitumor activity of recombinant soluble Apo2 ligand. <b>1999</b> , 104, 155-62	1732

1552	Overexpression of anti-apoptotic gene BAG-1 in human cervical cancer. <b>1999</b> , 247, 200-7	40
1551	Laminin 5 promotes activation and apoptosis of the T cells expressing alpha3beta1 integrin. <b>1999</b> , 247, 451-60	12
1550	UV radiation is a transcriptional inducer of p21(Cip1/Waf1) cyclin-kinase inhibitor in a p53-independent manner. <b>1999</b> , 248, 272-9	55
1549	Differential responses of proliferating versus quiescent cells to adriamycin. <b>1999</b> , 250, 131-41	69
1548	Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. <b>1999</b> , 251, 156-65	68
1547	Nuclear import of p53 during <i>Xenopus laevis</i> early development in relation to DNA replication and DNA repair. <b>1999</b> , 251, 46-56	14
1546	Involvement of cyclin-dependent kinase activities in CD437-induced apoptosis. <b>1999</b> , 252, 332-41	66
1545	Chromosome segregation and cancer. <b>1999</b> , 253, 308-14	4
1544	Accumulating active p53 in the nucleus by inhibition of nuclear export: a novel strategy to promote the p53 tumor suppressor function. <b>1999</b> , 253, 315-24	57
1543	HIF-1alpha and p53 promote hypoxia-induced delayed neuronal death in models of CNS ischemia. <b>1999</b> , 159, 65-72	95
1542	Guinea pig p53 mRNA: identification of new elements in coding and untranslated regions and their functional and evolutionary implications. <b>1999</b> , 58, 50-64	19
1541	Mouse Hus1, a homolog of the <i>Schizosaccharomyces pombe</i> hus1+ cell cycle checkpoint gene. <b>1999</b> , 59, 32-9	15
1540	Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. <b>1999</b> , 287, 821-8	557
1539	Cellular characterisation of p53 mutants with a single missense mutation in the beta-strand 326-333 and correlation of their cellular activities with in vitro properties. <b>1999</b> , 288, 891-7	14
1538	The RAD51 protein supports homologous recombination by an exchange mechanism in mammalian cells. <b>1999</b> , 289, 1231-8	64
1537	Preferential binding of tumor suppressor p53 to positively or negatively supercoiled DNA involves the C-terminal domain. <b>1999</b> , 292, 241-9	35
1536	DNA bending due to specific p53 and p53 core domain-DNA interactions visualized by electron microscopy. <b>1999</b> , 294, 1015-26	47
1535	Functional regulative pathways for p53, a protein of basic importance for the integrity of the cell genome. <b>1999</b> , 67, 93-9	2

1534	Effects of wild-type and mutated p53 and Id proteins on the induction of apoptosis by adenovirus E1A, c-Myc, Bax, and Nip3 in p53 null mouse cerebellum cells. <b>1999</b> , 255, 722-30	7
1533	Increased sensitivity of human colon cancer cells to DNA cross-linking agents after GRP78 up-regulation. <b>1999</b> , 257, 361-8	42
1532	The p38MAPK inhibitor SB203580 alleviates ultraviolet-induced phosphorylation at serine 389 but not serine 15 and activation of p53. <b>1999</b> , 261, 464-71	75
1531	Acetylucine chloromethyl ketone, an inhibitor of acylpeptide hydrolase, induces apoptosis of U937 cells. <b>1999</b> , 263, 139-42	19
1530	Mutations at position 277 modify the DNA-binding specificity of human p53 in vitro. <b>1999</b> , 263, 1-5	11
1529	Comparative gene expression profiling in response to p53 in a human lung cancer cell line. <b>1999</b> , 264, 891-5	6
1528	Abnormal accumulation of G2/M-phase cells from LEC strain rats after X-irradiation at S phase. <b>1999</b> , 61, 975-8	2
1527	Mutations in cancer genes of UV-induced skin tumors of hairless mice. <b>1999</b> , 9, S58-65	23
1526	Lack of p53-mediated G1 arrest in response to an environmental carcinogen. <b>1999</b> , 57, 258-64	25
1525	Adenovirus mediated p53 tumour suppressor gene therapy for human gastric cancer cells in vitro and in vivo. <b>1999</b> , 44, 366-71	33
1524	Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. <b>1999</b> , 13, 2490-501	368
1523	A role for MAPK/ERK in sympathetic neuron survival: protection against a p53-dependent, JNK-independent induction of apoptosis by cytosine arabinoside. <b>1999</b> , 19, 664-73	222
1522	Cancer predisposition in mutant mice defective in the XPC DNA repair gene. <b>1999</b> , 35, 37-52	18
1521	Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. <b>1999</b> , 13, 2658-69	648
1520	Chapter 8 Molecular progression of prostate cancer. <b>1999</b> , 3, 155-187	
1519	Centrosome replication in somatic cells: the significance of G1 phase. <b>2000</b> , 49, 251-66	
1518	Concerted regulation of wild-type p53 nuclear accumulation and activation by S100B and calcium-dependent protein kinase C. <b>1999</b> , 19, 7168-80	61
1517	p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. <b>1999</b> , 19, 1202-9	660

1516	New insights into the mechanism of inhibition of p53 by simian virus 40 large T antigen. <b>1999</b> , 19, 2746-53	56
1515	Transcription and growth regulatory functions of the HIN-200 family of proteins. <b>1999</b> , 19, 5833-8	103
1514	An ATP/ADP-dependent molecular switch regulates the stability of p53-DNA complexes. <b>1999</b> , 19, 7501-10	36
1513	Atm is dispensable for p53 apoptosis and tumor suppression triggered by cell cycle dysfunction. <b>1999</b> , 19, 3095-102	38
1512	Btf, a novel death-promoting transcriptional repressor that interacts with Bcl-2-related proteins. <b>1999</b> , 19, 4390-404	154
1511	CDC25A phosphatase is a target of E2F and is required for efficient E2F-induced S phase. <b>1999</b> , 19, 6379-95	292
1510	Metal ions as regulators of the conformation and function of the tumour suppressor protein p53: implications for carcinogenesis. <b>1999</b> , 58, 565-71	23
1509	Pharmacokinetics and Cerebrospinal Fluid Penetration of Daunorubicin, Idarubicin, and Their Metabolites in the Nonhuman Primate Model. <b>1999</b> , 21, 26-30	12
1508	p53-mediated regulation of proliferating cell nuclear antigen expression in cells exposed to ionizing radiation. <b>1999</b> , 19, 12-20	79
1507	Transcriptional cross talk between NF-kappaB and p53. <b>1999</b> , 19, 3485-95	520
1506	Regulation of p53 function and stability by phosphorylation. <b>1999</b> , 19, 1751-8	383
1505	The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation. <b>1999</b> , 19, 733-44	173
1504	Double-stranded-RNA-activated protein kinase PKR enhances transcriptional activation by tumor suppressor p53. <b>1999</b> , 19, 2475-84	124
1503	c-Myc overexpression uncouples DNA replication from mitosis. <b>1999</b> , 19, 5339-51	114
1502	p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells. <b>1999</b> , 19, 4825-31	37
1501	p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. <b>1999</b> , 19, 1438-49	365
1500	Thymidylate synthase protein and p53 mRNA form an in vivo ribonucleoprotein complex. <b>1999</b> , 19, 1582-94	80
1499	p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding. <b>1999</b> , 19, 1279-88	156

1498	The c-fos proto-oncogene is a target for transactivation by the p53 tumor suppressor. <b>1999</b> , 19, 2594-600	49
1497	Reversible tumorigenesis induced by deficiency of vasodilator-stimulated phosphoprotein. <b>1999</b> , 19, 3696-703	32
1496	Control of cell cycle progression by c-Jun is p53 dependent. <b>1999</b> , 13, 607-19	423
1495	Growth retardation, DNA repair defects, and lack of spermatogenesis in BRCA1-deficient mice. <b>1999</b> , 19, 7061-75	90
1494	Immunolocalization of Glutathione-Peroxidase (GSH-PO) in the Steroid-Producing Organs and Prostate.. <b>2000</b> , 33, 405-412	2
1493	Role of p53 in Growth Suppression by Bromodeoxyuridine in Human Gastric Cancer Cell Lines.. <b>2000</b> , 33, 429-437	
1492	Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts. <b>2000</b> , 14, 1490-1498	261
1491	The DNA damage checkpoint and human cancer. <b>2000</b> , 65, 489-98	17
1490	Proteasome inhibition by lipofuscin/ceroid during postmitotic aging of fibroblasts. <b>2000</b> , 14, 1490-8	209
1489	Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. <b>2000</b> , 14, 3102-14	431
1488	Malignancy: Tumor Suppressor Gene Aberrations in Acute Myelogenous Leukemia. <b>2000</b> , 5, 15-25	8
1487	Hepatitis B viral transactivator HBx alleviates p53-mediated repression of alpha-fetoprotein gene expression. <b>2000</b> , 275, 27806-14	48
1486	Focal adhesion kinase in cancer. <b>2000</b> , 4, 191-206	
1485	Ungelöste Probleme und Zukunftsperspektiven beim kolorektalen Karzinom. <b>2000</b> , 16, 273-279	
1484	Phosphorylation of human p53 on Thr-55. <b>2000</b> , 39, 9837-42	33
1483	Aging, immunity, and cancer. <b>2000</b> , 7, 513-22	45
1482	Stealth Properties Contribute to the Potent Action of Polycyclic Aromatic Hydrocarbon Carcinogens. <b>2000</b> , 16, 89-98	4
1481	Gene therapy for lung cancer. <b>2000</b> , 12, 138-42	3

1480	Does p53 status influence tumor response to anticancer therapies?. <b>2000</b> , 11, 419-32	49
1479	The tumour suppressor protein p53 can repress transcription of cyclin B. <b>2000</b> , 28, 4410-8	135
1478	Telomeres, telomerase, and cancer: life on the edge of genomic stability. <b>2000</b> , 12, 74-81	57
1477	Molecular aspects of multiple myeloma. <b>2000</b> , 11, 1217-28	55
1476	Serine/threonine-specific protein phosphatases and cancer. <b>2000</b> , 4, 581-608	3
1475	Der Tumorsuppressor p53 im Zentrum einer Strategie zur Linderung von Nebenwirkungen bei der Krebstherapie. <b>2000</b> , 112, 1838-1840	
1474	The Tumor Suppressor p53 in the Center of a Strategy Aiming at the Alleviation of Side Effects in Cancer Therapies. <b>2000</b> , 39, 1768-1770	4
1473	Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. <b>2000</b> , 89, 81-6	33
1472	Role of p53 in DNA strand break-induced apoptosis in organotypic slice culture from the mouse cerebellum. <b>2000</b> , 60, 450-7	27
1471	Cellular expression of MDM2 and p53 in childhood leukemias with poor prognosis. <b>2000</b> , 34, 117-24	17
1470	Transcriptional activation of tyrosinase and TRP-1 by p53 links UV irradiation to the protective tanning response. <b>2000</b> , 190, 39-46	81
1469	Molecular interactions in the Vogelstein model of colorectal carcinoma. <b>2000</b> , 190, 412-6	126
1468	p53 immunoexpression in non-malignant oral mucosa adjacent to oral squamous cell carcinoma: potential consequences for clinical management. <b>2000</b> , 191, 132-7	29
1467	Function, oligomerization, and conformation of tumor-associated p53 proteins with mutated C-terminus. <b>2000</b> , 76, 572-84	18
1466	Biochemical characterization of a nuclear factor that binds to NF1-like elements in the rat p53 promoter. <b>2000</b> , 78, 1-7	8
1465	Human papillomavirus type 16 E6 and HPV-16 E6/E7 sensitize human keratinocytes to apoptosis induced by chemotherapeutic agents: Roles of p53 and caspase activation. <b>2000</b> , 78, 334-349	33
1464	Role of p53 family members in apoptosis. <b>2000</b> , 182, 171-81	139
1463	The Ki-67 protein: from the known and the unknown. <b>2000</b> , 182, 311-22	3280

1462	Modification in the inherent mode of allelic replication in lymphocytes of patients suffering from renal cell carcinoma: A novel genetic alteration associated with malignancy. <b>2000</b> , 27, 270-277	27
1461	Isolation and characterization of a novel TP53-inducible gene, TP53TG5, which suppresses growth and shows cell cycle-dependent transition of expression. <b>2000</b> , 27, 345-52	4
1460	High frequency of clonal chromosome abnormalities in prostatic neoplasms sampled by prostatectomy or ultrasound-guided needle biopsy. <b>2000</b> , 28, 211-219	10
1459	BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. <b>2000</b> , 27, 57-64	71
1458	The carcinogen 2-acetylaminofluorene inhibits activation and nuclear accumulation of cyclin-dependent kinase 2 in growth-induced rat liver. <b>2000</b> , 27, 190-199	8
1457	Cancer proteomics: from identification of novel markers to creation of artificial learning models for tumor classification. <b>2000</b> , 21, 1210-7	106
1456	P53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. <b>2000</b> , 35, 96-103	98
1455	Prognostic impact of P53 status in Ewing sarcoma. <b>2000</b> , 89, 783-792	121
1454	p53 protein accumulation and mutations in normal and benign breast tissue. <b>2000</b> , 87, 73-8	31
1453	Oncogenic aberrations in the p53 pathway are associated with a high S phase fraction and poor patient survival in B-cell Non-Hodgkin's lymphoma. <b>2000</b> , 89, 313-24	25
1452	p53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. <b>2000</b> , 87, 528-533	76
1451	Tumor-derived p53 mutant C174Y is a gain-of-function mutant which activates the fos promoter and enhances colony formation. <b>2000</b> , 88, 162-71	22
1450	p53-dependent induction of heat shock protein 27 (HSP27) expression. <b>2000</b> , 88, 191-194	20
1449	p53-mediated negative regulation of stathmin/Op18 expression is associated with G(2)/M cell-cycle arrest. <b>2000</b> , 88, 685-91	79
1448	Apoptotic and non-apoptotic modes of programmed cell death in MCF-7 human breast carcinoma cells. <b>2000</b> , 24, 253-60	14
1447	Release of mitotic descendants by giant cells from irradiated Burkitt's lymphoma cell line. <b>2000</b> , 24, 635-48	77
1446	Intercellular adhesion molecule 1 underlies the functional heterogeneity of synovial cells in patients with rheumatoid arthritis: involvement of cell cycle machinery. <b>2000</b> , 43, 2513-22	8
1445	Impaired nuclear accumulation and shortened phosphorylation of ERK after growth factor stimulation in cultured hepatocytes from rats exposed to 2-acetylaminofluorene. <b>2000</b> , 28, 84-96	16



1444	Requirement of wild-type p53 protein for maintenance of chromosomal integrity. <b>2000</b> , 28, 203-14	43
1443	Bilirubin UDP-glucuronosyltransferase 1A1 gene polymorphisms: Susceptibility to oxidative damage and cancer?. <b>2000</b> , 29, 198-204	23
1442	Somatic mutation theory of carcinogenesis: why it should be dropped and replaced. <b>2000</b> , 29, 205-11	114
1441	p53 is phosphorylated at the carboxyl terminus and promotes the differentiation of human HaCaT keratinocytes. <b>2000</b> , 29, 251-62	15
1440	Normal growth and differentiation in a spontaneously immortalized near-diploid human keratinocyte cell line, NIKS. <b>2000</b> , 114, 444-55	169
1439	p53 allele deletion and protein accumulation occurs in the absence of p53 gene mutation in T-prolymphocytic leukaemia and Sezary syndrome. <b>2000</b> , 110, 180-7	21
1438	Evaluation of biological responses to polymeric biomaterials by RT-PCR analysis IV: study of c-myc, c-fos and p53 mRNA expression. <b>2000</b> , 21, 521-7	29
1437	Expression of topoisomerase II alpha, Ki-67 and p53 in early stage laryngeal carcinomas not featuring vocal cord fixation. <b>2000</b> , 108, 689-96	7
1436	Expression of apoptotic signaling proteins in leukoplakia and oral lichen planus: quantitative and topographical studies. <b>2000</b> , 29, 385-93	53
1435	The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. <b>2000</b> , 29, 413-25	143
1434	Molecular mechanisms of UV-induced apoptosis. <b>2000</b> , 16, 195-201	237
1433	Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild-type p53 in non-small-cell lung cancer. <b>2000</b> , 48, 1127-37	26
1432	Radiation-induced gadd45 expression correlates with clinical response to radiotherapy of cervical carcinoma. <b>2000</b> , 46, 411-6	11
1431	Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. <b>2000</b> , 47, 273-89	205
1430	Where cancer meets calcium--p53 crosstalk with EF-hands. <b>2000</b> , 7, 525-7	11
1429	Structure of the negative regulatory domain of p53 bound to S100B(beta-beta). <b>2000</b> , 7, 570-4	267
1428	Brca1 required for T cell lineage development but not TCR loci rearrangement. <b>2000</b> , 1, 77-82	69
1427	Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. <b>2000</b> , 26, 122-7	271

1426	c-Abl: activation and nuclear targets. <b>2000</b> , 7, 10-6	105
1425	Ceramide-induced cell death is independent of the Fas/Fas ligand pathway and is prevented by Nur77 overexpression in A20 B cells. <b>2000</b> , 7, 262-71	57
1424	p53 and thymic 'death by neglect': thymic epithelial cell-induced apoptosis of CD4+8+ thymocytes is p53-independent. <b>2000</b> , 7, 241-9	5
1423	DNA repair is activated in early stages of p53-induced apoptosis. <b>2000</b> , 7, 393-401	41
1422	p53 accumulation due to down-regulation of ubiquitin: relevance for neuronal apoptosis. <b>2000</b> , 7, 675-81	25
1421	Cell cycle progression and apoptosis after irradiation in an acidic environment. <b>2000</b> , 7, 729-38	33
1420	The role of p53 in neuronal cell death. <b>2000</b> , 7, 868-79	126
1419	Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer. <b>2000</b> , 7, 683-96	50
1418	Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2. <b>2000</b> , 7, 789-98	14
1417	Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors. <b>2000</b> , 7, 1069-76	44
1416	P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients. <b>2000</b> , 7, 1215-9	28
1415	Antisense ATM gene therapy: a strategy to increase the radiosensitivity of human tumors. <b>2000</b> , 7, 852-8	31
1414	Induction of IW32 erythroleukemia cell differentiation by p53 is dependent on protein tyrosine phosphatase. <b>2000</b> , 14, 1292-300	9
1413	Mechanisms involved in the pro- and anti-apoptotic role of NO in human leukemia. <b>2000</b> , 14, 1685-94	120
1412	Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. <b>2000</b> , 14, 1727-35	67
1411	Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control. <b>2000</b> , 19, 632-9	89
1410	A unique, short sequence determines p53 gene basal and UV-inducible expression in normal human cells. <b>2000</b> , 19, 21-31	31
1409	p53 is involved in the p120E4F-mediated growth arrest. <b>2000</b> , 19, 188-99	39

1408	Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. <b>2000</b> , 19, 358-64	77
1407	p73 transcriptional activity increases upon cooperation between its spliced forms. <b>2000</b> , 19, 831-5	10
1406	Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells. <b>2000</b> , 19, 661-9	26
1405	Non-activated p53 co-localizes with sites of transcription within both the nucleoplasm and the nucleolus. <b>2000</b> , 19, 85-96	71
1404	Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis. <b>2000</b> , 19, 933-42	33
1403	Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. <b>2000</b> , 19, 1245-56	323
1402	p27Kip1-deficient mice exhibit accelerated growth hormone-releasing hormone (GHRH)-induced somatotrope proliferation and adenoma formation. <b>2000</b> , 19, 1875-84	28
1401	Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain. <b>2000</b> , 19, 1834-42	28
1400	Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. <b>2000</b> , 19, 1843-8	134
1399	LMP1 of Epstein-Barr virus suppresses cellular senescence associated with the inhibition of p16INK4a expression. <b>2000</b> , 19, 2002-13	58
1398	c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells. <b>2000</b> , 19, 2194-204	54
1397	Extinction of rac1 and Cdc42Hs signalling defines a novel p53-dependent apoptotic pathway. <b>2000</b> , 19, 2377-85	33
1396	Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage. <b>2000</b> , 19, 2461-4	21
1395	An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. <b>2000</b> , 19, 2312-23	223
1394	Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer. <b>2000</b> , 19, 3078-85	58
1393	p51A (TAp63gamma), a p53 homolog, accumulates in response to DNA damage for cell regulation. <b>2000</b> , 19, 3126-30	85
1392	High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? <b>2000</b> , 19, 3439-44	173
1391	Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. <b>2000</b> , 19, 3138-45	100

1390	The consequence of p53 overexpression for liver tumor development and the response of transformed murine hepatocytes to genotoxic agents. <b>2000</b> , 19, 3498-507	25
1389	The human vaccinia-related kinase 1 (VRK1) phosphorylates threonine-18 within the mdm-2 binding site of the p53 tumour suppressor protein. <b>2000</b> , 19, 3656-64	103
1388	F9 embryonal carcinoma cells fail to stop at G1/S boundary of the cell cycle after gamma-irradiation due to p21WAF1/CIP1 degradation. <b>2000</b> , 19, 3858-65	31
1387	The contribution of the RING finger domain of MDM2 to cell cycle progression. <b>2000</b> , 19, 3849-57	32
1386	Isolation and characterization of sixteen novel p53 response genes. <b>2000</b> , 19, 3978-87	39
1385	Conformational phenotype of p53 is linked to nuclear translocation. <b>2000</b> , 19, 4042-9	22
1384	Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. <b>2000</b> , 19, 3829-39	59
1383	A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line. <b>2000</b> , 19, 5098-105	13
1382	Pituitary neoplasia induced by expression of human neurotropic polyomavirus, JCV, early genome in transgenic mice. <b>2000</b> , 19, 4840-6	48
1381	Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. <b>2000</b> , 19, 5123-33	210
1380	p53 mediates bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway. <b>2000</b> , 19, 5259-69	82
1379	Bcr-Abl protein tyrosine kinase activity induces a loss of p53 protein that mediates a delay in myeloid differentiation. <b>2000</b> , 19, 5487-97	26
1378	Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant. <b>2000</b> , 19, 5329-37	12
1377	Direct transactivation of c-Ha-Ras gene by p53: evidence for its involvement in p53 transactivation activity and p53-mediated apoptosis. <b>2000</b> , 19, 5831-41	23
1376	MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. <b>2000</b> , 19, 5892-7	90
1375	The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. <b>2000</b> , 19, 5851-7	51
1374	Differential gene expression in mouse mammary adenocarcinomas in the presence and absence of wild type p53. <b>2000</b> , 19, 5988-96	25
1373	Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. <b>2000</b> , 19, 6194-202	134

1372	Specific pattern of p53 phosphorylation during nitric oxide-induced cell cycle arrest. <b>2000</b> , 19, 6369-75	60
1371	Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. <b>2000</b> , 13, 945-53	24
1370	A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. <b>2000</b> , 404, 42-9	724
1369	p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. <b>2000</b> , 404, 99-103	872
1368	DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. <b>2000</b> , 404, 510-4	458
1367	Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. <b>2000</b> , 404, 897-900	489
1366	Benefits of bad telomeres. <b>2000</b> , 406, 573-4	34
1365	An intact HDM2 RING-finger domain is required for nuclear exclusion of p53. <b>2000</b> , 2, 563-8	283
1364	The MDM2 RING-finger domain is required to promote p53 nuclear export. <b>2000</b> , 2, 569-73	303
1363	The Grapes checkpoint coordinates nuclear envelope breakdown and chromosome condensation. <b>2000</b> , 2, 609-15	56
1362	The function of PML in p53-dependent apoptosis. <b>2000</b> , 2, 730-6	382
1361	Feedback control of intercellular signalling in development. <b>2000</b> , 408, 313-9	431
1360	Deacetylation of p53 modulates its effect on cell growth and apoptosis. <b>2000</b> , 408, 377-81	675
1359	Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. <b>2000</b> , 408, 381-6	487
1358	Surfing the p53 network. <b>2000</b> , 408, 307-10	5707
1357	P63 and P73: P53 mimics, menaces and more. <b>2000</b> , 1, 199-207	406
1356	Possible association of thioredoxin and p53 in breast cancer. <b>2000</b> , 75, 15-20	25
1355	Trans-regulated silencing and reactivation of TP53 tumor suppressor gene in malignant transformation and its reversion. <b>2000</b> , 91, 1111-8	3

1354	Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal-cancer patients. <b>2000</b> , 91, 190-8	33
1353	Gene therapy strategies for colon cancer. <b>2000</b> , 6, 82-7	26
1352	Epigenetic aspects of cellular senescence. <b>2000</b> , 35, 23-32	29
1351	SV40 T/t-antigens sensitize mammary gland epithelial cells to oxidative stress and apoptosis. <b>2000</b> , 29, 497-506	6
1350	The E2F transcription factors: key regulators of cell proliferation. <b>2000</b> , 1470, M1-12	122
1349	The Mdm2 gene of zebrafish ( <i>Danio rerio</i> ): preferential expression during development of neural and muscular tissues, and absence of tumor formation after overexpression of its cDNA during early embryogenesis. <b>2000</b> , 66, 61-70	28
1348	p73: structure and function. <b>2000</b> , 50, 589-93	17
1347	Role and regulation of Rel/NF-kappaB activity in anti-immunoglobulin-induced apoptosis in WEHI-231 B lymphoma cells. <b>2000</b> , 12, 245-53	2
1346	Triggering the cell cycle in plants. <b>2000</b> , 10, 245-50	129
1345	Protein transduction: unrestricted delivery into all cells?. <b>2000</b> , 10, 290-5	513
1344	P53 and breast cancer. <b>2000</b> , 9, 239-46	17
1343	p53 abnormality and chromosomal instability in the same breast tumor cells. <b>2000</b> , 121, 150-5	16
1342	The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. <b>2000</b> , 116, 1-5	33
1341	Complete loss of wild-type TP53 in a nontransformed human epithelial cell line is preceded by a phase during which a heterozygous TP53 mutant effectively outgrows the homozygous wild-type cells. <b>2000</b> , 116, 28-34	4
1340	Resistance to glucocorticoid-induced apoptosis in PLP peptide-specific T cell clones from patients with progressive MS. <b>2000</b> , 109, 197-210	23
1339	P53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CA IX in MaTu cells. <b>2000</b> , 1491, 20-6	15
1338	Detection of mutation of the p53 gene with high sensitivity by fluorescence-based PCR-SSCP analysis using low-pH buffer and an automated DNA sequencer in a large number of DNA samples. <b>2000</b> , 452, 83-90	25
1337	Radiosensitivity of HCV cells and their v-ras and v-raf transfectants. <b>2000</b> , 454, 63-9	1

1336	Ionizing radiation and genetic risks. XII. The concept of "potential recoverability correction factor" (PRCF) and its use for predicting the risk of radiation-inducible genetic disease in human live births. <b>2000</b> , 453, 129-81	10
1335	Primary mouse fibroblasts deficient for c-Fos, p53 or for both proteins are hypersensitive to UV light and alkylating agent-induced chromosomal breakage and apoptosis. <b>2000</b> , 457, 113-23	44
1334	New insights into p53 regulation and gene therapy for cancer. <b>2000</b> , 60, 1153-63	30
1333	Immunocytochemical study on the distribution of p53 in the hippocampus and cerebellum of the aged rat. <b>2000</b> , 885, 137-41	21
1332	Intercellular adhesion molecule 1 discriminates functionally different populations of human osteoblasts: characteristic involvement of cell cycle regulators. <b>2000</b> , 15, 1912-23	69
1331	Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. <b>2000</b> , 48, 89-94	70
1330	Absence of p21 WAF1 and p27 kip1 gene mutations in various feline tumours. <b>2000</b> , 24, 115-24	4
1329	Transcriptional activation of p21WAF1 by PTEN/MMAC1 tumor suppressor. <b>2000</b> , 203, 59-71	24
1328	Attenuation of macrophage apoptosis by the cAMP-signalling system. <b>2000</b> , 212, 35-43	28
1327	Establishment and characterization of immortalized hippocampal neural precursor cell lines. <b>2000</b> , 33, 53-61	1
1326	Assignment of <sup>1</sup> H(N), <sup>15</sup> N, <sup>13</sup> C(alpha), <sup>13</sup> CO and <sup>13</sup> C(beta) resonances in a 67 kDa p53 dimer using 4D-TROSY NMR spectroscopy. <b>2000</b> , 18, 173-6	27
1325	Biological features of premalignant disease in the human breast. <b>2000</b> , 5, 351-64	37
1324	Biological and molecular characterization of an ECV-304-derived cell line resistant to p53-mediated apoptosis. <b>2000</b> , 5, 277-90	10
1323	Genetics of hepatocellular carcinoma. <b>2000</b> , 10, 185-200	258
1322	Telomerase and human tumorigenesis. <b>2000</b> , 10, 399-406	119
1321	Ketoconazole induces G0/G1 arrest in human colorectal and hepatocellular carcinoma cell lines. <b>2000</b> , 169, 132-41	34
1320	Regulation of the 26S proteasome by adenovirus E1A. <b>2000</b> , 19, 4759-73	69
1319	p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. <b>2000</b> , 19, 4967-75	195

1318	Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. <b>2000</b> , 19, 6051-64	79
1317	Regulation of p53 activity in nuclear bodies by a specific PML isoform. <b>2000</b> , 19, 6185-95	287
1316	p53-inducible wip1 phosphatase mediates a negative feedback regulation of p38 MAPK-p53 signaling in response to UV radiation. <b>2000</b> , 19, 6517-26	332
1315	Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. <b>2000</b> , 19, 370-8	131
1314	HIF-1: using two hands to flip the angiogenic switch. <b>2000</b> , 19, 59-65	176
1313	Antitumor protein (AP) from a mushroom induced apoptosis to transformed human keratinocyte by controlling the status of prb, c-MYC, cyclin E-cdk2, and p21WAF1 in the G1/S transition. <b>2000</b> , 12, 157-60	4
1312	Influence of apoptosis on the enhancement of radiotoxicity by ouabain. <b>2000</b> , 176, 186-91	20
1311	[Molecular genetic and cell biology principles for the development of malignant tumors]. <b>2000</b> , 39, 214-21	1
1310	Multiple factors other than p53 influence colon cancer sensitivity to paclitaxel. <b>2000</b> , 46, 329-37	12
1309	p53 protein accumulation and p53 gene mutation in colorectal cancer. <b>2000</b> , 6, 275-9	14
1308	Differential induction of apoptosis in x-irradiated L5178Y sublines bearing p53 mutation. <b>2000</b> , 39, 33-40	6
1307	The role of protein kinase C in the regulation of cell growth and in signalling to the cell nucleus. <b>2000</b> , 126, 1-11	74
1306	Induction of apoptosis in cultured cells by extracts from shiitake ( <i>Lentinula edodes</i> ) mycelial culture broth. <b>2000</b> , 41, 623-631	2
1305	Molecular prognostic factors in rectal cancer treated by radiation and surgery. <b>2000</b> , 43, 451-9	56
1304	Inhibition of the growth of human hepatoma cell line bothin vitro andin vivo by transducing CKI genep21 ( WAF-1 ) with GE7 targeting gene delivery system. <b>2000</b> , 43, 663-8	
1303	Tumor angiogenesis as a prognostic predictor in pancreatic cancer. <b>2000</b> , 7, 489-95	48
1302	Regulation of proliferation and apoptosis in sporadic and hereditary medullary thyroid carcinomas and their putative precursor lesions. <b>2000</b> , 437, 256-63	7
1301	Apoptosis and cancer chemotherapy. <b>2000</b> , 301, 143-52	167



1300	LPS induces apoptosis in macrophages mostly through the autocrine production of TNF- $\alpha$ . <b>2000</b> , 95, 3823-3831	232
1299	Inducible loss of NF- $\kappa$ B activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B lymphocytes. <b>2000</b> , 95, 2068-2075	87
1298	Stable expression of Epstein-Barr virus BZLF-1-encoded ZEBRA protein activates p53-dependent transcription in human Jurkat T-lymphoblastoid cells. <b>2000</b> , 96, 625-634	27
1297	The retinoblastoma gene family: its role in cancer onset and progression. <b>2000</b> , 4, 765-783	7
1296	Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. <b>2000</b> , 96, 269-274	79
1295	Intratumor heterogeneity of k-ras and p53 mutations among human colorectal adenomas containing early cancer. <b>2000</b> , 21, 49-57	20
1294	The DNA Damage-Induced Cell Cycle Checkpoints. <b>2000</b> , 2, 237-243	
1293	Tumor suppressor p53 regulation and function. <b>2000</b> , 5, d424-437	4
1292	Mechanisms and implications of the age-associated decrease in DNA repair capacity. <b>2000</b> , 14, 1325-1334	157
1291	The effect of caffeine on p53-dependent radioresponses in undifferentiated mouse embryonal carcinoma cells after X-ray and UV-irradiations. <b>2000</b> , 41, 227-41	9
1290	The role of hydroxyl radical as a messenger in Cr(VI)-induced p53 activation. <b>2000</b> , 279, C868-75	92
1289	Analysis of multisite phosphorylation of the p53 tumor-suppressor protein by tryptic phosphopeptide mapping. <b>2000</b> , 99, 447-63	8
1288	Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. <b>2000</b> , 18, 2309-15	231
1287	Diverse chemical carcinogens fail to induce G1 arrest in MCF-7 cells. <b>2000</b> , 21, 1611-1618	24
1286	MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. <b>2000</b> , 18, 2685-94	69
1285	Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF- $\kappa$ B pathway and is dependent on p53 phosphorylation. <b>2000</b> , 20, 3377-86	118
1284	Evaluation of the Performance of a p53 Sequencing Microarray Chip Using 140 Previously Sequenced Bladder Tumor Samples. <b>2000</b> , 46, 1555-1561	80
1283	Diverse chemical carcinogens fail to induce G1 arrest in MCF-7 cells. <b>2000</b> , 21, 1611-1618	51

1282	Human Papillomavirus Oncogenesis. <b>2000</b> , 20, 383-406	30
1281	Basic Concepts of Tumor Biology. <b>2000</b> , 55, 1-16	
1280	Physical and functional interaction between p53 mutants and different isoforms of p73. <b>2000</b> , 275, 29503-12	192
1279	Ovarian Cancer. <b>2000</b> ,	3
1278	SUMO--nonclassical ubiquitin. <b>2000</b> , 16, 591-626	642
1277	Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. <b>2000</b> , 20, 8458-67	305
1276	Hepatocellular Carcinoma. <b>2000</b> ,	
1275	Effects of Oxidation Agents and Metal Ions on Binding of p53 to Supercoiled DNA. <b>2000</b> , 17 Suppl 1, 177-83	4
1274	Role of human cytomegalovirus immediate-early proteins in cell growth control. <b>2000</b> , 74, 8028-37	100
1273	The phosphotyrosyl phosphatase activator gene is a novel p53 target gene. <b>2000</b> , 275, 20488-95	17
1272	Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. <b>2000</b> , 275, 38905-11	104
1271	Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. <b>2000</b> , 20, 5540-53	85
1270	Protection of renal inner medullary epithelial cells from apoptosis by hypertonic stress-induced p53 activation. <b>2000</b> , 275, 18243-7	92
1269	Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. <b>2000</b> , 97, 8542-7	291
1268	Sustained activation of Ras/Raf/mitogen-activated protein kinase cascade by the tumor suppressor p53. <b>2000</b> , 97, 8302-5	100
1267	Human lung cancer and p53: the interplay between mutagenesis and selection. <b>2000</b> , 97, 12244-9	87
1266	p53 binds selectively to the 5' untranslated region of cdk4, an RNA element necessary and sufficient for transforming growth factor beta- and p53-mediated translational inhibition of cdk4. <b>2000</b> , 20, 8420-31	68
1265	Repression of RNA polymerase I transcription by the tumor suppressor p53. <b>2000</b> , 20, 5930-8	223

1264	Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription. <b>2000</b> , 20, 8643-54	88
1263	Tumor suppressor p53 is required to modulate BRCA1 expression. <b>2000</b> , 20, 7450-9	73
1262	Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis. <b>2000</b> , 275, 479-86	69
1261	Nitric oxide increases p21(Waf1/Cip1) expression by a cGMP-dependent pathway that includes activation of extracellular signal-regulated kinase and p70(S6k). <b>2000</b> , 275, 11389-96	62
1260	The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest. <b>2000</b> , 97, 1584-8	132
1259	The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. <b>2000</b> , 275, 18391-8	265
1258	The N terminus of p53 regulates its dissociation from DNA. <b>2000</b> , 275, 39944-53	42
1257	Differential gene expression in p53-mediated apoptosis-resistant vs. apoptosis-sensitive tumor cell lines. <b>2000</b> , 97, 13009-14	143
1256	Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. <b>2000</b> , 275, 20127-35	219
1255	Definition of the p53 functional domains necessary for inducing apoptosis. <b>2000</b> , 275, 39927-34	84
1254	Molecular mechanism of endothelial growth arrest by laminar shear stress. <b>2000</b> , 97, 9385-9	196
1253	p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. <b>2000</b> , 275, 37469-73	70
1252	Evaluation of cytotoxicity, cell proliferation, and genotoxicity induced by p-cresidine in hetero- and nullizygous transgenic p53 mice. <b>2000</b> , 55, 361-9	9
1251	p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. <b>2000</b> , 14, 1901-7	142
1250	Enhanced induction of Bax gene expression in H460 and H1299 cells with the combined treatment of cisplatin and adenovirus mediated wt-p53 gene transfer. <b>2000</b> , 32, 23-8	14
1249	A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. <b>2000</b> , 11, 1397-406	104
1248	Radiation-induced tissue abnormalities in fetal brain are related to apoptosis immediately after irradiation. <b>2000</b> , 76, 649-59	15
1247	Excessive apoptosis in low risk myelodysplastic syndromes (MDS). <b>2000</b> , 40, 1-24	35

1246	MOLECULAR PATHOLOGY AND MOLECULAR PHARMACOLOGY OF OSTEOSARCOMA. <b>2000</b> , 19, 391-413	7
1245	p53 regulates myogenesis by triggering the differentiation activity of pRb. <b>2000</b> , 151, 1295-304	101
1244	The MRE11-NBS1-RAD50 pathway is perturbed in SV40 large T antigen-immortalized AT-1, AT-2 and HL-1 cardiomyocytes. <b>2000</b> , 28, 2882-92	19
1243	E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53. <b>2000</b> , 74, 193-202	68
1242	Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1). <b>2000</b> , 102, 2124-30	100
1241	Defective nuclear localization of p53 protein in a Chinese hamster cell line is associated with the formation of stable cytoplasmic protein multimers in cells with gene amplification. <b>2000</b> , 21, 1631-8	8
1240	p53, p21(WAF1/CIP1), and MDM2 involvement in proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells. <b>2000</b> , 20, 636-44	12
1239	Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53. <b>2000</b> , 20, 8018-25	35
1238	The cell cycle. <b>2000</b> , 5, 510-3	47
1237	Apoptosis and chemoresistance in human ovarian cancer: is Xiap a determinant?. <b>2000</b> , 9, 122-30	40
1236	Mammalian follicular development and atresia: role of apoptosis. <b>2000</b> , 9, 87-95	63
1235	Multiparameter flow cytometry for simultaneous assessment of p53 protein expression and cellular DNA content in oral squamous cell carcinomas: evidence for the development of aneuploid clones from p53-deficient diploid progenitor cells. <b>2000</b> , 17, 933-7	
1234	Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). <b>2000</b> , 16, 567-76	63
1233	Cell cycle control as a basis for cancer drug development (Review).. <b>2000</b> , 16, 871	12
1232	Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage. <b>2000</b> , 5, 597-604	30
1231	Caspase-1 activity as a possible predictor of apoptosis induced by cisplatin in gastric cancer cells. <b>2000</b> , 6, 553-7	6
1230	Absence of p53-mediated G1 arrest with induction of MDM2 in sterigmatocystin-treated cells. <b>2000</b> , 17, 737-42	6
1229	UCN-01 and camptothecin induce DNA double-strand breaks in p53 mutant tumor cells, but not in normal or p53 negative epithelial cells. <b>2000</b> , 17, 1043-51	5

1228	Molecular markers for early cancer detection. <b>2000</b> , 18, 75-125	10
1227	Multiplex PCR (MPCR) Screening Can Detect Small Intragenic p53 Deletion and Insertion Mutations. <b>2001</b> , 39, 329-35	
1226	Tumor-selektive Apoptose-Induktion durch TRAIL: Ein neuer therapeutischer âWegâ in der Onkologie? - Induction of Tumor-selective Apoptosis by TRAIL: A New Road for Oncology? -. <b>2000</b> , 31, 347-352	
1225	Mutation of p53 Tumor Suppressor Gene in Hepatocellular Carcinoma. <b>2000</b> , 45, 113-30	1
1224	Regulation of thyroid follicular cell function by intracellular redox-active copper. <b>2000</b> , 141, 4373-82	18
1223	Expression and assay of recombinant ATM. <b>2000</b> , 99, 99-108	10
1222	Polycyclic aromatic hydrocarbon carcinogens increase ubiquitination of p21 protein after the stabilization of p53 and the expression of p21. <b>2000</b> , 22, 747-54	31
1221	P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers. <b>2000</b> , 21, 101-6	19
1220	Transcriptional control of hepatocanalicular transporter gene expression. <b>2000</b> , 20, 323-37	43
1219	Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. <b>2000</b> , 97, 11250-5	438
1218	Acetylation of histones and transcription-related factors. <b>2000</b> , 64, 435-59	1272
1217	NFBD1/KIAA0170 is a novel nuclear transcriptional transactivator with BRCT domain. <b>2000</b> , 19, 475-85	37
1216	p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. <b>2000</b> , 275, 7337-42	427
1215	Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. <b>2000</b> , 20, 6147-58	249
1214	Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. <b>2000</b> , 192, 755-60	427
1213	The p53 response to DNA damage in vivo is independent of DNA-dependent protein kinase. <b>2000</b> , 20, 4075-83	44
1212	pRB-dependent, J domain-independent function of simian virus 40 large T antigen in override of p53 growth suppression. <b>2000</b> , 74, 864-74	28
1211	The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. <b>2000</b> , 20, 1299-310	82

1210	A functional complex of adenovirus proteins E1B-55kDa and E4orf6 is necessary to modulate the expression level of p53 but not its transcriptional activity. <b>2000</b> , 74, 11407-12	57
1209	p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. <b>2000</b> , 28, 513-9	40
1208	Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis. <b>2000</b> , 46, 842-8	34
1207	Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability. <b>2000</b> , 275, 34122-30	131
1206	ei24, a p53 response gene involved in growth suppression and apoptosis. <b>2000</b> , 20, 233-41	101
1205	The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. <b>2000</b> , 97, 6763-8	870
1204	Mediation of nerve growth factor-driven cell cycle arrest in PC12 cells by p53. Simultaneous differentiation and proliferation subsequent to p53 functional inactivation. <b>2000</b> , 275, 37829-37	58
1203	Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. <b>2000</b> , 92, 1217-27	234
1202	Primary renal hypoplasia in humans and mice with PAX2 mutations: evidence of increased apoptosis in fetal kidneys of Pax2(1Neu) +/- mutant mice. <b>2000</b> , 9, 1-11	147
1201	Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization. <b>2000</b> , 20, 741-8	67
1200	Dissection of the XChk1 signaling pathway in <i>Xenopus laevis</i> embryos. <b>2000</b> , 11, 3101-8	34
1199	MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. <b>2000</b> , 97, 12547-52	151
1198	The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis. <b>2000</b> , 275, 18503-10	12
1197	Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. <b>2000</b> , 97, 10544-8	116
1196	Arrest of G(1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcription. <b>2000</b> , 20, 1797-815	193
1195	Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1. <b>2000</b> , 275, 35256-63	80
1194	The tumor suppressor p53 can both stimulate and inhibit ultraviolet light-induced apoptosis. <b>2000</b> , 11, 2543-51	45
1193	DNA-damaging aryl hydrocarbons induce Mdm2 expression via p53-independent post-transcriptional mechanisms. <b>2000</b> , 275, 26024-31	27

1192	Possible involvement of bcl-2 suppression in wild-type p53 gene-dependent cell growth repression in rat osteosarcoma cells. <b>2000</b> , 28, 575-9	3
1191	A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. <b>2000</b> , 20, 7826-37	114
1190	The p53 tumor suppressor protein does not regulate expression of its own inhibitor, MDM2, except under conditions of stress. <b>2000</b> , 20, 2023-30	76
1189	Dose-dependent biphasic accumulation of TP53 protein in normal human embryo cells after X irradiation. <b>2000</b> , 153, 305-11	18
1188	PKN binds and phosphorylates human papillomavirus E6 oncoprotein. <b>2000</b> , 275, 14824-30	48
1187	The paramyxovirus simian virus 5 V protein slows progression of the cell cycle. <b>2000</b> , 74, 9152-66	95
1186	Co-repressors 2000. <b>2000</b> , 14, 1876-88	179
1185	Expression of the p53 homologue p63alpha and deltaNp63alpha in normal and neoplastic cells. <b>2000</b> , 21, 153-60	60
1184	CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice. <b>2000</b> , 164, 5641-51	19
1183	p53, p21(WAF1/CIP1), and MDM2 involvement in the proliferation and apoptosis in an in vitro model of conditionally immortalized human vascular smooth muscle cells. <b>2000</b> , 20, 973-81	29
1182	Human TP53 from the malignant glioma-derived cell lines M059J and M059K has a cancer-associated mutation in exon 8. <b>2000</b> , 154, 473-6	33
1181	The molecular chaperone activity of simian virus 40 large T antigen is required to disrupt Rb-E2F family complexes by an ATP-dependent mechanism. <b>2000</b> , 20, 6233-43	105
1180	Epstein-Barr virus suppresses a G(2)/M checkpoint activated by genotoxins. <b>2000</b> , 20, 1344-60	47
1179	Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. <b>2000</b> , 21, 683-9	85
1178	Adenovirus-mediated p53 gene therapy for human cancer. <b>2000</b> , 4, 51-4	13
1177	Stress signals utilize multiple pathways to stabilize p53. <b>2000</b> , 20, 3224-33	319
1176	Computerized video time-lapse microscopy studies of ionizing radiation-induced rapid-interphase and mitosis-related apoptosis in lymphoid cells. <b>2000</b> , 153, 36-48	55
1175	Molecular cloning and developmental expression of AtGR1, a new growth-related Arabidopsis gene strongly induced by ionizing radiation. <b>2000</b> , 154, 355-64	25

1174	Transcription-coupled repair is inducible in hamster cells. <b>2000</b> , 28, 4674-8	12
1173	MCG10, a novel p53 target gene that encodes a KH domain RNA-binding protein, is capable of inducing apoptosis and cell cycle arrest in G(2)-M. <b>2000</b> , 20, 5602-18	95
1172	p53 deficiency increases transformation by v-Abl and rescues the ability of a C-terminally truncated v-Abl mutant to induce pre-B lymphoma in vivo. <b>2000</b> , 20, 628-33	9
1171	Cooperative signals governing ARF-mdm2 interaction and nucleolar localization of the complex. <b>2000</b> , 20, 2517-28	239
1170	The p53-inducible gene EI24/PIG8 localizes to human chromosome 11q23 and the proximal region of mouse chromosome 9. <b>2000</b> , 89, 230-3	13
1169	A male germ cell tumor-susceptibility-determining locus, pgct1, identified on murine chromosome 13. <b>2000</b> , 97, 8421-6	33
1168	Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1. <b>2000</b> , 97, 6427-32	146
1167	Identification and characterization of a p53 homologue in <i>Drosophila melanogaster</i> . <b>2000</b> , 97, 7301-6	178
1166	Chromosome instability contributes to loss of heterozygosity in mice lacking p53. <b>2000</b> , 97, 7405-10	67
1165	Peg3/Pw1 promotes p53-mediated apoptosis by inducing Bax translocation from cytosol to mitochondria. <b>2000</b> , 97, 12050-5	168
1164	c-Jun and p53 activity is modulated by SUMO-1 modification. <b>2000</b> , 275, 13321-9	326
1163	Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. <b>2000</b> , 275, 16202-12	686
1162	A novel DNA damage checkpoint involving post-transcriptional regulation of cyclin A expression. <b>2000</b> , 275, 1715-22	31
1161	p53 regulates the expression of the tumor suppressor gene maspin. <b>2000</b> , 275, 6051-4	205
1160	ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. <b>2000</b> , 275, 20444-9	276
1159	Oncogenic Ras-mediated cell growth arrest and apoptosis are associated with increased ubiquitin-dependent cyclin D1 degradation. <b>2000</b> , 275, 22916-24	59
1158	Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. <b>2000</b> , 275, 39458-65	133
1157	The p53/retinoblastoma-mediated repression of testicular orphan receptor-2 in the rhesus monkey with cryptorchidism. <b>2000</b> , 275, 23877-83	25



1156	Species-specific regulation of alternative splicing in the C-terminal region of the p53 tumor suppressor gene. <b>2000</b> , 28, 1489-97	17
1155	The Werner syndrome protein contributes to induction of p53 by DNA damage. <b>2000</b> , 14, 2138-40	39
1154	Mechanisms and implications of the age-associated decrease in DNA repair capacity. <b>2000</b> , 14, 1325-34	124
1153	Evidence that dynamin-2 functions as a signal-transducing GTPase. <b>2000</b> , 150, 145-54	98
1152	High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis. <b>2000</b> , 21, 563-5	50
1151	Cell-specific modulation of papovavirus replication by tumor suppressor protein p53. <b>2000</b> , 74, 4688-97	10
1150	Loss of heterozygosity at the Ink4a/Arf locus facilitates Abelson virus transformation of pre-B cells. <b>2000</b> , 74, 9479-87	6
1149	Nitric oxide nitrates tyrosine residues of tumor-suppressor p53 protein in MCF-7 cells. <b>2000</b> , 267, 609-13	65
1148	Downregulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas. <b>2000</b> , 273, 54-61	49
1147	Activation of LEDGF gene by thermal-and oxidative-stresses. <b>2000</b> , 276, 1320-4	56
1146	Induction of oxidative DNA damage in u937 cells by TNF or anti-Fas stimulation. <b>2000</b> , 12, 881-7	16
1145	Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53. <b>2000</b> , 255, 86-94	51
1144	p53 localizes to the centrosomes and spindles of mitotic cells in the embryonic chick epiblast, human cell lines, and a human primary culture: An immunofluorescence study. <b>2000</b> , 256, 122-30	71
1143	The human cyclin B1 protein modulates sensitivity of DNA mismatch repair deficient prostate cancer cell lines to alkylating agents. <b>2000</b> , 257, 127-34	7
1142	Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity. <b>2000</b> , 256, 571-7	45
1141	The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene. <b>2000</b> , 64, 298-306	49
1140	Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability. <b>2000</b> , 295, 1009-21	34
1139	Post-translational modification of p53 protein in response to ionizing radiation analyzed by mass spectrometry. <b>2000</b> , 295, 853-64	49

1138	A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. <b>2000</b> , 299, 245-53	135
1137	Scanning force microscopy of the complexes of p53 core domain with supercoiled DNA. <b>2000</b> , 299, 585-92	40
1136	p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. <b>2000</b> , 7, 613-22	99
1135	Apoptotic mechanisms in acute renal failure. <b>2000</b> , 108, 403-15	165
1134	PAX2 suppresses apoptosis in renal collecting duct cells. <b>2000</b> , 157, 833-42	83
1133	Deregulation of the Rb and p53 pathways in uveal melanoma. <b>2000</b> , 157, 1795-801	100
1132	INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. <b>2000</b> , 156, 1987-96	79
1131	MDM2--master regulator of the p53 tumor suppressor protein. <b>2000</b> , 242, 15-29	511
1130	Molecular characterization of the first non-mammalian p73 cDNA. <b>2000</b> , 126, 49-57	4
1129	Differential changes of bax, caspase-3 and p21 mRNA expression after transient focal brain ischemia in the rat. <b>2000</b> , 79, 88-101	39
1128	Mechanisms underlying hypoxia-induced neuronal apoptosis. <b>2000</b> , 62, 215-49	239
1127	Absence of p51 mutation in human hepatocellular carcinoma. <b>2000</b> , 148, 161-4	4
1126	Diverse effects of 9-hydroxyellipticine on the chemosensitivity of human pancreatic cancer cells harboring p53 mutations. <b>2000</b> , 149, 85-94	5
1125	Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma. <b>2000</b> , 150, 165-70	25
1124	Diminished expression of ING1 mRNA and the correlation with p53 expression in breast cancers. <b>2000</b> , 152, 15-22	50
1123	Cell cycle regulatory failure in neurones: causes and consequences. <b>2000</b> , 21, 761-9	82
1122	[Serum p53 antibody assay: evaluation in colorectal cancer]. <b>2000</b> , 21, 167-73	5
1121	Modelling in tumour biology part 1: modelling concepts and structures. <b>2000</b> , 26, 87-94	5

1120	The (patho)physiological functions of the MRP family. <b>2000</b> , 3, 289-302	78
1119	Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. <b>2000</b> , 478, 183-6	49
1118	Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis. <b>2000</b> , 460, 17-28	37
1117	Going APE over ref-1. <b>2000</b> , 461, 83-108	432
1116	Karyotypic abnormalities associated with haemopoietic lineage switching are not linked with mutations to p53. <b>2000</b> , 32, 509-17	1
1115	The effect of dibenzo[a,1]pyrene and benzo[a]pyrene on human diploid lung fibroblasts: the induction of DNA adducts, expression of p53 and p21(WAF1) proteins and cell cycle distribution. <b>2000</b> , 471, 57-70	104
1114	Regulation of p53 stability and activity in response to genotoxic stress. <b>2000</b> , 462, 179-88	121
1113	Cholesterol and caveolae: structural and functional relationships. <b>2000</b> , 1529, 210-22	157
1112	Chromosome synapsis defects and sexually dimorphic meiotic progression in mice lacking Spo11. <b>2000</b> , 6, 989-98	531
1111	DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. <b>2000</b> , 5, 993-1002	408
1110	The ARF/p53 pathway. <b>2000</b> , 10, 94-9	565
1109	Cloak and dagger in the avoidance of immune surveillance. <b>2000</b> , 10, 114-9	8
1108	Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. <b>2000</b> , 36, 2007-17	24
1107	The use of structure-activity relationships and markers of cell toxicity to detect non-genotoxic carcinogens. <b>2000</b> , 14, 387-99	47
1106	Combined analysis of p53 and retinoblastoma protein expressions in esophageal cancer. <b>2000</b> , 70, 913-7	27
1105	Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. <b>2000</b> , 40, 183-215	102
1104	G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. <b>2000</b> , 55, 316-22	13
1103	p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. <i>Cell</i> , <b>2000</b> , 102, 849-62	56.2 1005

1102	The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. <i>Cell</i> , <b>2000</b> , 103, 897-907	56.2	257
1101	<i>Drosophila</i> p53 is a structural and functional homolog of the tumor suppressor p53. <i>Cell</i> , <b>2000</b> , 101, 91-101	56.2	333
1100	<i>Drosophila</i> p53 binds a damage response element at the reaper locus. <i>Cell</i> , <b>2000</b> , 101, 103-13	56.2	392
1099	The hallmarks of cancer. <i>Cell</i> , <b>2000</b> , 100, 57-70	56.2	20934
1098	The molecular biology of cancer. <b>2000</b> , 21, 167-223		290
1097	Profile of gene expression regulated by induced p53: connection to the TGF-beta family. <b>2000</b> , 470, 77-82		81
1096	Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. <b>2000</b> , 480, 2-16		229
1095	Convergent evolution with combinatorial peptides. <b>2000</b> , 480, 55-62		49
1094	Cell-cycle regulation of the p53-inducible gene B99. <b>2000</b> , 481, 57-62		23
1093	Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines. <b>2000</b> , 465, 124-8		38
1092	The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. <b>2000</b> , 1, 130-44		99
1091	Activation of p53 or loss of the Cockayne syndrome group B repair protein causes metaphase fragility of human U1, U2, and 5S genes. <b>2000</b> , 5, 801-10		81
1090	p53 is associated with cellular microtubules and is transported to the nucleus by dynein. <b>2000</b> , 2, 709-17		304
1089	Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. <b>2000</b> , 26, 291-9		309
1088	HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. <b>2000</b> , 19, 1491-9		111
1087	Rapid destruction of human Cdc25A in response to DNA damage. <b>2000</b> , 288, 1425-9		673
1086	An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. <b>2000</b> , 289, 304-6		404
1085	Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stress. <b>2000</b> , 2, 208-25		155

1084	Stress Response. <b>2000</b> ,	3
1083	Driving p53 response to Bax activation greatly enhances sensitivity to taxol by inducing massive apoptosis. <b>2000</b> , 2, 202-7	17
1082	Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. <b>2000</b> , 35, 71-103	482
1081	Molecular Pathology and Molecular Pharmacology of Osteosarcoma. <b>2000</b> , 19, 391-413	16
1080	The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells. <b>2000</b> , 10, 17-27	21
1079	Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines. <b>2000</b> , 37, 649-55	25
1078	Altered gene expression in lymphocytes of patients with normal-tension glaucoma. <b>2000</b> , 21, 867-76	54
1077	Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. <b>2000</b> , 275, 22627-30	136
1076	DNA Structure and Polymerase Fidelity: A New Role for A-DNA. <b>2000</b> , 17 Suppl 1, 169-76	2
1075	p53 regulates caveolin gene transcription, cell cholesterol, and growth by a novel mechanism. <b>2000</b> , 39, 1966-72	93
1074	Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. <b>2000</b> , 39, 13916-24	74
1073	Molecular mechanism of ultraviolet-induced keratinocyte apoptosis. <b>2000</b> , 20, 445-54	54
1072	Identification of a sequence element from p53 that signals for Mdm2-targeted degradation. <b>2000</b> , 20, 1243-53	54
1071	OUTCOME PREDICTION WITH p53 IMMUNOSTAINING AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER. <b>2000</b> , 163, 1756-1760	20
1070	Cell cycle and apoptosis. <b>2000</b> , 2, 291-9	382
1069	p16 Expression Begins Early in Human Colon Neoplasia and Correlates Inversely With Markers of Cell Proliferation. <b>2000</b> , 119, 929-942	6
1068	Gamma-radiation-induced growth arrest and apoptosis in p53-null lymphoma cells is accompanied by modest transcriptional changes in many genes. <b>2000</b> , 19, 29-37	5
1067	Apoptosis and schizophrenia: is the tumour suppressor gene, p53, a candidate susceptibility gene?. <b>2000</b> , 41, 405-15	133

1066	p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. <b>2000</b> , 119, 929-42	81
1065	Transfer of SV40 temperature-sensitive early gene into human epidermal keratinocytes by the recombinant adenovirus vector. <b>2000</b> , 36, 110-6	1
1064	p53 pathway in apoptosis induced by all-trans-retinoic acid in acute myeloblastic leukaemia cells. <b>2000</b> , 103, 135-43	25
1063	Development of a p53 responsive GFP reporter; identification of live cells with p53 activity. <b>2001</b> , 84, 79-86	10
1062	Induction of cell proliferation arrest and apoptosis in hepatoma cells through adenoviral-mediated transfer of p53 gene. <b>2000</b> , 32, 771-82	11
1061	P53 but not p16INK4a induces growth arrest in retinoblastoma-deficient hepatocellular carcinoma cells. <b>2000</b> , 33, 254-65	4
1060	Ah receptor ligands and tumor promotion: survival of neoplastic cells. <b>2000</b> , 112-113, 69-77	47
1059	Activation of apoptosis pathways by anticancer treatment. <b>2000</b> , 112-113, 41-8	91
1058	The relevance of spontaneous- and chemically-induced alterations in testicular germ cell apoptosis to toxicology. <b>2000</b> , 112-113, 79-86	116
1057	Animal models of melanoma: recent advances and future prospects. <b>2000</b> , 79, 123-56	37
1056	In-cell NMR spectroscopy. <b>2001</b> , 40, 14317-23	138
1055	The cell cycle. <b>2001</b> , 19, 88-91	40
1054	Cisplatin and taxol induce different patterns of p53 phosphorylation. <b>2001</b> , 3, 10-6	63
1053	Molecular targets for selenium in cancer prevention. <b>2001</b> , 40, 50-4	54
1052	Apoptosis and cerebral ischemia. <b>2001</b> , 6, 137-167	2
1051	A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. <b>2001</b> , 85, 1499-503	52
1050	Rb dephosphorylation and suppression of E2F activity in human breast tumor cells exposed to a pharmacological concentration of estradiol. <b>2001</b> , 388, 243-52	4
1049	Analysis of molecular interactions of the p53-family p51(p63) gene products in a yeast two-hybrid system: homotypic and heterotypic interactions and association with p53-regulatory factors. <b>2001</b> , 281, 1170-5	23

1048	Cadmium induces phosphorylation of p53 at serine 15 in MCF-7 cells. <b>2001</b> , 282, 1120-5	50
1047	p73beta, a variant of p73, enhances Wnt/beta-catenin signaling in Saos-2 cells. <b>2001</b> , 283, 327-33	19
1046	Rapid downregulation of cyclin D1 mRNA and protein levels by ultraviolet irradiation in murine macrophage cells. <b>2001</b> , 284, 71-6	27
1045	Expression of the cell cycle phosphatase cdc25C is down-regulated by the tumor suppressor protein p53 but not by p73. <b>2001</b> , 284, 743-50	56
1044	Identification of a novel retrovirus long terminal repeat (LTR) that is targeted by p51A (TAp63gamma) and selective dominant-negative activity of p73L (DeltaNp63alpha) toward p53-responsive promoter activities. <b>2001</b> , 286, 628-34	6
1043	Functional cross-talk of HIV-1 Tat with p53 through its C-terminal domain. <b>2001</b> , 287, 556-61	35
1042	Dynamic interactions of p53 with DNA in solution by time-lapse atomic force microscopy. <b>2001</b> , 314, 233-43	81
1041	Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition. <b>2001</b> , 21, 4246-55	275
1040	p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. <b>2001</b> , 262, 154-69	124
1039	Regulation of p53 function. <b>2001</b> , 264, 56-66	287
1038	Caspase-dependent cytosolic release of cytochrome c and membrane translocation of Bax in p53-induced apoptosis. <b>2001</b> , 265, 145-51	91
1037	Analysis of apoptosis induced by HIV-1 Vpr and examination of the possible role of the hHR23A protein. <b>2001</b> , 267, 243-57	34
1036	Characterization of human myocardial fibroblasts immortalized by HPV16 E6--E7 genes. <b>2001</b> , 268, 252-61	17
1035	Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. <b>2001</b> , 270, 66-77	118
1034	Conformation and rigidity of DNA microcircles containing waf1 response element for p53 regulatory protein. <b>2001</b> , 306, 227-38	10
1033	Structure and functionality of a designed p53 dimer. <b>2001</b> , 307, 605-17	65
1032	Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. <b>2001</b> , 72, 155-63	31
1031	Persistent p53 mutations in single cells from normal human skin. <b>2001</b> , 159, 1247-53	85

1030	p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease. <b>2001</b> , 159, 2095-105	103
1029	p53 Involvement in the control of murine hair follicle regression. <b>2001</b> , 158, 1913-9	65
1028	p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. <b>2001</b> , 158, 2067-77	79
1027	Topographical analysis of p53 expression and DNA ploidy in early bronchial squamous cell carcinoma and preneoplastic lesions. <b>2001</b> , 34, 351-61	6
1026	Preferential expression of Mdm2 oncogene during the development of neural crest and its derivatives in mouse early embryogenesis. <b>2001</b> , 103, 163-5	12
1025	Over-expression of the SUV39H1 histone methyltransferase induces altered proliferation and differentiation in transgenic mice. <b>2001</b> , 107, 141-53	46
1024	Mutations in apoptosis genes: a pathogenetic factor for human disease. <b>2001</b> , 488, 211-31	100
1023	Alterations in p53 and E2F-1 function common to immortalized chicken embryo fibroblasts. <b>2001</b> , 20, 2671-82	33
1022	Mechanisms of resistance to rapamycins. <b>2001</b> , 4, 378-91	106
1021	Protection against <i>Leishmania donovani</i> infection by DNA vaccination: increased DNA vaccination efficiency through inhibiting the cellular p53 response. <b>2001</b> , 19, 3169-78	44
1020	Cloning and characterization of murine p53 upstream sequences reveals additional positive transcriptional regulatory elements. <b>2001</b> , 274, 129-37	9
1019	The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. <b>2001</b> , 277, 15-30	190
1018	Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. <b>2001</b> , 65, 135-72	933
1017	Cloning and chromosomal localization of human WIG-1/PAG608 and demonstration of amplification with increased expression in primary squamous cell carcinoma of the lung. <b>2001</b> , 174, 179-87	9
1016	Proliferative activity and p53 expression in primary and recurrent pterygia. <b>2001</b> , 108, 985-8	61
1015	Mutation analysis of p53 in ovarian tumors by DHPLC. <b>2001</b> , 47, 73-81	49
1014	Association study of the p53-gene Pro72Arg polymorphism in schizophrenia. <b>2001</b> , 105, 279-83	17
1013	Regulation of apoptosis by somatostatin and substance P in peritoneal macrophages. <b>2001</b> , 101, 43-9	25



1012	Aggravation of brain injury after transient focal ischemia in p53-deficient mice. <b>2001</b> , 88, 54-61	30
1011	[Pro- and anti-apoptotic role of nitric oxide, NO]. <b>2001</b> , 324, 413-24	5
1010	Fluoroquinolones as chemical tools to define a strategy for photogenotoxicity in vitro assessment. <b>2001</b> , 15, 131-42	35
1009	Control of interferon signaling in human papillomavirus infection. <b>2001</b> , 12, 157-70	73
1008	Identification of genotoxic stress in human cells by fluorescent monitoring of p53 expression. <b>2001</b> , 494, 73-85	20
1007	The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. <b>2001</b> , 37, 930-8	77
1006	Biology and genetics of colorectal cancer. <b>2001</b> , 37 Suppl 7, S163-72	8
1005	Monoclonality of endocrine tumours: What does it mean?. <b>2001</b> , 12, 301-7	23
1004	p53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma. <b>2001</b> , 6, 63-67	12
1003	A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. <b>2001</b> , 7, 283-92	247
1002	PUMA induces the rapid apoptosis of colorectal cancer cells. <b>2001</b> , 7, 673-82	1046
1001	PUMA, a novel proapoptotic gene, is induced by p53. <b>2001</b> , 7, 683-94	1812
1000	A TPR motif cofactor contributes to p300 activity in the p53 response. <b>2001</b> , 8, 71-84	56
999	Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. <b>2001</b> , 8, 57-69	375
998	p53DINP1, a p53-inducible gene, regulates p53-dependent apoptosis. <b>2001</b> , 8, 85-94	283
997	Identification of hTAF(II)80 delta links apoptotic signaling pathways to transcription factor TFIID function. <b>2001</b> , 8, 591-600	59
996	Involvement of PIAS1 in the sumoylation of tumor suppressor p53. <b>2001</b> , 8, 713-8	392
995	Hypoxia death stimulus induces translocation of p53 protein to mitochondria. Detection by immunofluorescence on whole cells. <b>2001</b> , 488, 110-5	136

994	From p63 to p53 across p73. <b>2001</b> , 490, 163-70		74
993	Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. <b>2001</b> , 490, 196-201		34
992	MDM2 and MDMX can interact differently with ARF and members of the p53 family. <b>2001</b> , 490, 202-8		64
991	Analysis of trk A and p53 association. <b>2001</b> , 497, 20-5		9
990	A plant steroid, diosgenin, induces apoptosis, cell cycle arrest and COX activity in osteosarcoma cells. <b>2001</b> , 506, 225-30		122
989	Transcriptional repression of the human p53 gene by cobalt chloride mimicking hypoxia. <b>2001</b> , 507, 259-63		28
988	Overproduced p73alpha activates a minimal promoter through a mechanism independent of its transcriptional activity. <b>2001</b> , 509, 47-52		5
987	Suppression of spontaneous chromosomal rearrangements by S phase checkpoint functions in <i>Saccharomyces cerevisiae</i> . <i>Cell</i> , <b>2001</b> , 104, 397-408	56.2	276
986	Parsing Ink4a/Arf: "pure" p16-null mice. <i>Cell</i> , <b>2001</b> , 106, 531-4	56.2	62
985	Negative control of p53 by Sir2alpha promotes cell survival under stress. <i>Cell</i> , <b>2001</b> , 107, 137-48	56.2	1840
984	hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. <i>Cell</i> , <b>2001</b> , 107, 149-59	56.2	2208
983	VARIOUS FORMS OF MUTANT p53 CONFER SENSITIVITY TO CISPLATIN AND DOXORUBICIN IN BLADDER CANCER CELLS. <b>2001</b> , 166, 304-310		35
982	Apoptotic proteins. p53 and c-myc related pathways. <b>2001</b> , 19, 75-89, viii		6
981	Targeting apoptosis in prostate cancer. <b>2001</b> , 15, 509-24		29
980	p53, un gen supresor tumoral. <b>2001</b> , 98, 21-27		1
979	THE ROLE OF HYPOXIA AND p53 IN THE REGULATION OF ANGIOGENESIS IN BLADDER CANCER. <b>2001</b> , 165, 2075-2081		23
978	Cellular stress response and apoptosis in cancer therapy. <b>2001</b> , 98, 2603-14		669
977	Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved--deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. <b>2001</b> , 12, 1323-32		70

976	Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells. <b>2001</b> , 11, 21-9	13
975	Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells. <b>2001</b> , 11, 315-25	61
974	p53 as a drug target in cancer therapy. <b>2001</b> , 11, 923-935	15
973	INACTIVATION OF BOTH Rb AND p53 PATHWAYS IN MOUSE LUNG EPITHELIAL CELL LINES. <b>2001</b> , 27, 297-318	2
972	Current advances in the inhibition of the auto-regulatory interaction between the p53 tumour suppressor protein and MDM2 protein. <b>2001</b> , 11, 1825-1835	4
971	The chemistry and biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. <b>2001</b> , 22, 535-45	257
970	Checkpoint and DNA-repair proteins are associated with the cores of mammalian meiotic chromosomes. <b>2001</b> , 51, 109-34	25
969	Protein-DNA binding correlates with structural thermostability for the full-length human p53 protein. <b>2001</b> , 40, 3847-58	17
968	Histological and biological evolution of human premalignant breast disease. <b>2001</b> , 8, 47-61	263
967	Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. <b>2001</b> , 21, 1297-310	301
966	SAG/ROC/Rbx/Hrt, a zinc RING finger gene family: molecular cloning, biochemical properties, and biological functions. <b>2001</b> , 3, 635-50	74
965	Exposure to ultraviolet radiation (290-400 nm) causes oxidative stress, DNA damage, and expression of p53/p73 in laboratory experiments on embryos of the spotted salamander, <i>Ambystoma maculatum</i> . <b>2001</b> , 74, 733-41	29
964	Direct transcriptional activation of human caspase-1 by tumor suppressor p53. <b>2001</b> , 276, 10585-8	68
963	P53 mutations in thyroid carcinoma: tidings from an old foe. <b>2001</b> , 24, 536-45	34
962	JC virus in Experimental and Clinical Brain Tumorigenesis. 409-430	17
961	Polyamine depletion arrests growth of IEC-6 and Caco-2 cells by different mechanisms. <b>2001</b> , 281, G37-43	36
960	Ensuring the stability of the genome: DNA damage checkpoints. <b>2001</b> , 1, 684-702	16
959	Rapid Onset of Nucleolar Segregation Followed by DNA Fragmentation in Roscovitine-Treated MCF-7 Cells Supports Its Pro-Apoptotic Potential. <b>2001</b> , 1, 58	

958	Bromodeoxyuridine induces p53-dependent and -independent cell cycle arrests in human gastric carcinoma cell lines. <b>2001</b> , 69, 77-85	5
957	SV40 and Human Tumors. 461-489	13
956	Establishment and characterization of a new cell line (SKS) from neuroendocrine small cell carcinoma of the uterine cervix and its chemosensitivity. <b>2001</b> , 60, 367-72	7
955	Genetic Stabilization by p53 Involves Growth Regulatory and Repair Pathways. <b>2001</b> , 1, 7-10	10
954	. <b>2001</b> ,	26
953	Expression of P53 protein after exposure to ionizing radiation. <b>2001</b> ,	
952	Ethylene induces cell death at particular phases of the cell cycle in the tobacco TBY-2 cell line. <b>2001</b> , 52, 1615-1623	29
951	Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. <b>2001</b> , 19, 1405-13	232
950	Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. <b>2001</b> , 233, 630-8	62
949	Ultraviolet B-induced melanoma in <i>Monodelphis domestica</i> occurs in the absence of alterations in the structure or expression of the p53 gene. <b>2001</b> , 11, 239-45	6
948	Effects of p53 mutations on cellular sensitivity to ionizing radiation. <b>2001</b> , 24, 486-90	37
947	Effect of ultraviolet light, methyl methanesulfonate and ionizing radiation on the genotoxic response and apoptosis of mouse fibroblasts lacking c-Fos, p53 or both. <b>2001</b> , 16, 233-41	48
946	Regulation of BRCA1 and BRCA2 transcript in response to cisplatin, adriamycin, taxol and ionising radiation is correlated to p53 functional status in ovarian cancer cell lines. <b>2001</b> , 8, 663	
945	Mitomycin C and cisplatin enhanced the antitumor activity of p53-expressing adenovirus in cervical cancer cells. <b>2001</b> , 19, 360-8	5
944	Evaluation of methods to detect p53 mutations in ovarian cancer. <b>2001</b> , 60, 176-88	29
943	Transcriptional activities of p73 splicing variants are regulated by inter-variant association. <b>2001</b> , 356, 859-66	14
942	Transcriptional activities of p73 splicing variants are regulated by inter-variant association. <b>2001</b> , 356, 859-866	25
941	Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. <b>2001</b> , 359, 459-464	57

940	Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. <b>2001</b> , 359, 459-64	43
939	p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. <b>2001</b> , 98, 814-22	215
938	The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: The mechanisms involved in inhibiting cell-cycle progression. <b>2001</b> , 98, 842-50	200
937	p53 abnormalities in splenic lymphoma with villous lymphocytes. <b>2001</b> , 97, 3552-8	79
936	Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)--mediated cytotoxicity by selective up-regulation of TRAIL-R1. <b>2001</b> , 97, 2596-603	85
935	Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. <b>2001</b> , 97, 2798-807	217
934	Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. <b>2001</b> , 98, 3066-73	77
933	DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway. <b>2001</b> , 98, 834-41	78
932	Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis. <b>2001</b> , 98, 2084-90	39
931	Activation of the nitric oxide synthase pathway represents a key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated cytotoxicity on hematologic malignancies. <b>2001</b> , 98, 2220-8	68
930	Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. <b>2001</b> , 19, 1750-8	189
929	Human herpesvirus-8 and Kaposi's sarcoma: relationship with the multistep concept of tumorigenesis. <b>2001</b> , 81, 125-59	59
928	Lucilactaene, a new cell cycle inhibitor in p53-transfected cancer cells, produced by a <i>Fusarium</i> sp. <b>2001</b> , 54, 850-4	43
927	Establishment of a Tcrb and Trp53 genes deficient mouse strain as an animal model for spontaneous colorectal cancer. <b>2001</b> , 50, 41-7	10
926	Stabilization and activation of p53 by the coactivator protein TAFII31. <b>2001</b> , 276, 13852-7	34
925	Li-Fraumeni Syndrome. <b>2001</b> ,	
924	DNA arrays and functional genomics in neurobiology. <b>2001</b> , 48, 219-53	9
923	Immortalization of primary rodent cells by SV40. <b>2001</b> , 5, 7-41	

922	The induction and suppression of apoptosis by viruses. <b>2001</b> , 5, 351-411	
921	Models for studying genomic instability during aging. <b>2001</b> , 73-90	
920	Poly(ADP-ribose) polymerase and aging. <b>2001</b> , 4, 113-133	
919	Apoptosis in breast cancer. <b>2001</b> , 6, 1-22	
918	Telomerase, DNA damage and apoptosis. <b>2001</b> , 131-150	1
917	Anchorage-independent growth of p53-knockout dermal fibroblasts is reversed by wild-type p53. <b>2001</b> , 5, 18-24	1
916	What we could do now: molecular pathology of bladder cancer. <b>2001</b> , 54, 215-21	103
915	129/Sv mice--a model system for studying germ cell biology and testicular cancer. <b>2001</b> , 12, 89-94	31
914	[Gene therapy of solid tumors]. <b>2001</b> , 42, 1321-7	
913	p53 mutations are rare events in recurrent cervical cancer. <b>2001</b> , 79, 283-8	19
912	Human molecular embryogenesis: an overview. <b>2001</b> , 4, 324-43	13
911	Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells. <b>2001</b> , 101, 605-15	24
910	Caffeine-inhibitable control of the radiation-induced G2 arrest in L5178Y-S cells deficient in non-homologous end-joining. <b>2001</b> , 40, 137-43	6
909	Precancerous lesions of the colorectum. <b>2001</b> , 36, 587-94	30
908	Prognostic value of p53 mutations in patients with locally advanced esophageal carcinoma treated with definitive chemoradiotherapy. <b>2001</b> , 36, 303-11	26
907	Ionising radiation induces the expression of PARP-1 and PARP-2 genes in Arabidopsis. <b>2001</b> , 265, 954-63	107
906	Relationship between apoptosis regulator proteins (bcl-2 and p53) and Gleason score in prostate cancer. <b>2001</b> , 7, 209-12	8
905	Rapid senescence induced by overexpression of p53 in NIH3T3 cells. <b>2001</b> , 46, 653-656	

904	Interaction between potential doubling time and TP53 mutation: predicting radiotherapy outcome in squamous cell carcinoma of the head and neck. <b>2001</b> , 49, 519-25	16
903	HIPK2 overexpression leads to stabilization of p53 protein and increased p53 transcriptional activity by decreasing Mdm2 protein levels. <b>2001</b> , 2, 8	32
902	p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours. <b>2001</b> , 34, 1-14	22
901	Keratinocyte adhesion and the missing link: from Dowling-Meara to Hay-Wells. St John's Hospital Dermatological Society Annual Oration 2000. <b>2001</b> , 26, 296-304	5
900	De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. <b>2001</b> , 125, 3-9	57
899	Role of DNA-dependent protein kinase in neuronal survival. <b>2001</b> , 78, 141-54	48
898	Dynamic forces in the cell cycle affecting fibroblasts in pressure ulcers. <b>2001</b> , 9, 19-27	11
897	The genetics of transitional cell carcinoma: progress and potential clinical application. <b>1999</b> , 84, 412-27	77
896	Binding of p53 and its core domain to supercoiled DNA. <b>2001</b> , 268, 573-81	33
895	Hydrogen exchange of the tetramerization domain of the human tumour suppressor p53 probed by denaturants and temperature. <b>2001</b> , 268, 4868-77	10
894	Action of glucocorticoids on survival of nerve cells: promoting neurodegeneration or neuroprotection?. <b>2001</b> , 13, 749-60	101
893	An approach to enhancing the phototoxicity of a novel hypocrellin congener to MGC803 cells. <b>2001</b> , 51, 103-110	9
892	Radiation-induced chromatid breaks and deficient DNA repair in cancer predisposition. <b>2001</b> , 37, 87-96	38
891	Gene mutation as a target for early detection in cancer diagnosis. <b>2001</b> , 40, 195-213	11
890	Mutation and abnormal expression of the p53 gene in the viral skin carcinogenesis of epidermodysplasia verruciformis. <b>2001</b> , 117, 935-42	36
889	Genotyping single nucleotide polymorphisms using intact polymerase chain reaction products by electrospray quadrupole mass spectrometry. <b>2001</b> , 15, 1752-9	23
888	2-methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. <b>2001</b> , 31, 111-24	68
887	P53 mutations in primary tumors and subsequent liver metastases are related to survival in patients with colorectal carcinoma who undergo liver resection. <b>2001</b> , 91, 727-736	23

886	Expression of p53 and human herpesvirus-8 (HHV-8)-encoded latency-associated nuclear antigen with inhibition of apoptosis in HHV-8-associated malignancies. <b>2001</b> , 92, 3076-84	74
885	Association between CagA+ Helicobacter pylori infection and p53, bax and transforming growth factor-beta-RII gene mutations in gastric cancer patients. <b>2001</b> , 91, 481-5	21
884	Potential molecular prognostic markers in head and neck squamous cell carcinomas. <b>2001</b> , 23, 147-59	119
883	Emerging roles for telomerase in neuronal development and apoptosis. <b>2001</b> , 63, 1-9	58
882	Characterization of a nuclear factor that binds to AP1-like element in the rat p53 promoter during liver regeneration. <b>2000</b> , 80, 124-32	2
881	Characterization of nuclear factors binding to AT-rich element in the rat p53 promoter. <b>2001</b> , 80, 580-8	6
880	Wild-type p53 inhibits protein kinase CK2 activity. <b>2001</b> , 81, 172-83	47
879	Retinoic acid-induced apoptosis of the CHP134 neuroblastoma cell line is associated with nuclear accumulation of p53 and is rescued by the GDNF/Ret signal. <b>2001</b> , 36, 122-6	14
878	Analysis of p53-dependent mechanisms in the maintenance of genetic stability in diploid tumourigenic line SK-UT-1B of human uterine leiomyosarcoma. <b>2001</b> , 25, 1101-15	5
877	Motor neurons rapidly accumulate DNA single-strand breaks after in vitro exposure to nitric oxide and peroxynitrite and in vivo axotomy. <b>2001</b> , 432, 35-60	50
876	Injury-induced apoptosis of neurons in adult brain is mediated by p53-dependent and p53-independent pathways and requires Bax. <b>2001</b> , 433, 299-311	54
875	Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma. <b>2001</b> , 92, 805-11	25
874	Role of p53 in the responses of human urothelial cells to genotoxic damage. <b>2001</b> , 93, 199-203	9
873	Superficial and metachronous invasive bladder carcinomas are clonally related. <b>2001</b> , 93, 699-702	20
872	The gene PC3(TIS21/BTG2), prototype member of the PC3/BTG/TOB family: regulator in control of cell growth, differentiation, and DNA repair?. <b>2001</b> , 187, 155-65	192
871	Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. <b>2001</b> , 188, 98-105	117
870	Apoptosis and its clinical impact. <b>2001</b> , 23, 409-25	53
869	Use of mutation spectra analysis software. <b>2001</b> , 17, 83-102	34



868	Perspectives for mass spectrometry and functional proteomics. <b>2001</b> , 20, 1-57	232
867	Caenorhabditis elegans p53: role in apoptosis, meiosis, and stress resistance. <b>2001</b> , 294, 591-5	381
866	Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. <b>2001</b> , 491, 369-402	329
865	Nitric oxide protects thymocytes from gamma-irradiation-induced apoptosis in correlation with inhibition of p53 upregulation and mitochondrial damage. <b>2001</b> , 214, 72-80	10
864	p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. <b>2001</b> , 83, 348-54	38
863	Cellular transformation by SV40 large T antigen: interaction with host proteins. <b>2001</b> , 11, 15-23	295
862	Role of T antigen interactions with p53 in tumorigenesis. <b>2001</b> , 11, 23-30	155
861	The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model. <b>2001</b> , 11, 201-18	30
860	Hydrocarbon carcinogens evade cellular defense mechanism of G1 arrest in nontransformed and malignant lung cell lines. <b>2001</b> , 173, 105-13	22
859	Dual interaction of a geminivirus replication accessory factor with a viral replication protein and a plant cell cycle regulator. <b>2001</b> , 279, 570-6	62
858	Sp1-p53 heterocomplex mediates activation of HTLV-I long terminal repeat by 12-O-tetradecanoylphorbol-13-acetate that is antagonized by protein kinase C. <b>2001</b> , 281, 10-20	53
857	Integration of the pRB and p53 cell cycle control pathways. <b>2001</b> , 51, 183-204	18
856	The INK4A/ARF locus: role in cell cycle control and apoptosis and implications for glioma growth. <b>2001</b> , 51, 219-29	61
855	The role of p53 in human cancer. <b>2001</b> , 51, 231-43	40
854	Genetic basis of pituitary adenoma invasiveness: a review. <b>2001</b> , 52, 195-204	29
853	Absence of germline and somatic p53 alterations in children with sporadic brain tumors. <b>2001</b> , 52, 227-35	15
852	TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme. <b>2001</b> , 52, 263-72	30
851	The interface between the cell cycle and plant growth regulators: a mini review. <b>2001</b> , 33, 1-12	99

850	The potential of TRAIL for cancer chemotherapy. <b>2001</b> , 6, 191-7	116
849	A putative protein inhibitor of activated STAT (PIASy) interacts with p53 and inhibits p53-mediated transactivation but not apoptosis. <b>2001</b> , 6, 221-34	54
848	Induction of apoptosis by estramustine phosphate mediated by phosphorylation of bcl-2. <b>2001</b> , 54, 23-9	
847	Translational regulation as a novel mechanism for the development of cellular drug resistance. <b>2001</b> , 20, 33-41	15
846	The molecular determinants of sunburn cell formation. <b>2001</b> , 10, 155-60	102
845	Regulation of the cell cycle by p53 after DNA damage in an amphibian cell line. <b>2001</b> , 20, 3766-75	12
844	Germline TP53 alterations in Finnish breast cancer families are rare and occur at conserved mutation-prone sites. <b>2001</b> , 84, 116-9	29
843	Detection of p73 antibodies in patients with various types of cancer: immunological characterization. <b>2001</b> , 84, 57-63	19
842	Contrasting molecular pathology of colorectal carcinoma in Egyptian and Western patients. <b>2001</b> , 85, 1037-46	62
841	Spontaneous and inducible apoptosis in oesophageal adenocarcinoma. <b>2001</b> , 85, 1781-6	9
840	The death substrate Gas2 binds m-calpain and increases susceptibility to p53-dependent apoptosis. <b>2001</b> , 20, 2702-14	84
839	Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice. <b>2001</b> , 20, 3535-43	58
838	Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. <b>2001</b> , 20, 4163-72	76
837	Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. <b>2001</b> , 20, 4912-22	169
836	Two molecularly distinct intracellular pathways to oligodendrocyte differentiation: role of a p53 family protein. <b>2001</b> , 20, 5261-8	67
835	hADA3 is required for p53 activity. <b>2001</b> , 20, 6404-13	72
834	p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. <b>2001</b> , 20, 1931-9	108
833	Werner syndrome: genetic and molecular basis of a premature aging disorder. <b>2001</b> , 58, 857-67	41

832	Carcinogenesis of cancer of the papilla and ampulla: pathophysiological facts and molecular biological mechanisms. <b>2001</b> , 386, 163-71	24
831	ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture. <b>2001</b> , 50, 511-23	76
830	Role of MMP-2 in alveolar epithelial cell repair after bleomycin administration in rabbits. <b>2001</b> , 81, 1309-18	51
829	Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation. <b>2001</b> , 27, 31-9	567
828	A structural view of mitochondria-mediated apoptosis. <b>2001</b> , 8, 394-401	246
827	P53 and Ki-67 as outcome predictors for advanced squamous cell cancers of the head and neck treated with chemoradiotherapy. <b>2001</b> , 111, 1878-92	30
826	Latent and active p53 are identical in conformation. <b>2001</b> , 8, 756-60	227
825	Ectopic expression of cyclin D1 impairs the proliferation and enhances the apoptosis of a murine lymphoid cell line. <b>2001</b> , 8, 51-62	18
824	Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. <b>2001</b> , 8, 457-69	25
823	p53-dependent pathways of apoptosis. <b>2001</b> , 8, 1049-51	148
822	Functional interactions and signaling properties of mammalian DNA mismatch repair proteins. <b>2001</b> , 8, 1076-92	159
821	Effects of adenoviral wild-type p53 gene transfer in p53-mutated lymphoma cells. <b>2001</b> , 8, 430-9	20
820	Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. <b>2001</b> , 8, 803-14	35
819	p53-independent upregulation of p21WAF1 in NIH 3T3 cells malignantly transformed by mot-2. <b>2001</b> , 11, 55-60	5
818	Intravascular injections of a conditional replicative adenovirus (adl118) prevent metastatic disease in human breast carcinoma xenografts. <b>2001</b> , 8, 1627-34	12
817	The leukemogenic transcription factor E2a-Pbx1 induces expression of the putative N-myc and p53 target gene NDRG1 in Ba/F3 cells. <b>2001</b> , 15, 362-70	21
816	Comparison of the effects of recombinant adenovirus-mediated expression of wild-type p53 and p27Kip1 on cell cycle and apoptosis in SUDHL-1 cells derived from anaplastic large cell lymphoma. <b>2001</b> , 15, 1225-31	9
815	Mdr1b facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo. <b>2001</b> , 20, 303-13	17

814	Negative regulation of bcl-2 expression by p53 in hematopoietic cells. <b>2001</b> , 20, 240-51	190
813	p53 upregulates cFLIP, inhibits transcription of NF-kappaB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells. <b>2001</b> , 20, 571-80	86
812	A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function. <b>2001</b> , 20, 659-68	71
811	p53 activation in response to microtubule disruption is mediated by integrin-Erk signaling. <b>2001</b> , 20, 899-909	58
810	p53 regulates ceramide formation by neutral sphingomyelinase through reactive oxygen species in human glioma cells. <b>2001</b> , 20, 1368-78	85
809	Human ARF binds E2F1 and inhibits its transcriptional activity. <b>2001</b> , 20, 1033-41	142
808	Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis. <b>2001</b> , 20, 1445-54	22
807	A monoclonal antibody against DNA binding helix of p53 protein. <b>2001</b> , 20, 1398-401	5
806	The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. <b>2001</b> , 20, 1267-75	67
805	Evidence that wild-type p53 in neuroblastoma cells is in a conformation refractory to integration into the transcriptional complex. <b>2001</b> , 20, 1307-17	31
804	Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. <b>2001</b> , 20, 3290-300	118
803	Enhancement of p53-dependent gene activation by the transcriptional coactivator Zac1. <b>2001</b> , 20, 2134-43	86
802	Mutant K-ras enhances apoptosis in embryonic stem cells in combination with DNA damage and is associated with increased levels of p19(ARF). <b>2001</b> , 20, 2144-52	30
801	The 'wildtype' conformation of p53: epitope mapping using hybrid proteins. <b>2001</b> , 20, 2318-24	39
800	DNA microarrays identification of primary and secondary target genes regulated by p53. <b>2001</b> , 20, 2225-34	282
799	p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis. <b>2001</b> , 20, 2720-5	26
798	Regulation of p53 expression by the RAS-MAP kinase pathway. <b>2001</b> , 20, 2527-36	43
797	Retinoic acid activates p53 in human embryonal carcinoma through retinoid receptor-dependent stimulation of p53 transactivation function. <b>2001</b> , 20, 2559-69	47

796	The role of tetramerization in p53 function. <b>2001</b> , 20, 2611-7	197
795	Transcription factors Oct-1 and NF-YA regulate the p53-independent induction of the GADD45 following DNA damage. <b>2001</b> , 20, 2683-90	91
794	Accumulation of high levels of the p53 and p130 growth-suppressing proteins in cell lines stably over-expressing cyclin-dependent kinase 6 (cdk6). <b>2001</b> , 20, 2889-99	17
793	p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. <b>2001</b> , 20, 3193-205	247
792	DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1. <b>2001</b> , 20, 3449-55	130
791	A sequence element of p53 that determines its susceptibility to viral oncoprotein-targeted degradation. <b>2001</b> , 20, 3519-27	16
790	p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. <b>2001</b> , 20, 3573-9	120
789	Hormonal Regulation of Germ Cell Apoptosis. <b>1998</b> , 150-164	2
788	The Multifunctional Nucleolar Protein Nucleophosmin/NPM/B23 and the Nucleoplasmin Family of Proteins. <b>2011</b> , 213-252	3
787	Molecular Mechanisms of Colorectal Carcinogenesis. <b>2013</b> , 25-65	5
786	Genetic Studies on the Effects of Nanomaterials. <b>2014</b> , 177-199	2
785	Hypoxia and the DNA Damage Response. <b>2014</b> , 21-41	1
784	Pyridoxal isonicotinoyl hydrazone and its analogues. <b>2002</b> , 509, 205-29	28
783	Therapeutic potential of iron chelators in cancer therapy. <b>2002</b> , 509, 231-49	31
782	Evolution of Secondary Hematologic Disorders: PREMDS->MDS->sAML. <b>2001</b> , 185-230	8
781	Relationship between Ras pathways and cell cycle control. <b>2000</b> , 4, 1-17	18
780	Circadian variation of cell proliferation and cell cycle protein expression in man: clinical implications. <b>2000</b> , 4, 193-206	79
779	Histone acetylation and the control of the cell cycle. <b>2000</b> , 4, 41-7	20

778	Alternative product of the p16/CKDN2A locus connects the Rb and p53 tumor suppressors. <b>2000</b> , 4, 71-81	19
777	Activation of apoptosis pathways by anticancer drugs. <b>1999</b> , 457, 237-44	25
776	BCL-2 stimulates Apoptin-induced apoptosis. <b>1999</b> , 457, 245-9	34
775	Repair of Oxidative DNA Damage and Aging. <b>1999</b> , 295-311	3
774	Control of Apoptosis Through Gene Regulation. <b>1998</b> , 119-142	1
773	In vitro survival of human neoplastic germ cells. <b>1998</b> , 444, 59-65; discussion 65-6	5
772	Deciphering Molecular Circuitry Using High-Density DNA Arrays. <b>1998</b> , 85-108	1
771	Viral Mechanisms of Human Carcinogenesis. <b>2002</b> , 233-247	1
770	Novel Molecular Targets for Cancer Drug Discovery. <b>2002</b> , 521-540	2
769	Cancer Genes. <b>2002</b> , 45-64	6
768	Apoptosis in Ischemic Disease. <b>2003</b> , 225-236	1
767	Molecular Pathways of Drug Resistance. <b>2004</b> , 463-489	1
766	The Role of Tumor Suppressor Genes in Breast Cancer Progression. <b>1999</b> , 119-132	1
765	The Cell Cycle. <b>1998</b> , 65-72	1
764	Oncogenes and Tumor Suppressor Genes. <b>1998</b> , 73-82	4
763	Apoptosis. <b>2006</b> , 709-719	1
762	Compounds that Abrogate the G2 Checkpoint. <b>2008</b> , 117-133	1
761	Inflammatory bowel disease: a model of chronic inflammation-induced cancer. <b>2009</b> , 511, 193-233	33

760	Molecular Basis of Lung Carcinogenesis. <b>2017</b> , 447-496	1
759	Malignant Peripheral Nerve Sheath Tumors. <b>2008</b> , 43-81	3
758	Of Escherichia coli and Man: Understanding Glioma Resistance to Temozolomide Therapy. <b>2009</b> , 679-711	3
757	The NF- $\kappa$ B Signaling Pathway in GBMs: Implications for Apoptotic and Inflammatory Responses and Exploitation for Therapy. <b>2009</b> , 1011-1036	3
756	Post-translational modification of p53 by ubiquitin. <b>2010</b> , 647, 305-15	1
755	IERS Is a p53-Regulated Activator of HSF1 That Contributes to Promotion of Cancer. <b>2019</b> , 253-272	1
754	Ubiquitin-Regulated Cell Proliferation and Cancer. <b>2020</b> , 1233, 3-28	5
753	Targeted Senolytic Strategies Based on the Senescent Surfaceome. <b>2020</b> , 103-130	2
752	Genetic instability and tumor cell variation. <b>1998</b> , 179-234	1
751	Targeting Heat Shock Proteins in Colorectal Cancer. <b>2015</b> , 345-379	2
750	Zinc and Zinc-Dependent Proteins in Cancer and Chemotherapeutics. <b>2017</b> , 69-94	2
749	Structure and function of latency-associated nuclear antigen. <b>2007</b> , 312, 101-36	103
748	Mutation accumulation in vivo and the importance of genome stability in aging and cancer. <b>2000</b> , 29, 165-80	6
747	The p53 tumor suppressor gene: structure, function and mechanism of action. <b>1999</b> , 23, 145-72	5
746	CD95 (APO-1/Fas) in hematopoietic diseases. <b>1998</b> , 24, 157-74	2
745	Regulation of the cell cycle by the Rb tumor suppressor family. <b>1998</b> , 22, 149-79	14
744	Differences in the molecular biology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. <b>2010</b> , 182, 65-72	10
743	Genetic Predisposition and Genetic Susceptibility. <b>2012</b> , 69-94	3

742	Systemic and Topical Use of Green Tea Polyphenols for Healthy Skin. <b>2010</b> , 71-83	1
741	Overview of viruses, cancer, and vaccines in concept and in reality. <b>1998</b> , 154, 345-62	3
740	Mutation spectra resulting from carcinogenic exposure: from model systems to cancer-related genes. <b>1998</b> , 154, 97-124	22
739	Pathology of human bronchioloalveolar carcinoma and its relationship to the ovine disease. <b>2003</b> , 275, 225-48	46
738	Molecular Dissection of the Prostate Cancer Genome. <b>2003</b> , 25-40	2
737	p21/p53, cellular growth control and genomic integrity. <b>1998</b> , 227, 121-37	111
736	Toxicology of cadmium and its damage to mammalian organs. <b>2013</b> , 11, 415-90	104
735	Interaction of Dimeric S100B with the Tumor Suppressor Protein p53: A Model for Ca <sup>2+</sup> -Dependent S100-Target Protein Interactions. <b>2000</b> , 521-539	6
734	UVR-Induced Skin Cancer. <b>2019</b> , 41-46	2
733	DNA Damage Response Pathways and Cancer. <b>2008</b> , 139-152	3
732	Gene Therapy of Ovarian Cancer—State-of-the-Art and Future Perspectives. <b>2003</b> , 277-304	1
731	Apoptosis in the Gastrointestinal Tract. <b>2006</b> , 345-373	5
730	Genetic Modification and Cloning in Mammals. <b>2002</b> , 227-246	1
729	Role of Thioredoxin and Redox Regulation in Oxidative Stress Response and Signaling. <b>2000</b> , 297-310	2
728	Pemphigus an Autoimmune Disease of the Skin: Cell-Cell Separation Versus Membranal Signaling and Apoptosis in Acantholysis. <b>1999</b> , 197-207	2
727	Cell Survival and Death in Rheumatic Diseases. <b>2009</b> , 379-395	1
726	Osteosarcoma. <b>2009</b> , 871-910	4
725	Gene Therapy in the Treatment of Knee Disorders. <b>2012</b> , e4-1-e4-31	2



724	IRF9 promotes apoptosis and innate immunity by inhibiting SIRT1-p53 axis in fish. <b>2020</b> , 103, 220-228	4
723	Design and development of high affinity dual anticancer peptide-inhibitors against p53-MDM2/X interaction. <b>2020</b> , 245, 117358	7
722	Mixed adenoneuroendocrine carcinoma of the gallbladder, ampicrine type: Case report and review of literature. <b>2020</b> , 216, 152997	3
721	Stable binding of the eukaryotic acidic phosphoproteins to the ribosome is not an absolute requirement for in vivo protein synthesis.. <b>1992</b> , 267, 12061-12067	62
720	Nâ and nâ polyunsaturated fatty acids induce cytostasis in human urothelial cells independent of p53 gene function. <b>2000</b> , 41, 1509-1515	12
719	Cyclin-dependent kinases as targets for cancer therapy. <b>2003</b> , 21, 145-70	15
718	Cyclin-dependent kinases as targets for cancer therapy. <b>2005</b> , 22, 135-62	13
717	Treacher Collins syndrome: etiology, pathogenesis and prevention.	1
716	Saving face: rescuing a craniofacial birth defect.	1
715	Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function.	1
714	PARP-1 modifies the effectiveness of p53-mediated DNA damage response.	1
713	Expression of p53, bcl-2, and bax as predictors of response to radiotherapy in esophageal cancer. <b>2000</b> , 13, 185-90	8
712	p53 accumulates but is functionally impaired when DNA synthesis is blocked. <b>2001</b> , 98, 1036-41	75
711	Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. <b>2001</b> , 98, 1188-93	142
710	MEKK1/JNK signaling stabilizes and activates p53. <b>1998</b> , 95, 10541-6	386
709	Potential dynamic analysis of tumor suppressor p53 regulated by Wip1 protein. <b>2020</b> , 29, 068704	3
708	Multiple Primary Cancers. <b>2006</b> , 1269-1280	6
707	Hypermotability in carcinogenesis. <b>1998</b> , 148, 1619-26	38

706	SEL-5, a serine/threonine kinase that facilitates lin-12 activity in <i>Caenorhabditis elegans</i> . <b>1999</b> , 153, 1641-54	13
705	Likelihood models of somatic mutation and codon substitution in cancer genes. <b>2003</b> , 165, 695-705	30
704	Modeling and measurement of signaling outcomes affecting decision making in noisy intracellular networks using machine learning methods. <b>2020</b> , 12, 122-138	1
703	The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer. <b>2001</b> , 165, 2075-81	10
702	p53 AND MICROVESSEL DENSITY IN PRIMARY RESECTION SPECIMENS OF SUPERFICIAL BLADDER CANCER. <b>2002</b> , 1469-1474	3
701	Prolonged survival of heart allografts from p53-deficient mice. <b>2000</b> , 69, 2634-40	9
700	Polyomavirus large- and small-T relieve middle-T-induced cell cycle arrest in normal fibroblasts. <b>1999</b> , 80 ( Pt 11), 2917-2921	2
699	Failure of viral oncoproteins to target the p53-homologue p51A. <b>1999</b> , 80 ( Pt 12), 3251-3255	25
698	The adenovirus E4 ORF6 and E1b 55 kDa proteins cooperate in a p53-independent manner to enhance transduction by recombinant adeno-associated virus vectors. <b>2000</b> , 81, 2983-2991	3
697	Adenovirus E1-transformed cells grow despite the continuous presence of transcriptionally active p53. <b>2002</b> , 83, 2047-2057	13
696	Role of p53/NF- $\kappa$ B functional balance in respiratory syncytial virus-induced inflammation response. <b>2018</b> , 99, 489-500	9
695	Hepatitis B virus X protein stimulates cell growth by downregulating p16 levels via PA28-mediated proteasomal degradation. <b>2020</b> , 101, 963-971	1
694	Transcription factor activities enhance markers of drug response in cancer.	3
693	High mobility group protein-1 (HMG-1) is a unique activator of p53. <b>1998</b> , 12, 462-72	255
692	p53-mediated apoptosis is attenuated in Werner syndrome cells. <b>1999</b> , 13, 1355-60	136
691	Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1. <b>2000</b> , 14, 34-44	535
690	Hypersensitivity to DNA damage leads to increased apoptosis during early mouse development. <b>2000</b> , 14, 2072-2084	101
689	Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. <b>2000</b> , 14, 278-288	419

688	The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. <b>2000</b> , 14, 289-300	470
687	PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. <b>2000</b> , 14, 704-718	165
686	Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. <b>2000</b> , 14, 981-993	247
685	Cofactor requirements for transcriptional activation by Sp1. <b>1998</b> , 63, 189-99	38
684	Role of general and gene-specific cofactors in the regulation of eukaryotic transcription. <b>1998</b> , 63, 201-18	137
683	The interplay between nonhomologous end-joining and cell cycle checkpoint factors in development, genomic stability, and tumorigenesis. <b>2000</b> , 65, 395-403	17
682	The transcriptional program following p53 activation. <b>2000</b> , 65, 475-82	26
681	Transcriptional regulation by p53 and p73. <b>2005</b> , 70, 121-8	15
680	Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis. <b>2020</b> , 111, 2482-2487	7
679	The Many Forks in FOXO's Road. <b>2003</b> , 2003, re5-re5	42
678	Introduction to DNA Tumor Viruses: Adenovirus, Simian Virus 40, and Polyomavirus. 51-86	9
677	Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells. <b>1997</b> , 71, 8149-56	29
676	The relative role of lymphocyte granule exocytosis versus death receptor-mediated cytotoxicity in viral pathophysiology. <b>1998</b> , 72, 1-9	50
675	Adenovirus E1B 55K represses p53 activation in vitro. <b>1998</b> , 72, 3146-54	119
674	Evidence of a role for phosphatidylinositol 3-kinase activation in the blocking of apoptosis by polyomavirus middle T antigen. <b>1998</b> , 72, 3221-6	51
673	Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. <b>1998</b> , 72, 6348-55	108
672	p53 protein is a suppressor of papillomavirus DNA amplificational replication. <b>1998</b> , 72, 6822-31	32
671	Human cytomegalovirus UL69 protein induces cells to accumulate in G1 phase of the cell cycle. <b>1999</b> , 73, 676-83	94

670	Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. <b>1999</b> , 73, 8245-55	164
669	Baculovirus p33 binds human p53 and enhances p53-mediated apoptosis. <b>1999</b> , 73, 1227-34	27
668	The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. <b>1999</b> , 73, 2074-83	92
667	p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. <b>1999</b> , 73, 5333-44	213
666	The presence of human immunodeficiency virus type 1 Vpr correlates with a decrease in the frequency of mutations in a plasmid shuttle vector. <b>1999</b> , 73, 7132-7	16
665	Middle T antigen activation of signal transduction pathways does not overcome p53-mediated growth arrest. <b>1999</b> , 73, 7882-5	3
664	Suprabasal p53 immunoexpression is strongly associated with high grade dysplasia and risk for malignant transformation in potentially malignant oral lesions from Northern Ireland. <b>2002</b> , 55, 98-104	52
663	New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. <b>2002</b> , 55, 180-3	13
662	A mouse model of human oral-esophageal cancer. <b>2002</b> , 110, 761-769	77
661	p53-dependent ceramide response to genotoxic stress. <b>1998</b> , 102, 329-39	132
660	A mouse model of human oral-esophageal cancer. <b>2002</b> , 110, 761-9	48
659	Cellular senescence in cancer treatment: friend or foe?. <b>2004</b> , 113, 169-74	76
658	Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism. <b>2006</b> , 116, 2901-13	80
657	Disruption of p53 in human cancer cells alters the responses to therapeutic agents. <b>1999</b> , 104, 263-9	793
656	Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. <b>2000</b> , 105, 533-9	80
655	Biochemical and Genetic Control of Apoptosis: Relevance to Normal Hematopoiesis and Hematological Malignancies. <b>1999</b> , 93, 3587-3600	7
654	Regulated Genomic Instability and Neoplasia in the Lymphoid Lineage. <b>1999</b> , 94, 3997-4010	3
653	The Potential of Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class as Effective Antiproliferative Agents III: The Effect of the Ligands on Molecular Targets Involved in Proliferation. <b>1999</b> , 94, 781-792	2

652	Mutation of the p53 Gene Is Not a Typical Feature of Hodgkin and Reed-Sternberg Cells in Hodgkin's Disease. <b>1999</b> , 94, 1755-1760	53
651	Mutation of the p53 Gene Is Not a Typical Feature of Hodgkin and Reed-Sternberg Cells in Hodgkin's Disease. <b>1999</b> , 94, 1755-1760	3
650	LPS induces apoptosis in macrophages mostly through the autocrine production of TNF- $\alpha$ . <b>2000</b> , 95, 3823-3831	35
649	Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. <b>2000</b> , 96, 269-274	5
648	Stable expression of Epstein-Barr virus BZLF-1-encoded ZEBRA protein activates p53-dependent transcription in human Jurkat T-lymphoblastoid cells. <b>2000</b> , 96, 625-634	10
647	Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells. <b>2004</b> , 3, 8	70
646	Exploring the multiple roles of guardian of the genome: P53. <b>2020</b> , 21,	16
645	Redox Regulation of Gene Expression and Transcription Factors in Response to Environmental Oxidants. <b>2001</b> ,	1
644	Carbon Monoxide and Vascular Smooth Muscle Cell Growth. <b>2001</b> , 45-65	2
643	Genetic Instability of Cancer. <b>2013</b> , 63-91	1
642	p53--the link between inflammation and cancer?. <b>2000</b> , 47, 573	3
641	Pax3 functions in cell survival and in pax7 regulation. <b>1999</b> , 126, 1665-1674	122
640	Activation of p53-mediated cell cycle checkpoint in response to micronuclei formation. <b>1998</b> , 111, 977-984	42
639	Reversal of myogenic terminal differentiation by SV40 large T antigen results in mitosis and apoptosis. <b>1998</b> , 111, 1081-1093	44
638	p53-independent apoptosis induced by muscle differentiation stimuli in polyomavirus large T-expressing myoblasts. <b>1999</b> , 112, 2397-2407	5
637	The p53/p63/p73 family of transcription factors: overlapping and distinct functions. <b>2000</b> , 113, 1661-1670	373
636	Unscheduled re-entry into the cell cycle induced by NGF precedes cell death in nascent retinal neurones. <b>2000</b> , 113, 1139-1148	52
635	Low-energy laser irradiation promotes the survival and cell cycle entry of skeletal muscle satellite cells. <b>2002</b> , 115, 1461-1469	128

634	DNA ligase I null mouse cells show normal DNA repair activity but altered DNA replication and reduced genome stability. <b>2002</b> , 115, 1551-1561	52
633	Loss of Heterochromatin Protein 1 (HP1) chromodomain function in mammalian cells by intracellular antibodies causes cell death. <b>2002</b> , 115, 1803-1813	20
632	Hypoxia-inducible factor-1 $\beta$ protects cervical carcinoma cells from apoptosis induced by radiation via modulation of vascular endothelial growth factor and p53 under hypoxia. <b>2015</b> , 21, 318-25	39
631	Flavonoids: A new generation molecule to stimulate programmed cell deaths in cancer cells.. <b>2017</b> , 18, 30-37	1
630	Prolonged Effect of 5-Fluorouracil and Its Derivatives on Apoptosis Induction and Mitotic Inhibition in the Intestinal Epithelium of Male BDF1 Mice.. <b>1998</b> , 11, 177-182	4
629	Tongue Carcinogenic Susceptibility of p53 Deficient Mice to Methyl-n-amyl nitrosamine. <b>2002</b> , 15, 209-214	4
628	Susceptibility of Heterozygous and Nullizygous p53 Knockout Mice to Chemical Carcinogens: Tissue Dependence and Role of p53 Gene Mutations. <b>2005</b> , 18, 121-134	2
627	Feedbacks, Bifurcations, and Cell Fate Decision-Making in the p53 System. <b>2016</b> , 12, e1004787	33
626	Homeostatic imbalance between apoptosis and cell renewal in the liver of premature aging Xpd mice. <b>2008</b> , 3, e2346	24
625	Characterization of the p53 response to oncogene-induced senescence. <b>2008</b> , 3, e3230	32
624	Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression. <b>2009</b> , 4, e6654	56
623	Cyclin B1/Cdk1 phosphorylation of mitochondrial p53 induces anti-apoptotic response. <b>2010</b> , 5, e12341	40
622	Gene profiling of MTA1 identifies novel gene targets and functions. <b>2011</b> , 6, e17135	28
621	High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. <b>2012</b> , 7, e38892	66
620	Simulating molecular mechanisms of the MDM2-mediated regulatory interactions: a conformational selection model of the MDM2 lid dynamics. <b>2012</b> , 7, e40897	13
619	p53 inactivation upregulates p73 expression through E2F-1 mediated transcription. <b>2012</b> , 7, e43564	27
618	Vapor of volatile oils from Litsea cubeba seed induces apoptosis and causes cell cycle arrest in lung cancer cells. <b>2012</b> , 7, e47014	34
617	Cross-species genome wide expression analysis during pluripotent cell determination in mouse and rat preimplantation embryos. <b>2012</b> , 7, e47107	10

616	An approach for the identification of targets specific to bone metastasis using cancer genes interactome and gene ontology analysis. <b>2012</b> , 7, e49401	14
615	ATM suppresses SATB1-induced malignant progression in breast epithelial cells. <b>2012</b> , 7, e51786	16
614	SUMOylation of mouse p53b by SUMO-1 promotes its pro-apoptotic function in ovarian granulosa cells. <b>2013</b> , 8, e63680	9
613	Association of a genetic variation in a miR-191 binding site in MDM4 with risk of esophageal squamous cell carcinoma. <b>2013</b> , 8, e64331	52
612	IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. <b>2013</b> , 8, e68782	74
611	Preclinical evaluation of 4-methylthiobutyl isothiocyanate on liver cancer and cancer stem cells with different p53 status. <b>2013</b> , 8, e70846	13
610	Clonal expansion analysis of transposon insertions by high-throughput sequencing identifies candidate cancer genes in a PiggyBac mutagenesis screen. <b>2013</b> , 8, e72338	12
609	CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status. <b>2013</b> , 8, e72849	15
608	Reactive oxygen species mediate Epstein-Barr virus reactivation by N-methyl-N'-nitro-N-nitrosoguanidine. <b>2013</b> , 8, e84919	26
607	Metallic nickel nanoparticles may exhibit higher carcinogenic potential than fine particles in JB6 cells. <b>2014</b> , 9, e92418	32
606	A novel ATM/TP53/p21-mediated checkpoint only activated by chronic irradiation. <b>2014</b> , 9, e104279	23
605	The functional TP53 rs1042522 and MDM4 rs4245739 genetic variants contribute to Non-Hodgkin lymphoma risk. <b>2014</b> , 9, e107047	21
604	Analysis of tumor suppressor genes based on gene ontology and the KEGG pathway. <b>2014</b> , 9, e107202	37
603	Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice. <b>2015</b> , 10, e0118029	3
602	Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells. <b>2015</b> , 10, e0125779	37
601	Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment. <b>2015</b> , 10, e0128807	19
600	Inactivation of p53 Is Sufficient to Induce Development of Pulmonary Hypertension in Rats. <b>2015</b> , 10, e0131940	32
599	Long Noncoding RNA MEG3 Interacts with p53 Protein and Regulates Partial p53 Target Genes in Hepatoma Cells. <b>2015</b> , 10, e0139790	102

598	Hydrophobic Interactions Are a Key to MDM2 Inhibition by Polyphenols as Revealed by Molecular Dynamics Simulations and MM/PBSA Free Energy Calculations. <b>2016</b> , 11, e0149014	43
597	Mice with a Mutation in the Mdm2 Gene That Interferes with MDM2/Ribosomal Protein Binding Develop a Defect in Erythropoiesis. <b>2016</b> , 11, e0152263	12
596	TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence from a meta-analysis. <b>2017</b> , 12, e0174809	11
595	Overexpression of heat shock protein 70 restores the structural stability and functional defects of temperature-sensitive mutant of large T antigen at nonpermissive temperature. <b>2006</b> , 11, 259-67	4
594	DNA base-excision repair enzyme apurinic/apyrimidinic endonuclease/redox factor-1 is increased and competent in the brain and spinal cord of individuals with amyotrophic lateral sclerosis. <b>2002</b> , 2, 47	4
593	Inhibits SW480 Cells Growth by Apoptosis Induction. <b>2018</b> , 8, 675-682	3
592	Positive Effects of PI3K/Akt Signaling Inhibition on PTEN and P53 in Prevention of Acute Lymphoblastic Leukemia Tumor Cells. <b>2019</b> , 9, 470-480	6
591	Berberine Induces p53-Dependent Apoptosis through Inhibition of DNA Methyltransferase3b in Hep3B Cells. <b>2020</b> , 52, 69-77	2
590	Mir-34a-5p and mir-34a-3p contribute to the signaling pathway of p53 by targeting overlapping sets of genes. <b>2018</b> , 3,	3
589	Quercetin Regulates Sestrin 2-AMPK-mTOR Signaling Pathway and Induces Apoptosis via Increased Intracellular ROS in HCT116 Colon Cancer Cells. <b>2013</b> , 18, 264-70	53
588	Effect of the Interaction Between Selenium and Zinc on DNA Repair in Association With Cancer Prevention. <b>2019</b> , 24, 146-154	32
587	Lack of correlation between DNA strand breakage and p53 protein levels in human fibroblast strains exposed to ultraviolet lights. <b>2000</b> , 72, 562-8	3
586	Extreme dark cytotoxicity of Nile Blue A in normal human fibroblasts. <b>2001</b> , 74, 707-11	12
585	The Contribution of Calpains in the Down-regulation of Mdm2 and p53 Proteolysis in Reconstructed Human Epidermis in Response to Solar Irradiation¶. <b>2005</b> , 81, 975	5
584	Detection of mutations within exons 4 to 8 of the p53 tumor suppressor gene in canine mammary glands. <b>2012</b> , 64, 341-348	1
583	Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors (GIST). <b>2012</b> , 27, 315-21	21
582	Physical and biological dosimetry for risk perception in radioprotection. <b>2005</b> , 48, 229-234	8
581	p53: The Challenge of Linking Basic Science and Patient Management. <b>1998</b> , 3, 218-224	7



580	Cyclooxygenase-2, p53 and glucose transporter-1 as predictors of malignancy in the development of gallbladder carcinomas. <b>2010</b> , 10, 192-6	12
579	Evaluation of 40-bp Insertion/Deletion Polymorphism of MDM2 and the Risk of Childhood Acute Lymphoblastic Leukemia. <b>2015</b> , 2,	1
578	Immunohistochemical Expression of p53 and Ki-67 Genes in Gastric Cancer and Precancerous Lesions in the Patients with Helicobacter pylori Infection. <b>2016</b> , 3,	6
577	Longevity regulation in flies: a role for p53. <b>2009</b> , 1, 6-8	12
576	p53, sex, and aging: lessons from the fruit fly. <b>2009</b> , 1, 881-3	2
575	cep-1/p53-dependent dysplastic pathology of the aging <i>C. elegans</i> gonad. <b>2012</b> , 4, 256-69	29
574	The p53/miR-17/Smurf1 pathway mediates skeletal deformities in an age-related model via inhibiting the function of mesenchymal stem cells. <b>2015</b> , 7, 205-18	44
573	TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation. <b>2016</b> , 7, 46203-46218	15
572	p53 elevation in human cells halt SV40 infection by inhibiting T-ag expression. <b>2016</b> , 7, 52643-52660	9
571	The associations between MDM4 gene polymorphisms and cancer risk. <b>2016</b> , 7, 55611-55623	14
570	C23 promotes tumorigenesis via suppressing p53 activity. <b>2016</b> , 7, 58274-58285	7
569	MDM4 rs4245739 A > C polymorphism correlates with reduced overall cancer risk in a meta-analysis of 69477 subjects. <b>2016</b> , 7, 71718-71726	14
568	Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients. <b>2016</b> , 7, 73876-73887	9
567	AKT mediates actinomycin D-induced p53 expression. <b>2014</b> , 5, 693-703	21
566	Otub1 stabilizes MDMX and promotes its proapoptotic function at the mitochondria. <b>2017</b> , 8, 11053-11062	17
565	Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells. <b>2017</b> , 8, 11302-11315	31
564	MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4. <b>2017</b> , 8, 29914-29924	21
563	Cathepsins in digestive cancers. <b>2017</b> , 8, 41690-41700	29

562	p53 upregulates PLC $\beta$ 3-Ca pathway and inhibits autophagy through its target gene Rap2B. <b>2017</b> , 8, 64657-64669	5
561	NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. <b>2017</b> , 8, 57246-57264	8
560	Analysis of splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia. <b>2017</b> , 8, 95163-95175	6
559	Novel Insights into the Molecular Mechanisms Governing Mdm2 Ubiquitination and Destruction. <b>2010</b> , 1, 685-690	35
558	A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF- $\kappa$ B pathways. <b>2014</b> , 5, 10830-9	10
557	The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer. <b>2019</b> , 10, 4907-4918	12
556	p53-inducible SESTRINs might play opposite roles in the regulation of early and late stages of lung carcinogenesis. <b>2019</b> , 10, 6997-7009	8
555	Tumor suppressor p53 regulates insulin receptor ( $\beta$ ) gene expression via direct binding to the promoter. <b>2020</b> , 11, 2424-2437	3
554	EBNA3C regulates p53 through induction of Aurora kinase B. <b>2015</b> , 6, 5788-803	25
553	MDM2 and P53 polymorphisms contribute together to the risk and survival of prostate cancer. <b>2016</b> , 7, 31825-31	9
552	NDRG4 is a novel oncogenic protein and p53 associated regulator of apoptosis in malignant meningioma cells. <b>2015</b> , 6, 17594-604	25
551	Singular v dual inhibition of SNF2L and its isoform, SNF2LT, have similar effects on DNA damage but opposite effects on the DNA damage response, cancer cell growth arrest and apoptosis. <b>2012</b> , 3, 475-89	4
550	UBE4B targets phosphorylated p53 at serines 15 and 392 for degradation. <b>2016</b> , 7, 2823-36	20
549	Estrogen receptor alpha (ER/ $\alpha$ /ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer. <b>2016</b> , 7, 16049-69	26
548	Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides. <b>2016</b> , 7, 11817-37	38
547	Effects of Amentoflavone on Anti-inflammation and Cytoprotection. <b>2016</b> , 14, 201-211	5
546	Relevance of genetic alterations in squamous and small cell lung cancer. <b>2017</b> , 5, 373	6
545	Pharmacological targeting of mutant p53. <b>2016</b> , 5, 698-706	13

544	Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis. <b>2016</b> , 5, 707-724	30
543	Do p53 stress responses impact organismal aging?. <b>2016</b> , 5, 685-691	6
542	Association of EGF, IGF1P-3 and TP53 Gene Polymorphisms with Major Depressive Disorder in Slovak Population. <b>2016</b> , 24, 223-230	5
541	Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1. <b>2015</b> , 16, 486-503	49
540	Targeting tumor suppressor networks for cancer therapeutics. <b>2014</b> , 15, 2-16	56
539	Recent Advances in Apoptosis: THE Role of Hydrazones. <b>2019</b> , 19, 1427-1442	12
538	The Role of Snail in EMT and Tumorigenesis. <b>2013</b> , 13, 963-972	507
537	The Current and Future Therapies for Human Osteosarcoma. <b>2013</b> , 9, 55-77	43
536	The Anti-Proliferative Activity of Anisosciodone: A New Guaiane Sesquiterpene from Anisosciodium lanatum. <b>2019</b> , 19, 1114-1119	4
535	Molecular basis of restenosis and potential therapeutic targets. <b>2005</b> , 39-45	1
534	The pituitary tumor transforming gene in thyroid cancer. <b>2012</b> , 35, 425-33	7
533	Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. <b>2020</b> , 22,	41
532	RESPONSE OF APOPTOTIC GENES TO APHANTOXIN-PARALYTIC SHELLFISH POISON IN FRESHWATER EXTRACTED FROM THE APHANIZOMENON FLOS-AQUAE DC-1 IN CELLS OF BRAIN ON ZEBRAFISH (DANIO RERIO). <b>2011</b> , 35, 238-245	4
531	Loss of heterozygosity on chromosome 10q22-10q23 and 22q11.2-22q12.1 and p53 gene in primary hepatocellular carcinoma. <b>2004</b> , 10, 1975-8	21
530	p53 polymorphism in human papillomavirus-associated Kazakh's esophageal cancer in Xinjiang, China. <b>2004</b> , 10, 2775-8	22
529	The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. <b>2004</b> , 10, 3583-9	28
528	Roles of syndecan-1, bcl6 and p53 in diagnosis and prognostication of immunoproliferative small intestinal disease. <b>2006</b> , 12, 3602-8	5
527	Effects of inositol hexaphosphate on proliferation of HT-29 human colon carcinoma cell line. <b>2006</b> , 12, 4137-42	16

526	Effects of ethanol on hepatic cellular replication and cell cycle progression. <b>2007</b> , 13, 4955-9	23
525	KN-93, a specific inhibitor of CaMKII inhibits human hepatic stellate cell proliferation in vitro. <b>2007</b> , 13, 1445-8	11
524	Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. <b>2014</b> , 20, 9775-827	88
523	Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes. <b>2016</b> , 22, 300-25	16
522	Synergistic anticancer effect of exogenous wild-type p53 gene combined with 5-FU in human colon cancer resistant to 5-FU in vivo. <b>2016</b> , 22, 7342-52	13
521	Synergetic anticancer effect of combined quercetin and recombinant adenoviral vector expressing human wild-type p53, GM-CSF and B7-1 genes on hepatocellular carcinoma cells in vitro. <b>2003</b> , 9, 73-8	28
520	Prognostic Value of the Expression of p53 in Patients with Non-small Cell Lung Cancer. <b>2009</b> , 2, 335-340	1
519	Cell Cycle Inhibition of Ethylacetate Fraction of . Fruit against T47D Cells. <b>2019</b> , 7, 726-729	4
518	Expression of vascular endothelial growth factor and p53 in pancreatic carcinomas. <b>2002</b> , 17, 153-9	10
517	The Influence of Circadian Gene Per2 on Cell Damaged by Ultraviolet C. <b>2011</b> , 19, 308-314	1
516	PIG3 Regulates p53 Stability by Suppressing Its MDM2-Mediated Ubiquitination. <b>2017</b> , 25, 396-403	4
515	Expression of apoptosis regulatory markers in the skin of advanced hepatitis-C virus liver patients. <b>2012</b> , 57, 187-93	4
514	Effect of p53 codon 72 polymorphism on the survival outcome in advanced stage cervical cancer patients in India. <b>2016</b> , 144, 359-365	5
513	Delayed hippocampal neuronal death in young gerbil following transient global cerebral ischemia is related to higher and longer-term expression of p63 in the ischemic hippocampus. <b>2015</b> , 10, 944-50	11
512	The influence of sleep deprivation on expression of apoptosis regulatory proteins p53, bcl-2 and bax following rat tongue carcinogenesis induced by 4-nitroquinoline 1-oxide. <b>2013</b> , 10, 247-53	4
511	Prophylactic mastectomy for the prevention of breast cancer: Review of the literature. <b>2018</b> , 8, 67-77	26
510	Odontogenic keratocyst: Analysis of recurrence by AgNOR, p53 and MDM2 profiling. <b>2020</b> , 24, 184-185	0
509	p63 and p73 in tumor suppression and promotion. <b>2004</b> , 36, 6-12	6

508	The effects of <i>Astragalus</i> polysaccharide on zebrafish cell apoptosis and senescence. <b>2012</b> , 02, 103-109	8
507	Molecular biology of colorectal cancer: Review of the literature. <b>2013</b> , 03, 72-80	20
506	P53 protein expression and cell viability in irradiated peripheral blood mononuclear cells as bioindicators of radiosensitivity. <b>2011</b> , 02, 63-67	3
505	Persimmon Leaf Flavonols Enhance the Anti-Cancer Effect of Heavy Ion Radiotherapy on Murine Xenograft Tumors. <b>2013</b> , 04, 1150-1157	4
504	The Effect of Antineoplastons A10 and AS2-1 and Metabolites of Sodium Phenylbutyrate on Gene Expression in Glioblastoma Multiforme. <b>2014</b> , 05, 929-945	9
503	Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1. <b>2014</b> , 5, 75-84	29
502	G2 checkpoint abrogation as a cancer specific, cell cycle disruption. <b>2005</b> , 13, 17-22	1
501	Cyclosporin A aggravates hydrogen peroxide-induced cell death in kidney proximal tubule epithelial cells. <b>2019</b> , 52, 312-323	6
500	Akt: versatile mediator of cell survival and beyond. <b>2002</b> , 35, 106-15	102
499	Biomarkers for the lung cancer diagnosis and their advances in proteomics. <b>2008</b> , 41, 615-25	112
498	Jab1 has negative effects on p53-mediated genotoxic stresses. <b>2009</b> , 42, 299-303	1
497	Phosphorylation of p53 at threonine 155 is required for Jab1-mediated nuclear export of p53. <b>2017</b> , 50, 373-378	15
496	THE SIGNIFICANCE OF KEY REGULATORS OF APOPTOSIS IN THE DEVELOPMENT AND PROGNOSIS OF PROSTATE CARCINOMA. I. PROTEINS OF THE BCL-2 FAMILY AND PROTEIN P53. <b>2003</b> , 147, 3-10	6
495	Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. <b>2000</b> , 124, 966-78	786
494	Identifications small molecules inhibitor of p53-mortalin complex for cancer drug using virtual screening. <b>2012</b> , 8, 426-9	20
493	A 40-bp insertion/deletion polymorphism of Murine Double Minute2 (MDM2) increased the risk of breast cancer in Zahedan, Southeast Iran. <b>2014</b> , 18, 245-9	14
492	Luteolin induced-growth inhibition and apoptosis of human esophageal squamous carcinoma cell line Eca109 cells in vitro. <b>2012</b> , 13, 5455-61	27
491	Updated meta-analysis of the TP53 Arg72Pro polymorphism and gastric cancer risk. <b>2012</b> , 13, 1787-91	9

490	P53 Arg72Pro polymorphism and bladder cancer risk--meta-analysis evidence for a link in Asians but not Caucasians. <b>2012</b> , 13, 2349-54	47
489	Knockdown of HMGN5 expression by RNA interference induces cell cycle arrest in human lung cancer cells. <b>2012</b> , 13, 3223-8	7
488	MDM2 T309G has a synergistic effect with P21 ser31arg single nucleotide polymorphisms on the risk of acute myeloid leukemia. <b>2012</b> , 13, 4315-20	8
487	DNA hypermethylation of cell cycle (p15 and p16) and apoptotic (p14, p53, DAPK and TMS1) genes in peripheral blood of leukemia patients. <b>2014</b> , 15, 75-84	33
486	Tumorigenic effects of endocrine-disrupting chemicals are alleviated by licorice ( <i>Glycyrrhiza glabra</i> ) root extract through suppression of AhR expression in mammalian cells. <b>2014</b> , 15, 4809-13	13
485	Tumorigenic Effects of Endocrine-Disrupting Chemicals are Alleviated by Licorice ( <i>Glycyrrhiza glabra</i> ) Root Extract through Suppression of AhR Expression in Mammalian Cells. <b>2014</b> , 15, 5117-5121	8
484	TP53 polymorphisms in sporadic North Indian breast cancer patients. <b>2014</b> , 15, 6871-9	11
483	Analysis of TP53 polymorphisms in North Indian sporadic esophageal cancer patients. <b>2014</b> , 15, 8413-22	3
482	Association of a p53 codon 72 gene polymorphism with environmental factors and risk of lung cancer: a case control study in Mizoram and Manipur, a high incidence region in North East India. <b>2014</b> , 15, 10653-8	8
481	Cytotoxic T lymphocytes elicited by dendritic cell-targeted delivery of human papillomavirus type-16 E6/E7 fusion gene exert lethal effects on CaSki cells. <b>2014</b> , 15, 2447-51	7
480	Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis. <b>2014</b> , 3, e02236	29
479	The REST remodeling complex protects genomic integrity during embryonic neurogenesis. <b>2016</b> , 5, e09584	42
478	Prosurvival long noncoding RNA regulates a subset of p53 targets in human colorectal cancer cells by binding to MatrIn 3. <b>2017</b> , 6,	50
477	Effects of rhodioloside on the neurological functions of rats with total cerebral ischemia/reperfusion and cone neuron injury in the hippocampal CA1 region. <b>2020</b> , 8, e10056	3
476	The carboline alkaloid harmine inhibits telomerase activity of MCF-7 cells by down-regulating hTERT mRNA expression accompanied by an accelerated senescent phenotype. <b>2013</b> , 1, e174	25
475	Anti-apoptotic response during anoxia and recovery in a freeze-tolerant wood frog ( <i>Rana sylvatica</i> ). <b>2016</b> , 4, e1834	28
474	Do polystyrene nanoplastics aggravate the toxicity of single contaminants (okadaic acid)? Using AGS cells as a biological model.	1
473	Thermal stress induces pyknosis in pigeon erythrocytes: digital image analysis. <b>2021</b> , 26, 726-731	

472	Association Analyses of Mutation With Prognosis, Tumor Mutational Burden, and Immunological Features in Acute Myeloid Leukemia. <b>2021</b> , 12, 717527	4
471	Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. <b>2021</b> , 13,	6
470	Comprehensive Identification of Deleterious Missense VUS Variants Based on Their Impact on TP53 Structural Stability. <b>2021</b> , 22,	0
469	Mesoporous nanoparticles for the delivery of (9S,E)-8-ethyl-9-methylnonadec-6-en-3-one (EME): A study of anti-inflammatory and tumor suppressing potential in RAW 264.7, He La and HepG2 cell lines. <b>2021</b> , 111, 1-11	2
468	Funktionelle Anatomie der Zelle. <b>2000</b> , 1-15	
467	A Structural Model for the P53 Complex with DNA Response Elements: Implications for P53 Function and Future Research Directions. <b>2000</b> , 257-272	
466	Genetic and cytogenetic studies in inherited cancer: Li-Fraumeni syndrome. <b>2000</b> , 245-255	
465	Molecular Genetics and Markers of Progression. <b>2000</b> , 47-70	
464	A Novel Radiobiological Cell Cycle Model. <b>2000</b> , 244-245	
463	Oncogenes. <b>2000</b> , 41-64	0
462	Attenuation of macrophage apoptosis by the cAMP-signaling system. <b>2000</b> , 35-43	2
461	Apoptosis. <b>2000</b> , 67-96	
460	OUTCOME PREDICTION WITH p53 IMMUNOSTAINING AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER. <b>2000</b> , 1756-1760	
459	Chromosomes and Cancer: Activation of Oncogenes. <b>2001</b> , 405-414	
458	Li-Fraumeni-Syndrom. <b>2001</b> , 393-399	1
457	Tumorerkrankungen â€“Einführung aus genetischer Sicht. <b>2001</b> , 3-12	
456	The Mitotic Cell Cycle. <b>2001</b> , 13-27	
455	Biologische Signale. <b>2001</b> , 465-518	

454 Hereditärer Brust- und Eierstockkrebs. **2001**, 257-281

453 Many genomic regions are required for normal embryonic programmed cell death in *Caenorhabditis elegans*. **2001**, 158, 237-52 10

452 VARIOUS FORMS OF MUTANT p53 CONFER SENSITIVITY TO CISPLATIN AND DOXORUBICIN IN BLADDER CANCER CELLS. **2001**, 304-310 1

451 Inactivation of Negative Growth Regulators During Neoplastic Transformation. **2002**, 81-111

450 Chromosomal Radiosensitivity as an Indicator of Genetic Predisposition to Breast Cancer. **2002**, 167-176

449 Induction of Proliferation-Related Signals by Hepatitis C Virus. **2002**, 81-98

448 p53 and Its Targets. **2002**, 77-96

447 Cellular Responses to Chemical Carcinogens. **2002**, 203-222

446 Cooperative Effects of Zinc / Selenium and Thiols in the Protection Against UV-Induced Genomic DNA Damage. **2002**, 77-82

445 Developing Gene-Based Neuroprotection Strategies Using Herpes Amplicon Vectors. **2002**, 335-357

444 CDK Inhibitors. **2002**, 123-143 1

443 The Molecular Basis of Lung Carcinogenesis. **2002**, 379-405 2

442 Epithelial cell cycling predicts p53 responsiveness to irradiation during post-natal mammary gland development. **2002**, 129, 2997-3008 14

441 Inhibition of Cell Growth and Induction of Apoptosis. **2002**, 125-147

440 Resveratrol Induced Serine Phosphorylation Of p53 Causes Apoptosis In A Mutant p53 Prostate Cancer Cell Line. **2002**, 748-755 1

439 Cellular Senescence Pathways in Mouse and Human. **2003**, 225-238

438 Molecular Biology. **2003**, 37-51

437 References. **2003**, 170-236



- 436 DNA Damages and Changes in Proliferating Activity in the Dorsal Epidermis of UVB-Irradiated WBN/ILA-Ht Rats. **2003**, 16, 191-194
- 435 Programmed Cell Death (Apoptosis) in Culture, Impact and Modulation.
- 434 Transactivation of human cdc2 promoter by adenovirus E1A. **2003**, 272, 365-97 2
- 433 Signals Induced by HCV Proteins. **2003**, 32-47
- 432 Apoptosis and Cancer. **2003**, 177-199
- 431 Maxizyme-mediated specific inhibition on mutant-type p53 in vitro. **2003**, 9, 1571-5 1
- 430 Biologische Strahlenwirkungen. **2003**, 203-261
- 429 Bronchiolar Epithelium in Idiopathic Pulmonary Fibrosis/Usual Interstitial Fibrosis. **2003**, 631-664
- 428 Inducible Nitric Oxide Synthase (iNOS) and Heart Failure. **2003**,
- 427 Potential Function of the Wernerâs Syndrome Homologue in the African Clawed Frog and the Mouse. **2004**, 107-122
- 426 Mammakarzinom. **2004**, 1011-1055
- 425 Disposition ferbliche Krebserkrankungen. **2004**, 147-173
- 424 Genetische Grundlagen der Kanzerogenese. **2004**, 75-145 1
- 423 Zellzyklus und Apoptose. **2004**, 175-191
- 422 Microcystin Toxicity. **2004**, 109-139
- 421 Biomedicine and the Human Condition: Challenges, Risks, and Rewards. **2005**, 1
- 420 Flavonoids. **2005**,
- 419 Tumor Suppressor Genes. **2005**, 131-150

- 418 Skin Cancer. **2005**, 379-402
- 417 Oncogenesis in Transgenic and Knockout Mice. **2005**, 179-197
- 416 Cholangiocarcinoma. **2006**, 1133-1146
- 415 Tumorsuppressorgene. **2006**, 29-33
- 414 THE ROLE OF RAD9 IN HEAD AND NECK CANCER. **2006**, 32, 417-422 1
- 413 MOLECULAR BIOLOGY OF HEAD AND NECK CANCER CELLS. **2006**, 32, 342-348
- 412 Intracellular Pathways of Neuronal Death. **2006**, 91-103
- 411 Etiology of Nonmelanocytic Skin Cancer. **2006**, 21-47
- 410 Molecular and Genetic Events in Neoplastic Transformation. **2006**, 47-64
- 409 Cancer Chemoprevention. **2006**, 1318-1340 1
- 408 Hypoxia-Induced Cytosine Deaminase Gene Expression for Cancer Therapy. **2006**, 061222090107001
- 407 The regulation of Rad9 for therapy of head and neck cancer. **2007**, 33, 425-428
- 406 Myelodysplasia-Related AML. **2007**, 43-70
- 405 P53: Gatekeeper, Caretaker or Both?. **2007**, 233-253
- 404 Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor. **2007**, 183-207
- 403 Regulation of the p53 Response by Cellular Growth and Survival Factors. **2007**, 115-140
- 402 Adenoviral p53 Gene Therapy for Lung Cancer. **2008**, 119, 229-234
- 401 Molecular Genetics of Lung and Pleural Neoplasms. **2008**, 47-157 1

400 Cdk5 May Be an Atypical Kinase, but Not in the Way You Think. **2008**, 119-137

399 XVI ??????????????????. **2008**, 120, 321-327

398 The expression of rad9 in head and neck cancer. **2008**, 34, 493-497

397 Transcription Factors. 1

396 Marking a path to transplant tolerance. **2008**, 118, 2684-6

6

395 Histone Deacetylase Inhibitors in Cancer Therapy. **2008**, 381-398

394 How Cancer Cells Escape Death. **2009**, 161-178

393 DNA Hypermethylation and Oncogenesis. **2008**, 39-49

392 Cellular Respiration and Tumor Suppressor Genes. **2009**, 131-144

391 Health Benefits of Phytochemicals for Older Adults. **2008**, 229-247

390 Transformation by Polyomaviruses. **2009**, 25-52

1

389 Molecular Signatures of Drug Resistance. **2009**, 271-294

388 Genomic Instability in Colorectal Cancer; from Bench to Bed. **2009**, 25, 129

387 The Role of Autophagy and Apoptosis in the Drug Resistance of Cancer. **2009**, 53-71

1

386 The Role of p53 in Colorectal Cancer. **2009**, 213-217

385 Expression of histone H3, p53, cyclin D1, and cyclin B1 in oral mucosal lesions. **2009**, 13, 119-126

384 Molecular Biology of Cancer. **2009**, 1-26

383 Activation of the p53 Tumor Suppressor and its Multiple Roles in Cell Cycle and Apoptosis. **2010**, 375-395

- 382 Aging and Cancer: Caretakers and Gatekeepers. **2010**, 397-416
- 381 Focal Adhesion Kinase with the Interacting Proteins and Signaling in Cancer. **2010**, 275-305
- 380 Molecular Carcinogenesis. **2010**, 975-1003
- 379 Restoration of p53 Function by MDM2 Inhibition: Potential Strategy to Treat KSHV-Associated Malignancies. **2010**, 167-180
- 378 Head and Neck Cancer Prevention. **2010**, 167-199
- 377 Pediatric Cancer Mechanisms of Cancer Growth and Progression. **2010**, 129-147
- 376 Molecular Chaperone Inducers Facilitate the Functional Restoration of Temperature-sensitive Mutant p53 Protein. **2010**, 26, 1-17 2
- 375 Gene-Based Therapy for Cancer: Brain Tumors. **2010**, 17-32
- 374 Analysis of p53-Dependency of Differentially Expressed Genes by Capsaicin in Human Colorectal Cancer Cell. **2010**, 20, 213-218 1
- 373 The Stem Cell Hypothesis of Aging. **2010**, 2, 26
- 372 Maintaining Energy Balance in Health and Disease: Role of the AMP-Activated Protein Kinase. **2011**, 199-232
- 371 Nuclear Subdomains and Cancer. **2011**, 1-58
- 370 Funktionelle Anatomie der Zelle. **2011**, 1-18
- 369 A Case Report of a Malignant Fibrous Histiocytoma in a T-cell Receptor  $\alpha$ Chain and p53 Double-knockout Mouse. **2011**, 24, 251-5
- 368 Biologische Signale. **2011**, 553-638
- 367 Biomarkers in Head and Neck Cancer. **2011**, 157-167
- 366 Association of p53 Expression with Metabolic Features of Stage I Non-Small Cell Lung Cancer. **2011**, 71, 417
- 365 Tumour Suppressor Genes.

- 364 Avaliaçã da superexpressã da proteïa p53 e das mutaõs no çon 8 do gene TP53 em carcinomas mamãrios caninos e glãndulas normais. **2011**, 31, 521-526
- 363 Molecular Genetics and Cancer Biology. **2012**, 530-567.e16
- 362 Bifurcation Analysis of a Model Accounting for the 14-3-3s Signalling Compartmentalisation. **2012**, 61-70
- 361 Cholangiocarcinoma. **2012**, 1032-1044
- 360 Molecular and Cellular Characteristics of Small Cell Lung Cancer. **2012**, 597-616
- 359 Molecular Biology of the Head and Neck Squamous Cell Carcinoma. **2012**, 105, 393-402
- 358 THE SHORT-TERM EFFECTS OF LOW-DOSE-RATE RADIATION ON EL4 LYMPHOMA CELL. **2012**, 37, 56-62
- 357 Mouse Models of Glioma Pathogenesis: History and State of the Art. **2013**, 87-107
- 356 Vitamin D and Its Role in Photoprotection of the Skin. **2012**, 165-184
- 355 Molecular Pathology of Colon and Small Bowel Cancers: Sporadic Type. **2013**, 131-140
- 354 The p.Pro47Ser Polymorphism of TP53: A Systematic Review. **2012**, 9, 1-8
- 353 Novel Anti-angiogenic Therapies Using Naturally Occurring and Synthetic Drugs to Combat Progesterin-Dependent Breast Cancer. **2013**, 123-147
- 352 Cell Survival and Death in Rheumatic Diseases. **2013**, 382-399.e4 1
- 351 -Omics Approaches in Biofuel Production for a Green Environment. **2013**, 646-659
- 350 Molecular Pathology of Melanocytic Skin Cancer. **2014**, 59-74
- 349 Cytokines of defender against cell death 1 and allograft inflammatory factor-1 with regard to innate immunity of fish. **2013**, 18, 237-242 1
- 348 Molecular Pathology and Diagnostics of Childhood Tumors. **2014**, 449-495
- 347 The DNA Damage Response Mediates Apoptosis and Tumor Suppression. **2014**, 135-165 0

- 346 HBx Gene Mutations in Hepatitis B Virus and Hepatocellular Carcinoma. **2014**, 7, 1-4 2
- 345 Expression Analysis of p53, Ki-67 and bcl-2 in Pre-Malignant Lesions of the Cervix. **2014**, 04, 462-469
- 344 The Biology of Aging: Role in Cancer, Metabolic Dysfunction, and Health Disparities. **2014**, 91-118
- 343 Fifty Years of Studies of the Biology and Therapy of Childhood Leukemia. **1997**, 90, 4243-4251 1
- 342 Major Cancer Genes. **1998**, 31-49
- 341 The Role for ink4a in Melanoma Pathogenesis. **1998**, 1-14
- 340 New insights into the kinetic resistance to anticancer agents. **1998**, 225-235
- 339 Recent Developments in the Molecular Biology of Human Brain Tumors. **1998**, 191-205
- 338 The role of p53 in apoptosis. **1998**, 5-35 0
- 337 Early Development and Neoplasia. **1998**, 243-263
- 336 Apoptosis resistance in tumor cells. **1998**, 293-308
- 335 The Chimeric E2A-HLF Transcription Factor Abrogates p53-Induced Apoptosis in Myeloid Leukemia Cells. **1998**, 92, 1397-1405 3
- 334 Mechanisms of Cell Growth and Tissue Repair. **1999**, 282-303
- 333 Function of the p53 Gene Family. **1999**, 53-68
- 332 Mechanisms of Viral Oncogenesis. **1999**, 177-191
- 331 Apoptosis and the Development of Breast Cancer. **1999**, 171-180
- 330 Gliale Neoplasien. **1999**, 450-509
- 329 p53, Apoptosis, and Chemosensitivity. **1999**, 21-36

- 328 Cellular proliferation and cell-cell cycle regulatory proteins as prognostic markers for transitional cell carcinoma of the bladder. **1999**, 462, 425-35 1
- 327 Molecular Genetics of Thyroid Cancer. **1999**, 201-211
- 326 Regulation of p53 function in normal and malignant cells. **1999**, 472, 89-100
- 325 Protein kinase CK2-dependent regulation of p53 function: Evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable. **1999**, 187-199
- 324 Antisense p53 RNA Abrogates Antisense Rb RNA-Induced Cell Death in Mouse Fibroblast SV-T2 Cells.. **1999**, 45, 419-424
- 323 Regulation of Apoptosis in the Testis. **1999**, 215-224
- 322 The Role of p53 in Chemosensitivity. **1999**, 37-52
- 321 Inflammation. **2014**, 29-114
- 320 Helicobacter pylori infection and a P53 codon 72 single nucleotide polymorphism: a reason for an unexplained Asian enigma. **2014**, 15, 9171-6 4
- 319 Cell Cycle Arrest Effects by Artemisia annua Linn<sup>in</sup> Hep3B Liver Cancer Cell. **2015**, 30, 175-181 1
- 318 Radiation Injury in the Gastrointestinal Tract. 2509-2520
- 317 Ligand-Appended Liposomes: Targeted Breast Cancer Therapy. 4316-4327 1
- 316 Molecular Insights into the Regulation of Apoptosis and Cellular Senescence and Their Implications for Cancer. **2016**, 449-465
- 315 Biomarkers in Head and Neck Cancer. **2016**, 149-162
- 314 Genetics and Epigenetics of Head and Neck Cancer. **2016**, 115-132
- 313 An Overview of Cancer Genes. **2017**, 121-142
- 312 Molecular Pathogenesis of Prostate Cancer. **2017**, 171-189
- 311 Calpain Activity and Expression in Human Colonic Tumors. **2017**, 161-170

310 p53 binding sites in normal and cancer cells are characterized by distinct chromatin context.

309 OVA12 promotes tumor growth by regulating p53 expression in human cancer cells. **2017**, 8, 52854-52865

308 Research Synergy and Drug Development: Bright Stars in Neighboring Constellations.

307 Directin vivomapping of functional suppressors in glioblastoma genome.

306 Cell-to-cell heterogeneity in p38-mediated cross-inhibition of JNK causes stochastic cell death.

305 Applying expression profile similarity for discovery of patient-specific functional mutations.

304 Tracing the genetic etiology of cardiovascular disease using a hierarchy of common genetic variants derived from patient subgroups stratified by differential levels in severity.

303 Aseptomatik Tam G $\eta$ m $\xi$  Alt Yirmi YaDilerinin Foliklilerinde Ki-67 ve p53 Ekspresyonunun De $\xi$ lendirilmesi.

302 Cholangiocarcinoma. **2018**, 693-707.e4

1

301 CRISPR-based editing reveals edge-specific effects in biological networks.

300 Immunohistochemical Expression of p53 and Bcl-2 in Algerian Cervical Carcinoma. **2018**, 11, 67-75

0

299 EZH2 co-opts gain-of-function p53 mutants to promote cancer growth and metastasis.

298 Prediction of Deleterious Single Nucleotide Polymorphisms in Human p53 Gene.

0

297 RBL1 (p107) functions as tumor suppressor in glioblastoma and small-cell pancreatic neuroendocrine carcinoma.

1

296 A Novel Technique to Characterize Conformational State of the Proteins: p53 Analysis. **2019**, 537-544

295 Surface plasmon resonance and cytotoxicity assays of drug efficacies predicted computationally to inhibit p53/MDM2 interaction. **2019**, 569, 53-58

294 Neuroprotective Effects of Picroside II on Rats Following Cerebral Ischemia Reperfusion Injury by Inhibiting p53 Signaling Pathway. **2019**, 15, 790-800

0

293 Heritable genetic variants in key cancer genes link cancer risk with anthropometric traits.



- 292 MOLECULAR GENETIC STRUCTURE OF MULTIPLE MYELOMA TUMOUR CELLS PRIOR TO TREATMENT AND AT THE TIME OF RELAPSE: SHORT REVIEW AND CASE REPORT. **2019**, 64, 362-374
- 291 A Primer on Modeling and Measurement of Signaling Outcomes Affecting Decision Making in Cells: Methods for Determining Optimal and Incorrect Outcomes in Noisy Biochemical Dynamics.
- 290 Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
- 289 OVER KANSERİHCİRELERİDE PRİMA-1 Met TEDAVİSİNE YANIT OLARAK DEĞİN miRNA EKSPRESYON ANALİZİ**2020**, 29, 19-25
- 288 The changes in the p53 protein across the animal kingdom pointing to its involvement in longevity. 0
- 287 Induction of intracellular wild-type p53 amyloids leading to cellular transformation and tumor formation in mice.
- 286 Relationship between Chromosomal Aberrations and Gene Expressions in the p53 Pathway in Chronic Lymphocytic Leukemia. **2020**, 23, 15-24 1
- 285 PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma. **2021**, 7, 323 0
- 284 CHAPTER 9. Biosynthesis of Curcumin and Molecular Targets and the Biological Mechanism of Curcumin. **2020**, 196-220
- 283 Effect of Stapling on the Thermodynamics of mdm2-p53 Binding.
- 282 The role of time delays in P53 gene regulatory network stimulated by growth factor. **2020**, 17, 3794-3835 1
- 281 Loss of TRP53 (p53) accelerates tumorigenesis and changes the tumor spectrum of SJL/J mice. **2020**, 11, 83-94 0
- 280 Cyclin F is involved in response to cisplatin treatment in melanoma cell lines. **2020**, 43, 765-772 1
- 279 Effect of dietary NiCl<sub>2</sub> on the cell cycle of cecal tonsil in the chicken broiler. **2020**, 92, e20181010
- 278 Analysis of expression of p53, p63 and proliferating cell nuclear antigen proteins in odontogenic keratocyst: An immunohistochemical study. **2020**, 24, 273-278 1
- 277 Cell Proliferation, Survival, Necrosis and Apoptosis. **2020**, 743-824 1
- 276 Effect of topotecan and zinc oxide nanoparticles combination on cytotoxicity and P53 gene expression against breast cancer (MCF-7) cell line. **2020**, 22, 192-197
- 275 Periodicity Scoring of Time Series Encodes Dynamical Behavior of the Tumor Suppressor p53.

- 274 Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
- 273 Ancestral cancer genes shaping evo-devo: An integrated biochemical and computational approach (Review).
- 272 CRISPR/Cas9-induced DNA damage enriches for mutations in a p53-linked interactome: implications for CRISPR-based therapies. **2021**, 3
- 271 Bifurcation Analysis of a Model Accounting for the 14-3-3s Signalling Compartmentalisation. 851-859
- 270 Effects of mutations on tetramer formation of tumor suppressor protein p53. **1999**, 303-305
- 269 Antitumor Protein (AP) from a Mushroom Induced Apoptosis to Transformed Human Keratinocyte by Controlling the Status of pRB, c-MYC, Cyclin E-CDK2, and p21WAF1 in the G1/S Transition. **2002**, 265-271
- 268 Immunology of Aging. **2003**, 783-800
- 267 Transcriptional Repression by the p53 Tumor Suppressor Protein. **2005**, 81-94
- 266 Apoptosis and Cancerogenesis of Basal Cell and Squamous Cell Carcinoma. **2006**, 108-114
- 265 Aetiology and pathogenesis of biliary cancer. 23-35
- 264 Gene therapy for thyroid cancer. **2004**, 122, 369-79
- 263 Pathobiological Basis of Treatment Strategies of Germ Cell Tumors. **2005**, 252-271
- 262 c-Jun: A Complex Tale of a Simple Transcription Factor. **2006**, 219-237
- 261 Post-translational Modifications of the p53 Transcription Factor. **2006**, 257-272
- 260 The Seed of Selfishness. **2008**, 9-26
- 259 Tumor Suppressor Gene Replacement for Cancer. **2005**, 19-33
- 258 Lung Cancer. **2006**, 736-742 1
- 257 The Clinical Implications of Basic Science Research in Peyronie's Disease. **2007**, 39-57 1

256	Integration of Genomics and Proteomics in Dissecting p53 Signaling. <b>2008</b> , 39-57	
255	Aberrations of DNA Damage in Checkpoints in Cancer. <b>2007</b> , 119-136	
254	Gene Therapy for Advanced Prostate Cancer. <b>2007</b> , 139-163	
253	Targeting the p53/MDM2 Pathway for Cancer Therapy. <b>2008</b> , 19-56	
252	Targeting ATM/ATR in the DNA Damage Checkpoint. <b>2008</b> , 93-116	
251	Genetic Association in the Open-Angle Glaucomas. <b>2008</b> , 275-288	
250	Benign Peripheral Nerve Sheath Tumors: Neurofibromas, Schwannomas, and Perineuriomas. <b>2008</b> , 1-41	
249	Medulloblastoma, Primitive Neuroectodermal Tumors, and Pineal Tumors. <b>2008</b> , 343-430	1
248	The 40bp indel polymorphism of increase the risk of cancer: An updated meta-analysis. <b>2019</b> , 8, 1-8	4
247	Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. <b>2000</b> , 14, 34-44	705
246	Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. <b>2000</b> , 14, 278-88	532
245	The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducibile sites. <b>2000</b> , 14, 289-300	616
244	PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. <b>2000</b> , 14, 704-18	242
243	Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. <b>2000</b> , 14, 981-93	299
242	Cooperative effects of genes controlling the G(2)/M checkpoint. <b>2000</b> , 14, 1584-8	67
241	Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. <b>2000</b> , 14, 1797-809	56
240	Inactivation of mouse Hus1 results in genomic instability and impaired responses to genotoxic stress. <b>2000</b> , 14, 1886-98	61
239	Hypersensitivity to DNA damage leads to increased apoptosis during early mouse development. <b>2000</b> , 14, 2072-84	134

238	The individualization of cancer therapy: the unexpected role of p53. <b>2006</b> , 117, 85-101; discussion 101	20
237	The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. <b>2004</b> , 6, 187-94	13
236	Molecular genetic analysis of giant cell glioblastomas. <b>1997</b> , 151, 853-7	64
235	CD95/CD95L-mediated apoptosis of the hepatic stellate cell. A mechanism terminating uncontrolled hepatic stellate cell proliferation during hepatic tissue repair. <b>1997</b> , 151, 1265-72	139
234	Soft tissue sarcomas and p53 mutations. <b>1998</b> , 4, 365-72	14
233	Transcription abnormalities potentiate apoptosis of normal human fibroblasts. <b>1997</b> , 3, 852-63	18
232	Cell cycle exit: growth arrest, apoptosis, and tumor suppression revisited. <b>1998</b> , 4, 205-13	1
231	Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. <b>1999</b> , 5, 21-34	18
230	Estrogens and neuroprotection in retinal diseases. <b>2008</b> , 14, 1480-6	6
229	The proteins and the mechanisms of apoptosis: a mini-review of the fundamentals. <b>2007</b> , 11, 108-13	30
228	p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. <b>2009</b> , 29, 3741-50	67
227	Inhibition of protein-protein interactions with low molecular weight compounds. <b>2008</b> , 5, 21-32	2
226	Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction. <b>2010</b> , 1, 685-90	23
225	Identification of Wnt/ $\beta$ -catenin modulated genes in the developing retina. <b>2012</b> , 18, 645-56	10
224	Cell cycle control in acute myeloid leukemia. <b>2012</b> , 2, 508-28	28
223	The role of tumor protein 53 mutations in common human cancers and targeting the murine double minute 2-p53 interaction for cancer therapy. <b>2012</b> , 37, 3-8	9
222	Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. <b>2002</b> , 62, 2715-20	107
221	Unbalanced replication as a major source of genetic instability in cancer cells. <b>2012</b> , 2, 160-9	7

220	Gene Expression upon Proliferation and Differentiation of Hematopoietic Cells with Ph Chromosome ex vivo. <b>2012</b> , 4, 95-114	1
219	RNAi screening identifies KAT8 as a key molecule important for cancer cell survival. <b>2013</b> , 6, 870-7	9
218	The intersection between DNA damage response and cell death pathways. <b>2012</b> , 34, 243-54	139
217	Expression of E6, p53 and p21 proteins and physical state of HPV16 in cervical cytologies with and without low grade lesions. <b>2014</b> , 7, 186-93	7
216	p53 and PCNA Expression in Keratocystic Odontogenic Tumors Compared with Selected Odontogenic Cysts. <b>2013</b> , 2, 185-93	6
215	Association of TP53 gene codon 72 polymorphism with endometriosis risk in Isfahan. <b>2013</b> , 11, 473-8	7
214	Involvement of P53 and Bax/Bad triggering apoptosis in thioacetamide-induced hepatic epithelial cells. <b>2006</b> , 12, 5175-81	27
213	Primary lymphoepithelioma-like carcinoma of salivary glands: a clinicopathological study of 21 cases. <b>2014</b> , 7, 7951-6	13
212	The TP53 codon 72 Pro/Pro genotype may be associated with an increased lung cancer risk in North China: an updated meta-analysis. <b>2015</b> , 8, 3120-6	2
211	Screening feature genes of osteosarcoma with DNA microarray: a bioinformatic analysis. <b>2015</b> , 8, 7134-42	2
210	TP53 codon 72 polymorphism and susceptibility to cervical cancer in the Chinese population: an update meta-analysis. <b>2015</b> , 8, 9055-62	6
209	Immunohistochemistry of p53 and Ki-67 and p53 mutation analysis in renal epithelioid angiomyolipoma. <b>2015</b> , 8, 9446-51	9
208	TP53 modulating agent, CP-31398 enhances antitumor effects of ODC inhibitor in mouse model of urinary bladder transitional cell carcinoma. <b>2015</b> , 5, 3030-41	6
207	Ginkgo biloba extract induce cell apoptosis and G0/G1 cycle arrest in gastric cancer cells. <b>2015</b> , 8, 20977-82	7
206	The association of mammalian DREAM complex and HPV16 E7 proteins. <b>2015</b> , 5, 3525-33	7
205	Molecular basis of differentiation therapy for soft tissue sarcomas. <b>2010</b> , 6, 69-90	5
204	Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice. <b>2016</b> , 6, 894-909	10
203	Dual role of GRK5 in cancer development and progression. <b>2016</b> , 14, 28-37	11

202	Does PTEN gene mutation play any role in Li-Fraumeni syndrome. <b>2016</b> , 30, 378	2
201	Drug resistance in lung cancer. <b>2010</b> , 1, 23-36	54
200	Lack of an Association between a Functional Polymorphism in the Promoter and Breast Cancer in Women in Northeast Iran. <b>2017</b> , 6, 112-117	1
199	Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells. <b>2017</b> , 9, 4652-4672	26
198	Extracted metabolite from ABRINW111 altered the gene expression in colon cancer. <b>2018</b> , 11, 34-41	3
197	[P53 family proteins provide new insights into lung carcinogenesis and clinical treatment]. <b>2013</b> , 16, 422-6	0
196	Heat shock factor function and regulation in response to cellular stress, growth, and differentiation signals. <b>1999</b> , 7, 271-82	91
195	G-protein-coupled receptor kinase-5 promotes glioblastoma progression by targeting the nuclear factor kappa B pathway. <b>2018</b> , 10, 3370-3384	2
194	S100A6/miR193a regulates the proliferation, invasion, migration and angiogenesis of lung cancer cells through the P53 acetylation. <b>2019</b> , 11, 4634-4649	12
193	Activation-induced cytidine deaminase expression in colorectal cancer. <b>2019</b> , 12, 4119-4124	1
192	TAS-102 has a tumoricidal activity in multiple myeloma. <b>2020</b> , 10, 3752-3764	
191	P53 Expression in benign Breast Disease Development: A Systematic Review. <b>2020</b> , 21, 2485-2491	
190	Clinical significance of CCN5 and mutant p53 in primary and recurrent lesions of breast cancer. <b>2021</b> , 13, 8433-8437	
189	Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. <b>2000</b> , 14, 1797-1809	71
188	Cooperative effects of genes controlling the G2/M checkpoint. <b>2000</b> , 14, 1584-1588	174
187	Inactivation of mouse Hus1 results in genomic instability and impaired responses to genotoxic stress. <b>2000</b> , 14, 1886-1898	96
186	Interference of p53:Twist1 interaction through competing nanobodies. <b>2021</b> , 194, 24-31	2
185	The Cross Talk Between p53 and mTOR Pathways in Response to Physiological and Genotoxic Stresses. <b>2021</b> , 9, 775507	1

184	Comparatively analyzing the liver-specific transcriptomic profiles in Kunming mice afflicted with streptozotocin- and natural food-induced type 2 diabetes mellitus. <b>2021</b> , 1	
183	Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities. <b>2021</b> , 9, 772315	0
182	Implication of ARID1A Undercurrents and PDL1, TP53 Overexpression in Advanced Gastric Cancer.. <b>2021</b> , 27, 1609826	
181	Amperometric detection of tumor suppressor protein p53 via pencil graphite electrode for fast cancer diagnosis.. <b>2021</b> , 639, 114528	2
180	Polymorphism of TP53 gene and the risk of high human papillomavirus load in cervical epithelial cells. <b>2022</b> , 26, 101456	
179	P53 Expression in benign Breast Disease Development: A Systematic Review. <b>2020</b> , 21, 2485-2491	1
178	Amelioration of DMH-induced colon cancer by eupafolin through the reprogramming of apoptosis-associated p53/Bcl2/Bax signaling in rats. <b>2022</b> , 20, 205873922110697	0
177	Cells to Surgery Quiz: January 2022.. <b>2022</b> , 142, e9-e14	
176	Role of Reactivating Mutant p53 Protein in Suppressing Growth and Metastasis of Triple-Negative Breast Cancer.. <b>2022</b> , 15, 23-30	1
175	A Systematic Review of Circulatory microRNAs in Major Depressive Disorder: Potential Biomarkers for Disease Prognosis.. <b>2022</b> , 23,	2
174	Acquisition of taxane resistance by p53 inactivation in ovarian cancer cells.. <b>2022</b> ,	1
173	New insights into the roles for DYRK family in mammalian development and congenital diseases. <b>2022</b> ,	0
172	Non-coding small nucleolar RNA SNORD17 promotes the progression of hepatocellular carcinoma through a positive feedback loop upon p53 inactivation.. <b>2022</b> ,	2
171	Mechanistic insight into the destabilization of p53TD tetramer by cancer-related R337H mutation: a molecular dynamics study.. <b>2022</b> ,	1
170	Significance of p53 overexpression in the prediction of the malignant transformation risk of oral potentially malignant disorders: A systematic review and meta-analysis.. <b>2022</b> , 126, 105734	2
169	Deficiency of ribosomal proteins reshapes the transcriptional and translational landscape in human cells.. <b>2022</b> ,	1
168	Glioma targeted therapy: insight into future of molecular approaches.. <b>2022</b> , 21, 39	26
167	Activating transcription factor 3 mediates apoptotic functions through a p53-independent pathway in human papillomavirus 18 infected HeLa cells.. <b>2022</b> , 58, 88	0

166	Deubiquitinases in Neurodegeneration.. <b>2022</b> , 11,	1
165	UXT, a novel DNMT3b-binding protein, promotes breast cancer progression via negatively modulating lncRNA MEG3/p53 axis.. <b>2022</b> , 24, 497-506	1
164	Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable. <b>1999</b> , 191, 187-99	17
163	Attenuation of macrophage apoptosis by the cAMP-signaling system. <b>2000</b> , 212, 35-43	8
162	E3 ligase ligand chemistries: from building blocks to protein degraders.. <b>2022</b> ,	8
161	Carbon Ion Induces Cell Death and G2/M Arrest Through pRb/E2F1Chk2/Cdc2 Signaling Pathway in X-ray Resistant B16F10 Melanoma Cells.. <b>2022</b> , 20, 15593258221092364	1
160	Detection of genetic mutations in patients with breast cancer from Saudi Arabia using Ion AmpliSeq <sup>®</sup> Cancer Hotspot Panel v.2.0.. <b>2022</b> , 16, 26	0
159	ZNF498 promotes hepatocellular carcinogenesis by suppressing p53-mediated apoptosis and ferroptosis via the attenuation of p53 Ser46 phosphorylation.. <b>2022</b> , 41, 79	3
158	The correlation between P53 and COX-2 expression and the pathological alteration in hepatocellular carcinoma. <b>2022</b> , 23,	0
157	Apoptosis-enhanced ferroptosis therapy of pancreatic carcinoma through PAMAM dendrimer-iron(III) complex-based plasmid delivery. <b>2022</b> , 65, 778-788	0
156	Using VBIM Technique to Discover ARMC4/ODAD2 as a Novel Negative Regulator of NF- $\kappa$ B and a New Tumor Suppressor in Colorectal Cancer.. <b>2022</b> , 23,	0
155	Towards a Molecular Classification of Sinonasal Carcinomas: Clinical Implications and Opportunities.. <b>2022</b> , 14,	3
154	Review <sup>®</sup> Progress in Electroanalysis of p53, CEA, and CA19 <sup>®</sup> . <b>2022</b> , 169, 037518	
153	Evolutionarily conserved transcription factors as regulators of longevity and targets for geroprotection.. <b>2022</b> ,	1
152	Risk Factors for Occurrence and Relapse of Soft Tissue Sarcoma.. <b>2022</b> , 14,	1
151	Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma.. <b>2022</b> , 23,	0
150	N-Acetyltransferase 10 inhibits invasion and metastasis of oral squamous cell carcinoma via regulating Pirh2-p53 signalling pathway.. <b>2022</b> ,	0
149	Small-molecule MDM2 inhibitors in clinical trials for cancer therapy.. <b>2022</b> , 236, 114334	0



148	Synthetic Design and Biological Evaluation of New p53-MDM2 Interaction Inhibitors Based on Imidazoline Core.. <b>2022</b> , 15,	1
147	Apolipoprotein C3-Rich Low-Density Lipoprotein Induces Endothelial Cell Senescence via FBXO31 and Its Inhibition by Sesamol In Vitro and In Vivo.. <b>2022</b> , 10,	1
146	Synthesis and Evaluation of Habiterpenol Analogs.. <b>2022</b> , 70, 261-268	1
145	Of the many cellular responses activated by TP53, which ones are critical for tumour suppression?. <b>2022</b> ,	3
144	Immunomodulatory effect of mushrooms and their bioactive compounds in cancer: A comprehensive review. <b>2022</b> , 149, 112901	3
143	Fatty acids and their lipid mediators in the induction of cellular apoptosis in cancer cells.. <b>2022</b> , 106637	1
142	Tanshinol suppresses osteosarcoma by specifically inducing apoptosis of U2-OS cells through p53-mediated mechanism.. <b>2022</b> , 292, 115214	0
141	Evaluation of the Response of HOS and Saos-2 Osteosarcoma Cell Lines When Exposed to Different Sizes and Concentrations of Silver Nanoparticles.. <b>2021</b> , 2021, 5013065	1
140	Synthesis and Biological Evaluation of S-, O- and Se-Containing Dispirooxindoles.. <b>2021</b> , 26,	2
139	Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53 Uterine Leiomyosarcoma.. <b>2021</b> , 14,	1
138	An updated view on the centrosome as a cell cycle regulator.. <b>2022</b> , 17, 1	0
137	Molecular cloning, characterization and expression analysis of P53 from high latitude fish Phoxinus lagowskii and its response to hypoxia.. <b>2022</b> , 1	
136	Dinitramine induces implantation failure by cell cycle arrest and mitochondrial dysfunction in porcine trophectoderm and luminal epithelial cells.. <b>2022</b> , 435, 128927	0
135	Targeting -Mutated Acute Myeloid Leukemia: Research and Clinical Developments.. <b>2022</b> , 15, 423-436	3
134	Progesterone regulates inflammation and receptivity of cells via the NF- $\kappa$ B and LIF/STAT3 pathways.. <b>2022</b> , 186, 50-59	1
133	MOLECULAR GENETICS OF SOFT TISSUE TUMORS. 127-180	
132	p73, p63 and Mutant p53: Members of Protein Complexes Floating in Cancer Cells. <b>2007</b> , 223-232	
131	p53: Gatekeeper, Caretaker or Both?. <b>2007</b> , 233-253	

130 Regulation of the p53 Response by Cellular Growth and Survival Factors. **2007**, 115-140

129 Manipulating the p53 Gene in the Mouse: Organismal Functions of a Prototype Tumor Suppressor. **2007**, 183-207

128 Table\_1.XLSX. **2020**,

127 Table\_2.XLSX. **2020**,

126 Data\_Sheet\_1.pdf. **2020**,

125 Image\_1.JPEG. **2018**,

124 Image\_2.JPEG. **2018**,

123 Data\_Sheet\_1.XLS. **2018**,

122 Data\_Sheet\_2.XLS. **2018**,

121 Image\_1.JPEG. **2018**,

120 Image\_2.JPEG. **2018**,

119 Image\_3.jpg. **2018**,

118 Table\_1.DOCX. **2018**,

117 Table\_2.DOCX. **2018**,

116 Image\_1.tif. **2020**,

115 Image\_2.tif. **2020**,

114 Image\_3.tif. **2020**,

113 Image\_4.tif. **2020**,

112	Early detection and intervention of clonal hematopoiesis for preventing hematological malignancies.. <b>2022</b> , 215691	0
111	Differential roles of the Wip1-p38-p53 DNA damage response pathway in early/advanced-stage ovarian clear cell carcinomas.. <b>2022</b> , 20, 139	
110	Infectious Spleen and Kidney Necrosis Virus (ISKNV) Triggers Mitochondria-Mediated Dynamic Interaction Signals via an Imbalance of Bax/Bak over Bcl-2/Bcl-xL in Fish Cells. <b>2022</b> , 14, 922	0
109	A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer.. <b>2022</b> , 1	0
108	Constitutive and DNA Damage Inducible Activation of pig3 and MDM2 Genes by Tumor-Derived p53 Mutant C277Y. <b>2004</b> , 2, 296-304	5
107	Hpv Proteins as Targets for Therapeutic Intervention. <b>2004</b> , 9, 665-678	2
106	Low-Dose Radiation Hypersensitivity Is Associated With p53-Dependent Apoptosis. <b>2004</b> , 2, 557-566	78
105	MDM2 and Prognosis. <b>2004</b> , 2, 1-8	153
104	The Effectiveness of Various Chemotherapeutic Agents in Cancer Treatment.	0
103	Tumor Suppressor p53 Regulates Heat Shock Factor 1 Protein Degradation in Huntington's Disease.	
102	Post-Translational Modifications of p53 in Ferroptosis: Novel Pharmacological Targets for Cancer Therapy. 13,	0
101	Stem Cell Biomarkers and Tumorigenesis in Gastric Cancer. <b>2022</b> , 12, 929	1
100	Molecular Investigation of the Dual Inhibition Mechanism for Targeted P53 Regulator MDM2/MDMX Inhibitors.	0
99	Identification of cancer-keeping genes as therapeutic targets by finding network control hubs.	
98	Effects of pH alterations on stress- and aging-induced protein phase separation. <b>2022</b> , 79,	2
97	A common pathway to cancer: Oncogenic mutations abolish p53 oscillations. <b>2022</b> ,	
96	Transcription factor YY1 contributes to human melanoma cell growth through modulating the p53 signaling pathway.	1
95	G2 checkpoint abrogators as anticancer drugs. <b>2004</b> , 3, 513-519	114

94	Functional Characterization of p53 in NPC&nbsp;C666-1 Cells by CRISPR-Based Gene Knockout and Transcriptome Sequencing.	
93	Field exposure to 50 Hz significantly affects wild-type and unfolded p53 expression in NB69 neuroblastoma cells. <b>2022</b> , 24,	
92	p53 Binding Sites in Long Terminal Repeat 5Hs (LTR5Hs) of Human Endogenous Retrovirus K Family (HML-2 Subgroup) Play Important Roles in the Regulation of LTR5Hs Transcriptional Activity.	3
91	Transcription-associated DNA DSBs activate p53 during hiPSC-based neurogenesis. <b>2022</b> , 12,	0
90	p53 Up-Regulates the Hsp70 Gene in Human Cancer. <b>2005</b> , 65, 758-766	24
89	Human Monocyte-Derived Dendritic Cells Pulsed with Wild-Type p53 Protein Efficiently Induce CTLs against p53 Overexpressing Human Cancer Cells. <b>2005</b> , 11, 1312-1318	5
88	Cyclooxygenase-2 and p53 Expressions in Endometrial Cancer. <b>2004</b> , 13, 1538-1542	14
87	Overexpression of m-Calpain in Human Colorectal Adenocarcinomas. <b>2004</b> , 13, 1604-1609	26
86	p53 Codon 72 Polymorphic Variants, Loss of Allele-Specific Transcription, and Human Papilloma Virus 16 and/or 18 E6 Messenger RNA Expression in Squamous Cell Carcinomas of the Head and Neck. <b>2004</b> , 13, 1805-1809	1
85	Executive compensation and bank stability: which role of the corruption control? An empirical evidence from OECD banks.	
84	Administration of 4-hexylresorcinol increases p53-mediated transcriptional activity in oral cancer cells with the p53 mutation. <b>2022</b> , 48,	0
83	Natural Products of Marine Origin for the Treatment of Colorectal and Pancreatic Cancers: Mechanisms and Potential. <b>2022</b> , 23, 8048	0
82	The Role of Sestrins in the Regulation of the Cellular Response to Stress. <b>2022</b> , 12, 347-364	
81	Etodolac Fortified Sodium Deoxycholate Stabilized Zein Nanoplatfoms for Augmented Repositioning Profile in Human Hepatocellular Carcinoma: Assessment of Bioaccessibility, Anti-Proliferation, Pro-Apoptosis and Oxidant Potentials in HepG2 Cells. <b>2022</b> , 15, 916	
80	LncRNA STK4 antisense RNA 1 (STK4-AS1) promoted osteosarcoma by inhibiting p53 expression. <b>2022</b> , 1-16	
79	Identify non-mutational p53 loss of function in human cancers.	
78	Deubiquitinases in Cancers: Aspects of Proliferation, Metastasis, and Apoptosis. <b>2022</b> , 14, 3547	2
77	Protooncogene MDM2 SNP309 (rs2279744) Analysis of Polymorphism in Thyroid Cancer: Pakistani Population. <b>2022</b> , 56, 391-397	

76	The role of oncogenes and tumor suppressor genes in determining survival rates of lung cancer patients in the population of North Sumatra, Indonesia. 11, 853	
75	FOXL2 and FOXA1 cooperatively assemble on the TP53 promoter in alternative dimer configurations. <b>2022</b> , 50, 8929-8946	0
74	Loss of the aryl hydrocarbon receptor increases tumorigenesis in p53-deficient mice. <b>2022</b> , 116191	1
73	Molekulare Prognosefaktoren in der onkologischen Viszeralchirurgie. <b>2022</b> , 147, 333-337	
72	HMG-CoA Reductase Inhibitor Statins Activate the Transcriptional Activity of p53 by Regulating the Expression of TAZ. <b>2022</b> , 15, 1015	1
71	Paradoxical tumor suppressive role of the musculoaponeurotic fibrosarcoma gene in colorectal cancer.	
70	Therapeutic capability of selected medicinal plants' bioactive constituents' against the mutant ovarian TP53 gene; A computational approach..	
69	miR-114 Derived from Bone Marrow Mesenchymal Stem Cells Regulates the Metastasis of Prostate Cancer Cells by Targeting P53 Gene. <b>2022</b> , 12, 1745-1750	
68	A novel glycosylated indolocarbazole derivative LCS1269 effectively inhibits growth of human cancer cells in vitro and in vivo through driving of both apoptosis and senescence by inducing of DNA damage and modulating of AKT/mTOR/S6K and ERK pathways. <b>2022</b> , 364, 110056	1
67	Noncoding RNAs in cataract formation: Star molecules emerge in an endless stream. <b>2022</b> , 184, 106417	1
66	mTORC1: Upstream and Downstream. <b>2022</b> ,	0
65	Cell Division/Death: Cell Cycle â Regulation of the p53 Pathway. <b>2022</b> ,	0
64	Introduction. <b>2022</b> , 1-20	0
63	Lessons Learned in Practice with Li-Fraumeni Syndrome: LFS-Related Breast Cancer Treatment Strategy and Establishment of a Surveillance System. <b>2022</b> , 68, 405-412	0
62	p53: From Fundamental Biology to Clinical Applications in Cancer. <b>2022</b> , 11, 1325	4
61	Introductory Chapter: p53 - The Miracle Protein That Holds the Distinction of Being âGuardian of the Genomeâ	0
60	Phase separation in immune regulation and immune-related diseases. <b>2022</b> , 100, 1427-1440	1
59	Drivers of Radioresistance in Prostate Cancer. <b>2022</b> , 11, 5637	1

58	Out of the cycle: Impact of cell cycle aberrations on cancer metabolism and metastasis.	0
57	A pan-cancer analysis of the oncogenic role of dual-specificity tyrosine (Y)-phosphorylation-regulated kinase 2 (DYRK2) in human tumors. <b>2022</b> , 12,	0
56	The effect of two types of diet on apoptosis indexes, lipid profile and histopathological outcome in acute kidney injury during exercise. <b>2022</b> , 23,	1
55	Physiological consequences of space flight, including abnormal bone metabolism, space radiation injury, and circadian clock dysregulation: Implications of melatonin use and regulation as a countermeasure.	1
54	A comprehensive study of p53 protein.	0
53	Probes and nano-delivery systems targeting NAD(P)H:quinone oxidoreductase 1: a mini-review.	0
52	Anticancer peptides mechanisms, simple and complex. <b>2022</b> , 110194	1
51	Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis.	0
50	Elucidating the Implications of Diverse Dynamical Responses in p53 Protein.	0
49	The emerging role of exosomes in radiotherapy. <b>2022</b> , 20,	0
48	Inhibition of late mRNA synthesis in the hippocampus impairs consolidation and reconsolidation of spatial memory in male rats. <b>2022</b> , 195, 107687	0
47	Deep Molecular and In Silico Protein Analysis of p53 Alteration in Myelodysplastic Neoplasia and Acute Myeloid Leukemia. <b>2022</b> , 11, 3475	0
46	Development of novel hydrazidoarylamino-pyrimidine-based BTK/FLT3 dual inhibitors with potent in vivo anti-hematological malignancies effects. <b>2023</b> , 245, 114913	0
45	Anti-proliferating and apoptosis-inducing activity of chemical compound FTI-6D in association with p53 in human cancer cell lines. <b>2023</b> , 369, 110257	0
44	p63 transcriptionally represses p53 target genes involved in the radiation-induced DNA damage response. <b>2022</b> , 17,	0
43	Anti-cancer activity of pyridoxal phosphate and metformin combination in human pancreatic cancer cells. 026010602211376	0
42	Metformin as a Potential Antitumor Agent. <b>2022</b> ,	0
41	Genetic association of TP53 Pro72Arg polymorphism (rs1042522) in Leukemia: An updated meta-analysis of 10 case-control studies. <b>2022</b> , 201130	0

40	Assessment of sulfamethoxazole toxicity to marine mussels ( <i>Mytilus galloprovincialis</i> ): Combine p38-MAPK signaling pathway modulation with histopathological alterations. <b>2023</b> , 249, 114365	0
39	The synergistic function of long and short forms of $\beta$ GalT1 in p53-mediated drug resistance in bladder cancer cells. <b>2023</b> , 1870, 119409	1
38	Dynamic behavior of P53-Mdm2-Wip1 gene regulatory network under the influence of time delay and noise. <b>2022</b> , 20, 2321-2347	0
37	Ethical Considerations of Genetic Testing. <b>2002</b> , 13, 316-323	1
36	Hallmarks of cancer: The insulin-like growth factors perspective. 12,	0
35	The Underestimated Role of the p53 Pathway in Renal Cancer. <b>2022</b> , 14, 5733	0
34	Evidence for Multilevel Chemopreventive Activities of Natural Phenols from Functional Genomic Studies of Curcumin, Resveratrol, Genistein, Quercetin, and Luteolin. <b>2022</b> , 23, 14957	0
33	PKR-Mediated Phosphorylation of eIF2 $\alpha$ and CHK1 Is Associated with Doxorubicin-Mediated Apoptosis in HCC1143 Triple-Negative Breast Cancer Cells. <b>2022</b> , 23, 15872	0
32	Regulation of IL-6 Signaling by p53: STAT3- and STAT5-Masking in p53-Val135-Containing Human Hepatoma Hep3B Cell Lines. <b>1998</b> , 161, 325-334	9
31	Increased Generation of CD8+ T Cell Clones in p53 Mutant Mice. <b>1999</b> , 162, 3957-3960	0
30	Bcl-2-Induced Changes in E2F Regulatory Complexes Reveal the Potential for Integrated Cell Cycle and Cell Death Functions. <b>1999</b> , 162, 5374-5379	9
29	Accelerated Development and Aging of the Immune System in p53-Deficient Mice. <b>1999</b> , 163, 1966-1972	4
28	Nutrition and Diet: A Double-Edged Sword in Development and Treatment of Brain Tumors. <b>2023</b> , 153-180	0
27	Signaling pathways in brain tumors and therapeutic interventions. <b>2023</b> , 8,	0
26	A Mitochondrion-Targeting Protein ( $\beta$ 2) Primes ROS/Nrf2-Mediated Stress Signals, Triggering Apoptosis and Necroptosis in Lung Cancer. <b>2023</b> , 11, 186	0
25	CircPLXNA2 affects the proliferation and apoptosis of myoblast through circPLXNA2/gga-miR-12207-5P/MDM4 axis.	0
24	Telomerase and Anticancer Treatment. <b>2022</b> , 15, 1881-1888	0
23	Cell differentiation modifies the p53 transcriptional program through a combination of gene silencing and constitutive transactivation.	0

- 22 Gain-of-Function p53N236S Mutation Drives the Bypassing of HRasV12-Induced Cellular Senescence via PGCα1. **2023**, 24, 3790 ○
- 21 Identification of p53-target genes in human papillomavirus-associated head and neck cancer by integrative bioinformatics analysis. 13, ○
- 20 PITAR, a DNA damage-inducible Cancer/Testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA. ○
- 19 Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma. **2023**, 161, 114452 ○
- 18 Multifunctional metallochaperone modifications for targeting subsite cavities in mutant p53-Y220C. **2023**, 242, 112164 ○
- 17 The SWIB/MDM2 motif of UBE4B activates the p53 pathway. **2023**, 31, 466-481 ○
- 16 Advances in mechanism and regulation of PANoptosis: Prospects in disease treatment. 14, ○
- 15 In vitro genotoxicity potential investigation of 7 oxy-PAHs. **2023**, 64, 176-186 ○
- 14 Effect of Nutlin-3a on stability of p53-MDM2 complex. **2023**, 72, 068702 ○
- 13 Cellular signals integrate cell cycle and metabolic control in cancer. **2023**, 397-423 ○
- 12 Role of RUNX3 in Restriction Point Regulation. **2023**, 12, 708 ○
- 11 A Brief Review on Chemoresistance; Targeting Cancer Stem Cells as an Alternative Approach. **2023**, 24, 4487 ○
- 10 Therapeutic capability of selected medicinal plants' bioactive constituents against the mutant ovarian TP53 gene; a computational approach. **2023**, 5, 8-32 ○
- 9 Tumor suppressor p53 regulates heat shock factor 1 protein degradation in Huntington's disease. **2023**, 42, 112198 ○
- 8 Introduction to Cancer Immunology. **2023**, 1-29 ○
- 7 CircPLXNA2 Affects the Proliferation and Apoptosis of Myoblast through circPLXNA2/gga-miR-12207-5P/MDM4 Axis. **2023**, 24, 5459 ○
- 6 Glis1 and oxaloacetate in nucleus pulposus stromal cell somatic reprogramming and survival. 9, ○
- 5 Tumor-suppressive role of the musculoaponeurotic fibrosarcoma gene in colorectal cancer. **2023**, 26, 106478 ○



- 4 Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis. **2023**, 23,
- 3 Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy. **2023**, 11, 1166
- 2 Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence. **2023**, 13, 560
- 1 Correlations of Disc Tissue Pathological Changes With Pfirrmann Grade in Patients With Disc Herniation Treated With Microdiscectomy. **2023**,